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LEGEND 
 
ALPPS Associating liver partition and portal vein ligation  
 
BMDC Bone marrow derived cells 
CEA Carcinoembryonic antigen 
CD31 Cluster of differentiation 31 
c-Met Cellular Mesenchymal and Epithelial transition factor 
CRC Colorectal cancer 
CRS Cytoreductive surgery 
CSF- Macrophage colony-stimulating factor 
DSF Disease free survival 
EGF Endothelial growth factor 
EPC Endothelial progenitor cells 
EPO Erythropoietin   
FGF Fibrinogen growth factor 
GFP Green fluorescent protein 
HIF Hypoxia-inducible factor 
HPC Hematopoietic progenitor cells  
HGF Hepatic growth factor 
HIPEC Hyperthermic intraperitoneal chemotherapy 
IL- Interleukin 
INF- Interferon  
LM Liver metastases 
LSEC Sinusoidal endothelial cells 
NK- Natural killer cell 
MMP Metalloproteinase 
OS Overall survival 
PC Peritoneal carcinomatosis 
PDGF Platelet derived growth factor 
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PlGF Placental growth factor 
RFA Radiofrequency ablation 
SDF- Stromal cell-derived factor 
TAM Tumor-associated macrophage 
TNF- Tumor necrosis factor 
TGF- Tumor growth factor 
VEGF Vascular endothelial growth factor 
VEGFR Vascular endothelial growth factor receptor 
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A. INTRODUCTION 
 
The gold standard of the therapeutic strategy of resectable liver metastases (LM) is surgical 
resection [1]. Also, cytoreduction, with hyperthermic intraperitoneal chemotherapy (HIPEC), 
is the only curative treatment for colorectal peritoneal carcinomatosis (PC) [2]. However, 
surgery in cases of LM associated with extra hepatic metastases is still being debated [3]. LM 
occur in 25% to 40% of patients who have colorectal cancer (CRC) [1]. After curative liver 
resection, 70% of patients relapsed despite peri-operative chemotherapy. If a second surgical 
procedure is not possible, the overall survival (OS) rate is 12-38 months [1]. Chemotherapy 
improves the operability of liver metastases. In cases of non-resectable metastases, 
chemotherapy improves the margins of resection, reduce the sizes to facilitate surgery in 
inaccessible locations, eventually treated the micro-metastases [4-6]. The long-term outcome 
for patients undergoing chemotherapy alone is poor, with a median OS of 16-17 months in 
CAIRO and CAIRO2 trials [7], and up to 31 months with intensification of the treatment in 
TRIBE trials [8]. The same results, in terms of OS, were obtained in Karoui’s study of 208 
patients operated on for primary tumours treated with adjuvant chemotherapy in association 
with an antiangiogenic factor (Bevacizumab) [9]. Over a period of ten years, the use of 
effective chemotherapy, when associated with new biotherapies, improved the OS [8,10-12]. 
Peri-operative chemotherapy, with FOLFOX, also improves OS and Disease Free Survival 
(DFS) in cases of resectable metastases when the CEA is elevated and the performance status 
is good [1].  
PC occurs in 8 to 20% of patients with CRC [13-16] and is associated with a low survival rate 
(inferior to 6 months if untreated [17] or barely reaching 12 months with systemic 
chemotherapy [13,18,19]). Cytoreduction surgery (CRS), with intraperitoneal chemotherapy, 
including HIPEC, eventually associated with early postoperative intraperitoneal 
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chemotherapy (EPIC), is accepted as the only potentially curative treatment for PC from CRC 
origin, leading to a mean DFS of 18.4 months and a mean OS of 27.4 months [2] and up to 63 
months in selected patients [20]. 
The synchronous presence of LM and PC from CRC origin is linked to very poor outcomes 
and is traditionally considered a contraindication to any surgical approach [21-25].  Recently, 
Franko et al. have shown that the presence of PC, with or without extra-peritoneal metastasis, 
is a prognostic factor of poor OS for patients with metastatic CRC [26].  
However, since 1999, following the encouraging results of the management of liver and 
peritoneal metastasis from CRC separately, some studies reported a prolonged survival rate 
after the management of synchronous colorectal LM and PC (reaching 3 years in selected 
patients) [27-33]. This suggests that PC is not an absolute contraindication to liver surgery and 
that a curative surgical management of LM and PC may be possible [3,29,30,34,35]. To date, no 
standard management pathway has been established for patients with simultaneous LM and 
PC, especially if major surgery (liver and peritoneal resection) has to be performed. So far, 
the presence of PC has been considered an absolute contraindication against a hepatectomy 
for LM of CRC. Indeed, the major decision of surgical treatment is justified only if the 
chances of remission are significant. Yet, if liver and peritoneal metastases associated, mono-
centric and limited series published promising results with median OS of up to 3 years (range 
3.5-8) after simoultaneous complete resection of LM and PC [30,31,34,35]. Similar results have 
been reported when there extra hepatic not peritoneal lesions (lung and lymph node) which 
can be fully resected [3]. Thus, extra hepatic metastases may be a systematic contraindication 
to liver surgery, except if all the lesions can be resected in a oncological surgery satisfactory. 
Cytoreductive surgery and HIPEC for peritoneal metastases combined with liver resection 
was recently analyzed, in a systematic review, as a possible option [33]. Authors claimed that 
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patients with metastatic CRC showed a tendency towards increased median OS, after 
cytoreductive surgery and HIPEC combined with resection of LM, when compared to 
treatment with modern systemic chemotherapies. At the present time, there is no specific 
surgical strategy for selecting patients with a high potential for success in view. In our study, 
we suggested that a surgical curative management of synchronous LM and PC is possible 
with acceptable mornbi/mortality rate. We analyzed a prospective international cohort of 
patients with PC associated with LM of CRC. The aim of this study was to describe and 
assess early outcomes (morbidity/mortality, hospital stay duration) and long-term results 
(DFS and OS) of patients undergoing liver resection and cytoreductive surgery with HIPEC 
for concomitant PC and LM. The secondary goal of this study was to identify variables 
potentially related to poor outcomes, in order to establish future guidelines for the 
management of those patients and optimize the selection of candidates for surgical treatment.  
However, in case of aggressive surgical approach with curative intent, there are no guidelines 
for choosing which surgery should be done first: should we operate on the liver first or on the 
peritoneum? The question of the optimal sequence thus remains unsolved. The choice 
depends primarily on the number, and location, of liver metastases. If liver metastases require 
minor and uncomplicated resection, liver resection and cytoreduction, with HIPEC, can be 
performed in one stage. If liver metastases require complex or important resection, in 
particular on an injured parenchyma (post-chemotherapy), hepatic resection and cytoreduction 
with HIPEC will be conducted in two stages. A recent publication reports a monogram to help 
with the selection of a patient for a complex strategy. The strategy is based on the number of 
liver metastases, the extent of peritoneal metastases evaluated by the peritoneal 
carcinomatosis index (PCI), as well as the type of surgery [36]. Postoperative mortality was 
2.7% after liver resection, 4.2% after CRS with HIPEC, and 8.1% after liver resection and 
CRS with HIPEC. The postoperative 3-4 grade morbidity rate reported was 11% after liver 
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resection, 17% after CRS and HIPEC, and 41% after liver resection and CRS with HIPEC 
(p<0.001). According to literature [30], the morbidity rate was high but the total number of 
reported patients with liver and peritoneal concomitant surgery was low (n=37) [37].  
To offer a strategy for patients we proposed to associate the cytoreduction with HIPEC for 
limited liver procedures such as radiofrequency tumor ablation (RFA) or wedge resection. In 
cases of major liver resection, and peritoneum metastases, we propose to separate the surgery 
into two procedures (Lo Dico et al., ASCO 2013 Abstract n° #113772). The first procedural 
choice could be liver surgery, or a peritoneal procedure with HIPEC. We postulate that the 
choice be based on specific technical problems and oncological aspects. Technical problems 
depend on the type of surgery, including the choice of laparoscopic liver surgical approach, or 
anti-adhesion barrier film used to limit postoperative adhesion [38]. The oncological aspect 
depends on the effects of the liver resection on the metastasis growth in liver remnant and, 
less knows, in extra-hepatic recurrences [39-41]. We assumed that liver regeneration, after liver 
resection, could promote peritoneal carcinomatosis. To test our hypothesis, we constructed an 
animal model to mimic the human clinical situation of concomitant liver resection and 
peritoneum metastases. To mimic the human situation, an immunocompetent animal mouse 
model was chosen. If the animal model confirmed our hypothesis, we could determine the 
best sequence for liver and peritoneum surgeries and definitively propose the peritoneal 
cytoreduction as the first step of the surgical strategy.  
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Metastatic process and interactions with the microenvironment 
In 1889, after scrutinizing more than 900 autopsy records of patients with different primary 
breast tumors, the English surgeon Stephen Paget published the seminal ‘seed and soil’ 
hypothesis to explain the non-random pattern of metastasis to visceral organs and bones. 
According to this hypothesis, he claimed the outcome of metastasis was not due to chance but 
rather that certain tumor cells (‘seed’) have specific affinities for the milieu of certain organs 
(‘soil’). Paget concluded that metastases formed only when the seed and soil were compatible 
[42]. In accordance, the Fidler studies showed that cancer cells can reach the vessels of all 
organs but the metastases only develop in some organs [43,44]. Paget affirmed that the tumor 
could give metastases in specific territories outside the drainage areas of the primary tumor 
which differed from the Ewing's theory, according to which the onset of metastases strictly 
follow the vascular and lymphatic drainage of the primary tumor [Ewing 6th edn.WB 
Sounders Co.1928]. Some tumor types, such as the uveal melanomas, have a particular 
tropism for the liver, with a high rate of hepatic localization (93% of a cohort of 1,003 
patients) [Collaborative ocular melanoma study (COMS): Arc Oph 2001]. Indeed, one has to 
take into account the genetic and epigenetic changes in the tumor cells, such as unlimited 
potential of replication and the acquisition of a phenotype resistance to apopotosis. However, 
stimulating angiogenesis and the spread of metastases (metastatic potential) could be linked 
to the genetic and epigenetic alterations as well as cellular changes and those of the 
microenvironment, in extra-peritoneal recurrences. Mediator metastases are organ specific 
and are not identical to those in the liver, bones, brain, lungs and peritoneum. The metastatic 
process depends on the intrinsic properties of tumor cells and extrinsic properties of the 
microenvironment of the original tumor and metastatic sites. A relation, between primary 
tumor sites and secondary organs, affected by the metastatic process, is evident in all theses 
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observations. Not all features of metastatic progression can be explained on the basis of the 
microenvironment.  
The metastasis process of the peritoneal carcinomatosis remains unknown. More theories are 
being developed to explain the tumoral process in the spread of PC. The tumoral process 
could follow the same manner as in lymphatic or hematologic abdominal cases; or could be 
the consequence of the exfoliation of neoplastic cells [45], from the primary tumor directly in 
the peritoneal cavity; it could also be the consequence of the adhesion and invasion of 
peritoneal tissue by the tumoral cell clusters [46]. 
Angiogenesis  
Angiogenesis refers to the development of neo-vessels from preexisting vessels. 
Physiological angiogenesis is a necessary component of tissue repair processes; this 
phenomenon is closely associated with liver regeneration. Pathological angiogenesis is 
responsible for tumor growth and metastasis. The angiogenesis phenomena are necessary in 
the development of the tumor. In 1971 Judah Folkman published the hypothesis (in the "New 
England Journal of Medicine") that solid tumors were able to induce the growth of new 
vessels (from pre-existing vasculature) by the secretion of pro angiogenic factors, such as the 
vascular endothelial growth factor (VEGF), in the tumor microenvironment. These factors 
will activate quiescent endothelial cells, stimulating them to proliferate and begin a program 
of morphogenesis. This tumor angiogenesis has long been regarded as the main model of 
tumor neovascularization, and the process was considered exclusively local for a long time 
[47-49]. The synthesis and secretion of angiogenic factors establish a capillary network from 
the surrounding host tissue [50]. However, it has also been suggested that circulating 
endothelial precursors could be recruited away to the formation of these new vessels [51]. 
Specific angiogenic molecules can initiate this process and specific inhibitory molecules can 
 Lo Dico Rea – Thèse de doctorat - 2017 
 
 
13 
stop it. These molecules, with opposing functions, appear to be continuously acting in concert 
to maintain a quiescent microvasculature [52].  
VEGF is present in the peritoneal cavity and plays an important role in ascites development 
from ovarian cancer [53]. Pre-clinical study of Passot et al. shows that VEGF intravenous and 
intraperitoneal levels burden increased significantly after CRS, and then decreased 
progressively (p<0.005) [54]. Its presence may have an impact on survival from PC and 
recurrence following potentially curative surgery [55,56].  In our murine model, to study the 
growth and development of the metastases, we decided to analyse the angiogenetic process by 
the marker of the pro-angiogenetic factors (most importantly, the VEGF and its receptor).  
The process of new vessels formation is defined as sprouting and starts with a detachment of 
pericytes and the dilation of pre-existing vessels. The consequence is an increase in capillary 
permeability and the degradation of the extracellular matrix (MEC) by the metalloproteinase. 
The endothelial cells migrate and proliferate in the peri-vascular space; the adhesion of 
endothelial cells to each other forms a new vascular tube; finally, the fusion of neo-vessels 
constructs an unstable vascular network [57]. Abnormal vascular remodeling in tumor 
neovascularization is called switch angiogenic and tumor vessels exhibit, not only 
quantitative, but also qualitative, abnormalities: the blood vessels are winding, overly 
permeable and unstable; they are surrounded by not-functional pericytes [57-59]. Tumor 
progresses from a non-angiogenic to angiogenic phenotype based on the imbalance of pro-
angiogenic and anti-angiogenic factors. The angiogenic switch is “off” when the effect of 
angiogenic activators is balanced by that of the inhibitor’s factors, and it is “on” when the 
balance is in favor of angiogenesis [60,61]. Tumor neovascularization is induced by the 
interaction between tumor cells and cells of the tumor’s microenvironment. These new 
vessels carry oxygen and nutrients essential to cancer cells and, thus, to tumor growth. 
Capillary blood vessels consist of endothelial cells and pericytes. These two cell types carry 
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all of the genetic information to form tubes, branches, and whole capillary networks [52]. 
Endothelial cells exhibit broad fenestral junctions, a discontinuous basal lamina favoring 
extravasation of tumor cells in the blood flow, which is abnormal with areas of slowed and 
accelerated flow [62]. This phenomenon generates zones of hypoxia which increases the 
concentration of HIF-1a [63], and favors the sinuses of the pro-angiogenic factors, VEGF and 
PlGF [64-68]. HIF is related to increased microvessel density in the adjacent area of necrosis, or 
hypoxia, and plays a pivotal role in tumor progression [69]. A tumor must continuously 
stimulate the growth of new capillary blood vessels for the tumor itself to grow. Furthermore, 
the new blood vessels embedded in a tumor provide a gateway for tumor cells to enter the 
circulation and to metastasize to distant sites, such as the liver, lungs, or bones.  
To confirm the development of aberrant neo-angiogenesis networks, in our model, we studied 
the vascular density on the endothelial cells by the positive marking of the CD31 and the 
circulating levels of some cytokines (such as VEGF, HIF-1a and PlGF).  
Local invasion of the host stroma by some tumor cells occurs by passing into the circulation: 
a lymphatic channel, and neo-capillary, offer very little resistance to penetration by tumor 
cells [70]. Most circulating tumor cells are quickly destroyed. After the tumor cells have 
survived the circulation, they become trapped in the capillary beds of distant organs by 
adhering, either to capillary endothelial cells, or to the sub-endothelial basement membrane 
that might be exposed [71].  
The microenvironment 
The tumor cells and the stroma are the two components of tumor tissue. The stroma is a non-
tumor tissue from the host and represents a supporting feeder to tumor cells. It consists of 
tissue structures, vascular and immune cells, and its formation is induced by the presence of 
cancer cells. It is present in all types of solid cancer tumors as well as in metastases. The 
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migration and the growth of malignant cells [73]. TAM can play a dual role in the tumor 
microenvironment, inhibiting tumor cells but also favoring tumor progression and 
angiogenesis when cancer cells begin to evade immune surveillance [74]. 
Metastatic process  
The metastatic process involves several steps through which tumor cells spreading from the 
primary tumor, colonize remote organs [75]. The steps, in part, take place in the primary 
tumor, partly in the systemic circulation and partly in the distant organs. During this process 
the cancer cells break away from the primary tumor, enter into the blood circulation 
(intravasation) preferentially occurring in close proximity to perivascular macrophages, 
interrupting endothelial cell contacts and degrading the vascular basement membrane 
(disruption). This process is mediated by proteases supplied from the cancer cells, 
macrophages, or both. Then, the cancer cells recognize and adhere to the host body 
(adhesion). In distant organs tissue invasion can be seen in secondary growths as tumor cells 
spread (extravasation) [76,77]. During the intravasation, cancer cell migration is controlled 
through a paracrine loop involving epidermal growth factor (EGF), colony-stimulating factor 
1 (CSF-1) and their receptors, which are differentially expressed on carcinoma cells and 
macrophages, resulting in the movement of cancer cells towards macrophages. VEGF, and its 
receptors (VEGFRs), are also involved in the migration and invasion process. A recent in 
vitro study shows that the depletion of VEGF and its receptors in multiple CRC cell lines led 
to strong inhibition of the migration and invasion of CRC cells resulting in the reduction in 
levels of phosphorylated focal adhesion kinase and its upstream regulators such as cMet and 
the EGF receptor [78]. Additional paracrine loops exist between cancer cells and stromal cells, 
such as fibroblasts and pericytes, producing the cognate ligand stromal cell-derived factor 1 
(SDF1), which contributes to directional cancer cell migration [72]. Lewis and Pollard had 
demonstrated that TAM secretes a number of potent pro-angiogenic growth factors and 
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This process, established for hepatic recurrences, has not yet been osberved for PC. In fact, 
the proliferation mechanisms of peritoneal metastases are unknown. After his clinical 
observations, Sugarbaker hypothesized that the tumoral process in the peritoneum may occur 
if the neoplastic cells first gain access to the peritoneal cavity and spread transcoelomic by 
peritoneal fluid [45]. Exfoliating malignant cells derived from the primary cancer can be 
absorbed through communications with the submesothelial lymphatic network (called stoma) 
remain entrapped, and then invade the peritoneal surface and proliferate. The lack of 
knowledge concerning the PC tumoral process has motivated our choice to develop an 
orthotopic murin model of the intraperitoneal neoplastic cells injection.  
Another way described is the entrapment of free cancer cells in the naturally or iatrogenically 
raw surfaces, like the ovarian surface in the Krukemberg syndrome, or in case of dissection, 
during abdominal surgery. We postulated that laparotomy plays an important role in the 
tumoral processes of PC. We studied the sham laparotomy to verify its pro-metastatic effects 
on the PC growth. 
Bone marrow progenitors initiate the “pre-metastatic niche”  
Previously, Asahara showed, for the first time, that endothelial progenitor bone marrow 
derived cells (BMDC) were able to move, become incorporated into the vessels and 
contribute to neovascularization on ischemia sites. It’s a vasculogenesis mechanism concept 
which was previously related to embryogenesis exclusively [48]. Following the work of Lyden 
it was demonstrated that the BMDC could participate in tumor vasculogenesis, tumor growth 
and neoangiogenesis, in the formation of the pro-metastatic niche and development of 
metastases [49].		
In advanced and metastatic CRC, even after complete resection of the primary tumors, the 
interaction between tumor and stroma in the tumor microenvironment often promotes cancer 
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invasion and/or metastasis through chemokine signaling in distant organs such as the liver, 
lung, lymph node, bone or peritoneum [80]. These chemokines	may affect tumor immunity by 
recruiting several types of BMDC to the tumor microenvironment. Following literature, we 
decided to analyse the roles played by pro-angiogenic and pro-metastase BMDC progenitors, 
as well as the growth factors secreted from our animal models concerning PC and liver 
regeneration.	 
In 2005, in animal models based on intradermal injection of B16 melanoma cells and Lewis 
lung carcinoma cells, Kaplan showed that VEGF-A, produced by the primary tumor, 
promotes entry in systemic circulation and mobilization towards metastatic sites derived from 
BMDC, hematopoietic progenitor cells (HPC) and endothelial progenitor cells (EPC), and 
prepares the future site of metastasis development [81]. This migration would precede the 
arrival of the tumor cells. The HPC circulate in the blood, expressing VEGFR-1, and the 
integrin VLA-4, enabling them to adhere to fibronectin and metalloproteinase degrading the 
basement membrane, which increases extravasation of HPC in the pre-metastatic niche before 
the arrival of tumor cells and EPC (VEGFR2+). The EPC can circulate in the blood and are 
able to migrate to the tumor site where they provide specific functions in neo-angiogenesis [82-
84]. All these events result in a change in the local microenvironment for attachment, survival 
and growth of circulating tumor cells, in which angiogenesis plays a fundamental role. In a 
subcutaneous injection of lung cancer cells and in a model of spontaneous breast cancer in 
transgenic mice, Gao et al. showed that the EPC infiltrated the periphery of the avascular pre-
metastatic niche and were then incorporated into the lumina of macrovascular metastasis 
vessels. At this stage the pre-metastatic niche is a micrometastasis. An angiogenic switch is 
associated with the progression of micrometastases (<1mm) to macrometastases (≥1mm), 
during which EPC are recruited to the metastastic foci and contribute luminally to the 
neovasculature in metastatic lesions [85]. To promote the progression of micrometastases in 
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macroscopically detectable metastases (macrometastases), EPC (VEGFR-2+) are recruited 
secondarily to promote angiogenesis [86]. To continue growing, the micrometastasis must 
develop an abnormal vascular network [50] and evade destruction by host defenses. 
Circulating endothelial cells and EPC were considered biomarkers of tumor angiogenesis. For 
the first time, a non-neoplastic cell population had been identified to be able to promote a 
future metastatic site. The impact of this evidence was strong: anti-VEGFR1 treatment has 
been found to prevent the formation of pre-metastatic HPC clusters and metastatic 
progression [81].  	 
Mechanisms of liver regeneration 
The mention of liver regeneration by Prometheus in Greek mythology indicates that ancient 
people had noticed the regenerative capacity of the liver. To illustrate this well known liver 
feature, we mention the work of Taub et al. After a 70% hepatectomy in rats, 95% of 
quiescent hepatocytes (G0 phase) go through mitosis, with a peak of DNA synthesis at H24 
and the restoration of 90% of the volume is obtained at H72 [87]. In mice there is a full 
recovery of the parenchyma in 7 to 10 days [88,89]. On a human level, restoration is achieved 
from 2 to 6 months in a healthy liver, but the biological function is restored in less than 3 
weeks [90]. As the resection of lobes does not induce damage to the remaining liver tissue, 
partial hepatectomy has long been considered an excellent experimental model for tissue 
regeneration. The liver regeneration is different that compensatory hyperplasia: in a severely 
damaged liver, liver stem cells, which have the potential to differentiate into hepatocytes and 
biliary epithelial cells, proliferate and are assumed to contribute to regeneration. By contrast, 
the liver does not recover the original lobular structure; the remnant tissue simply increases in 
size. Each hepatocyte can divide 1 to 2 times, thus allowing the recovery of liver mass, while 
in a normal liver, little spontaneous mitosis is observed in hepatocytes (mitosis about 1 to 
20,000 cells). Miyaoka et al. observed in a murine model that increased hepatocyte size 
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occurs as early as a few hours after a 70% partial hepatectomy, much earlier than their entry 
into the cell cycle. It peaks at 1 day, suggesting that cell size increase is the first response of 
hepatocytes to the loss of liver mass. [91]. In this phase hepatocytes dramatically change their 
gene expression necessary to entry into the cell cycle and prepare for regeneration [92]. A 
second phase of cellular division concerns the Kupffer and stellate cells at H48, followed by 
endothelial cells of liver sinusoids (LSEC) at H72. Ding et al. have shown that there is a    
synchronism between hepatocyte and endothelial proliferation [93]. Endothelial cells have a 
prominent role in hepatocyte proliferation and spatial distribution together with the platelets. 
A wave of hepatocyte apoptosis follows this DNA synthesis, performing a feedback 
regulation [94]. Hepatocyte proliferation results in the formation of avascular clusters of 10–14 
cells that are not organized in the final architecture of the liver. These clusters are not 
functional because the core cells are located outside of the oxygen diffusion capillary area 
[95]. This hypoxia activates the transcription of HIF-1 factor which, in turn, induces the 
expression of downstream target genes, including VEGF, and VEGFR-1 [96]. Stellate cells 
produce extracellular matrix on the fourth day to re-establish a connection between 
hepatocytes and endothelial cells. TGF-α is produced by stellate cells and allows the synthesis 
of the extracellular matrix. This is in response to the increase in portal pressure after liver 
surgery because there is a reduction of the vascular bed and portal flow as well as a  release of 
nitric oxide from the liver sinusoidal endothelial cells (LSEC) allowing a sensitization of 
hepatocytes to HGF [97]. VEGF production by hepatocytes increased during liver regeneration 
peaking at 48-72 h [98]. Most solid tumors overexpress and secrete VEGF [99]. During liver 
regeneration, it promotes new vasculature formation from preexisting blood vessels, the 
proliferation of endothelial cells and regulates the vascular permeability of the LSEC [100,101]. 
This production is accompanied by an increase of VEGFR-1 expression on hepatocytes and 
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HPC, and VEGFR-1 and VEGFR-2 expression on the LSEC [95,102,103]. After binding to 
VEGFR-1 hepatocyte, VEGF can induce autocrine hepatocyte proliferation [98].  
Our laboratory animal model, based on hepatic and limb ischemia, developed by Lim et al., 
shows that the hepatic ischemia and, consequently, liver regeneration, leads to the 
mobilization of EPC progenitors and enhanced intra-hepatic angiogenesis, which is associated 
with an increased tumor burden in an animal model of colorectal liver metastasis [104]. 
Accordingly, we have postulated that the liver regeneration process, consequently after major 
hepatectomy, could mobilize the progenitor BMDC to promote the increase of tumoral 
angiogenesis of the PC and, thus, have a pro-metastastic effect. 
Cytokines and liver regeneration  
In addition to pro-tumoral and pro-angiogenic effets, the cytokines and angiogenic factors 
play a role in liver regeneration. [105,106]. Usual, in humans, liver regeneration is mainly 
studied in the context of hepatic resection for liver cancers, liver failure or liver transplant 
recipients. In the clinical setting, right lobe donor hepatectomy for healthy donors liver 
transplantation is an ideal model to study liver regeneration after partial hepatectomy. 
Sasturkar et al. affirm that the cytokines and growth factors play prominent roles in liver 
regeneration for these patients. HGF, IL-6, and TNF-α are involved in upregulation of the 
early phase, whereas TGF-β1 and IFN are involved in the termination phase of liver 
regeneration. However, factors such as underlying liver diseases, the degree of portal 
hypertension, or immunosuppressant use may influence liver regeneration [107]. The 
expression of HGF increases 6 to 8 hours after partial hepatectomy. It is probably the most 
important growth factor upregulated during liver regeneration. Secreted by stellate cells, 
Kupffer cells and LSEC, HGF stimulates the production of the transforming growth factor 
αTGF, an autocrine growth factor, active on hepatocyte after binding to its tyrosine kinase 
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receptor [108]. During the tumoral process, HGF accelerates angiogenesis, tumor migration 
and infiltration [109] and increases the MMP activity and secretion of proteinases which lyse 
basal membrane and promote metastasis [110]. IL-6 is released from the hepatocytes and 
Kupffer cells in response to portal-system-carried factors and contributes to the initiation of 
the cell cycle (G0 to G1) [111]. It induces the transcription of many genes involved in cell 
division and survival by controlling apoptosis pathways [112]. Several experimental studies 
have shown that IL-6 is necessary for proper liver regeneration [94,111].  
The increased level of local and systemic IL-6 is important for inflammatory processes. In 
this study, we considered that the IL-6 plays a key role in cancer development and 
progression; is the common factor between the immuno-regulation and the angiogenesis [113]. 
Stone et al. analyzing the effect of cancer on platelet counts in human primary tumors and a 
orthotopic murine model of epithelial ovarian cancer, demostrated that the thrombocytosis 
was correlated with the number of peritoneal metastases and a shortened survival [114]. In 
their animal model, platelet counts were strongly correlated with mean BMDC counts. The 
use of an anti–IL-6 antibody treatment significantly reduced platelet counts in tumor-bearing 
mice, as well as in patients, and enhanced the therapeutic efficacy of the systemic 
chemotherapy (Paclitaxel) in their mouse model.  
TNF-α secreted by hepatocytes, is a potent regulator in the initiation of liver regeneration. In 
rodent studies, TNF-α enhances the effects of direct mitogen such as HGF [115]. Antibodies 
against TNF-α administered at the time of hepatectomy lower the regenerative response [116]. 
The last step is to stop the proliferation engineered by the TGF-ß1. TGF-ß1 is produced 
predominantly by hepatic stellate cells [117] and is known to have growth inhibitory effects on 
liver regeneration. These factors play an exogenous monitoring role on liver regeneration, 
which enables the adaptation of the size of the liver to its new environment [118]. In 
experimental studies, after partial hepatectomy, matrix-bound TGF-ß1 is activated and 
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released into the circulation and thus an increased concentration is detected within 1 hour of 
partial hepatectomy [89].  
In our study, the blood levels of these cytokines were analysed at different times to monitor 
the phases of liver regeneration.  
Pro-metastatic effects of liver surgery  
Although portal flow drains the tumor cells through the hepatic parenchima, this metastatic 
process is not very effective: in a murine model of hepatic melanoma metastases, only 0.02% 
of the tumor cells injected into the portal system will become metastases [119]. Liver surgery 
and, consequently, liver regeneration, play a crucial role in tumor recurrence by stimulating 
tumor cells to proliferate following resection. Clinical studies show that partial hepatectomy 
for metastases of colorectal cancer is associated with a 60 to 80% tumor recurrence rate and is 
a major cause of treatment failure [120,121]. Cellular and molecular changes resulting from liver 
regeneration after hepatectomy contribute to extrahepatic and hepatic recurrences [21].  
The extent of hepatectomy is an important factor influencing the tumor growth. To show the 
effects induce of the liver resction, we have chosen a murine model of 68% of liver 
parenchyma resection.  
In a mouse model Brandt et al. analyzed the mechanism behind the development of recurrent 
malignant lesions after liver resection. The animals were treated with a sham laparotomy 
without liver injury, a 30% liver resection, or a 70% liver resection. After surgery, the animals 
received a tumor cell injection into the remaining liver tissue. After a 70% liver resection, the 
tumor volume, weight and tumor proliferation rate of Ki-67 were significantly increased 
compared to a laparotomy alone (p <0.05) [122]. Previous experiment for colorectal cancer 
reported that on mice model liver surgery, 70% partial hepatectomy induced tumor growth 
and the spread of extrahepatic metastases more than limited 37% hepatectomy. The increased 
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growth in liver metastases occurred predominantly in the late phase of liver regeneration 
rather than the early phase [123]. In a rat tumor model, Mizutani et al. have shown that 
resection is a potential promoter for the growth of micrometastases. After surgery, the 
immediate intraportal injection of hepatocarcinoma AH130 cells resulted in an increased 
number of hepatic metastases, compared with the control animals that did not undergo liver 
resection. In contrast, tumor cell injection, 2 weeks after major hepatectomy, revealed no 
significant differences, compared with controls. In a third group, the removal of half of the 
caudate lobe resulted in the same number of metastases as in control animals. The authors 
concluded that the promotion of hepatic metastases was increased in the initial period of 
active liver regeneration and was proportional to the volume of hepatectomy [124]. de Jong et 
al. suggest that specific factors and phases involved in liver regeneration may influence the 
growth patterns of residual or dormant micrometastases after 70% liver resection [125]. In an 
animal model of liver metastases after an injection of GFP-transfected CT-26 cells under 
capsula in right lobe, Breitenbuch et al. observed that RFA increased the metastasis of 
residual neoplastic cells compared with resection. The reasons for the neoplastic growth, after 
RFA or liver resection, remain unclear but this model shows the pro-metastatic effect in 
residual intrahepatic neoplastic cells. Possible explanations may involve factors such as the 
immunologic and biological effects of heat trauma [126].  
Togo et al. showed that the incidence of residual liver and lung metatsases increased after a 
two–stage hepatectomy, when a complete resection was not achievable after a single 
hepatectomy [41]. The same result was observed by Elias et al. after portal embolization [127]. 
To confirms the pro-tumoral role of the liver surgery, we created a murine model of major 
liver surgery to test the effects of consequent liver regeneration in the angiogenesis and 
proliferation of PC. To confirms the major incidence of the tumoral growth after 
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hepatectomy, our model was compared to a sham laparotomy and natural history after intra-
peritoneal tumor cells injection.   
Peritoneum: the first-line of defense in carcinomatosis 
The peritoneum acts as a barrier to macromolecules that enter the submesothelial layer and 
reduce the friction between the visceral organs by the secretion of a surfactant phospholipid 
by each mesothelial cell. It consists of a monolayer of mesothelial cells supported by a basal 
membrane that rests on a layer of connective tissue. Laparotomy, laparoscopy, the suture line 
of digestive anastomoses, and surgical dissection, are the most common causes of breaches of 
the peritoneal barrier and, consequently, the most frequent sites of peritoneal implants. 
Because laparotomy stimulates the growth factors associated with the healing phenomena, in 
our animal model, we analyzed the effects of the sham laparotomy on the growths of the 
peritoneal metastases growth.		
In the case of recurrence after abdominal or pelvic surgery, the cancer cells are often free, 
dispersed in the peritoneal cavity, sometimes derived from colic or rectal light and they 
sometimes remain trapped in the anastomotic sites (or in the tissues crushed by the surgical 
resection).There they are trapped in fibrin and their growth is favored by the growth factors 
brought on by platelets, neutrophils and monocytes in the injured sites. The result is a 
peritoneal dissemination of the tumor disease [45,128].  
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1) PART ONE  
 
1a) HYPOTHESIS AND OBJECTIVES 
 
- Scientific methodology 
 
The main objective of this study was to evaluate the effect of hepatic surgery on the growth 
and tumor angiogenesis of peritoneal carcinomatosis. Our hypothesis was that the surgery for 
resection of liver metastases can accelerate the tumor progression of peritoneal 
carcinomatosis. In order to test our hypothesis, we decided to study the growth of peritoneal 
carcinomatosis, in vivo, in murine models of intra-peritoneal grafting of carcinomatosis (CT-
26) on BalbC mice after a major hepatectomy.  
 
A preliminary exsperiment was neccessary to develop a reproductible immunocompetent 
murine model of limited PC to monitor the increase and the proliferation of peritoneal lesions. 
These results are listed in Annex 1. 
 
The secondary objectives were: 
1 - To determine the tumor growth of peritoneal carcinomatosis after hepatectomy 
2 - To verify whether these results in the mobilization of circulating progenitor cells derived 
from the bone marrow (Endhotelial and Hematopoietic progenitor cells) 
3 – To evaluate the effect induced by surgery on the mobilization of these progenitors  
4 - To evaluate the effect of these progenitors on tumor growth.  
The approach taken by my PhD thesis was to design animal models that mimic the natural 
history of human disease, in order to transfer our results to the clinic in a translational way, 
from patients with peritoneal carcinomatosis and synchronous hepatic metastases. 
 
Annex 2 shows the construction of a murine model of liver regeneration. 
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1b) RESULTS AND DISCUSSION 
 
- Article 1 (Original article currently submitted to the EJSO) 
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unknown. Our hypothesis was that LR promotes peritoneal growth resulting 
in a non-resectable PM. We sought to analyse the effects of major LR and 
liver regeneration after hepatectomy in a murine model of PM and the 
associated angiogenesis. 
Methods: murine model of colorectal PM in Balb/C mice was developed by 
intraperitoneal injection of different CT-26 tumour cell concentrations. 
Five days after the injection, mice were randomized into three groups: 
68% hepatectomy group, sham laparotomy and control group without surgery. 
On post-operative days 1, 5 and 20, PM was evaluated macroscopically, 
tumour growth and liver regeneration by immunohistochemistry, and 
angiogenesis by immunofluorescence. Circulating progenitor cells, 
plasmatic cytokines and digestive arterial blood flow velocity 
measurements were also analysed.  
Results:  reproducible murine model of limited colorectal PM was 
obtained. Surgery induced PM increases and promoted neo-angiogenesis. 
Major hepatectomy influenced the tumour growth in the late phase after 
surgery, the extent of extra-peritoneal metastasis and the increase of 
Ki-67 expression in the remnant liver.  
Conclusions: This animal model confirms the pro-tumoural and pro-
angiogenic role of surgery, laparotomy and major LR, which promotes the 
increase of angiogenic factors and their participation in PM growth. 
These results suggest that peritoneal resection should be first step in 
the case of two-step liver and peritoneal surgery for patients with 
colorectal PM and LM. 
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INTRODUCTION 
Curative management of liver metastases (LM) is based on surgical resection. However, in 70% of 
cases, LM will recur despite the use of multimodal and adjuvant chemotherapy1. A recent meta-
analysis by Franko et al. reported an overall survival rate (OS) of 19 months in patients with LM of 
colorectal cancer (CRC) origin2. In the same study, the presence of isolated peritoneal metastases 
(PM) was associated with a worse prognosis than other isolated metastases2. Synchronous LM and 
PM of CRC origin were traditionally considered as a palliative stage and a contraindication to the 
curative surgical approach3-7. Extensive surgery with curative intent has been recently investigated 
as feasible8. For some authors, LM is no longer an absolute contraindication to peritoneal 
cytoreduction9. This aggressive approach is associated with an increased but acceptable rate of 
postoperative severe complications10. No guidelines currently exist concerning the relative timing 
of peritoneal and liver surgery. A recent study reported a nomogram to select patients suitable for 
this complex curative strategy by taking into account the number of LM, the extent of PM and the 
surgery11. However, when curative liver surgery and peritoneal cytoreduction with Hyperthermic 
Intraperitoneal Chemotherapy (HIPEC) cannot be achieved synchronously, the choice of the main 
surgical procedure remains unclear. Traditional systemic chemotherapies are effective at varying 
degrees to control LM but less for PM. Our aim was to evaluate a strategy of liver resection (LR) 
first12. We postulated that the LR, through the consequent liver regeneration process, would 
promote PM growth. The objective of our study was to analyse the effects of major LR and liver 
regeneration on PM growth and the associated angiogenesis process, after hepatectomy in an 
immunocompetent murine model of PM. 
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METHODS 
Cell culture 
Luciferase-expressing CT-26 cells (CT-26luc+) were kindly provided by Prof. Lea Eisembach 
Weizmann (Institute of Science Rehovot, Israel). CT-26luc+ cells were grown as monolayers in 
DMEM culture medium supplemented with 10% foetal calf serum (FCS), 5% antibiotics (penicillin 
and streptomycin), 5% Fungizone and 5% HEPES buffer solution in a humidified incubator at 37°C 
(5% CO2 and 95% air).  
Animals  
The protocol used was approved by Local Ethic Committee (Protocol N° 02095.03). Five-week-old 
murine, hepatitis virus-free, and immunocompetent BALB/c females weighing 20±0.5 g (Charles 
River, Arbresle, France) were housed in our specific pathogen-free compliant animal facility. 
Animals were acclimated for one week before experimentation. Preliminary limited PM model was 
obtained testing the intraperitoneal injection of five different concentrations (5×105, 2.5×105, 
1.25×105, 6.2×104 and 3×104 cells) of CT-26luc+ cells in 1 mL of DMEM culture medium. The 
extension of PM was quantified, post-mortem, using the Peritoneal Cancer Index (PCI) score13 
adapted to tumour sizes in mice14,15. Surgical procedures were performed under isoflurane 
anaesthesia using an oxygen (30%)/nitrous oxide (70%) mixture. After medial laparotomy, partial 
68% hepatectomy was performed by removing three anterior hepatic lobes as previously 
described16. During the procedure, 9% saline solution was administered subcutaneously to prevent 
dehydration. Buprenorphine (0.1 mg/kg) was administered immediately after surgery and every 12 
hours for 48 hours to prevent pain. In separate animal experiments, five days after CT26luc+ 
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injection, mice were randomized into three groups: control animals that only received the CT26luc+ 
cells injection (natural history, NH, n=30), animals subjected to major hepatectomy (liver surgery, 
LS, n=30), and sham laparotomy animals (n=30). The flow charts are shown in Annex 1. Animals 
were euthanized by cervical dislocation. Heparinized blood was obtained by cardiac puncture, and 
liver, lungs, abdominal lymph nodes and peritoneal tissue were collected for analysis. To assess the 
kinetics of tumour growth, after randomization, 10 mice of each group were sacrificed at days 1, 5 
and 20. 
Tissue analysis  
Tissues were immediately fixed overnight in 4% paraformaldehyde and embedded into paraffin or 
directly embedded into optimal cutting temperature compound (OCT, Tissue-tek O.C.T. Compound 
Sakura? München, Germany) to be frozen. Standard Haematoxylin-Eosin (H&E) and 
Haematoxylin-Eosin-Safran (HES) staining were performed on paraffin-embedded tissue sections 
for standard histology and PM analysis, respectively. Ki-67 immunohistochemistry (IHC) was 
performed on frozen tissue sections fixed with ice-cold acetone (90%) using an 
immunohistochemical stainer (Bond Max, Leica Biosystems, Nussloch, Germany) for standardized 
procedure. Ki-67 antibody (ab16667, Abcam) was diluted to 1/200 using the ER1 (citrate, pH 6) 
procedure according to the manufacturer’s instruction. IHC slides were then scanned using an 
Aperio AT Turbo automat. For immunofluorescence, CD31 staining was performed on frozen 
tissue sections using a rat/mouse anti-CD31 primary antibody (1/50, clone MEC13.3, BD 
Pharmingen). Alexa Fluor 488-conjugated goat anti-rat IgG was used as a secondary antibody 
(1/200, Life Technologies). Samples were mounted using Dako Fluorescent Mounting Medium 
(S3023, Dako, Germany). All images were obtained with a Z1 Zeiss microscope (Germany) 
equipped with an Axiocam Icc 1 camera (Zeiss, Germany). Tumour growth was evaluated by 
measuring the mitotic rate/10 high-power fields (HPF)17. Tumour growth was considered as 
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unmodified for ≤2 mitoses/10 HPF and accelerated for ≥5 mitoses/10 HPF. Proliferation was 
measured as the number of Ki-67-positive cells per field over three different fields per sample. Neo-
angiogenesis was evaluated by the number of CD31-positive cells per field over three different 
fields per sample. 
Cytokines 
Plasma was obtained by the centrifugation of heparinized blood at 700 rpm for 30 min at 4°C. 
Plasma samples were frozen at -80°C until use. Plasma levels of IL-6, VEGF-A, sVEGFR-1, TGF-
β, and TNF-α were measured using sandwich immunoassay methods with commercially available 
electrochemiluminescent detection systems, plates and reagents (V-PLEX cytokine Plex kits - 
Meso-Scale Discovery (MSD), Gaithersburg, USA), according to manufacturer’s instructions. 
Other parameters (sVEGFR-2, EGF, sEGFR-1 and HGF) were measured similarly using 
commercially available (R&D) or homemade antibodies. Briefly, 50 μL of diluted plasma were 
loaded per well in the MSD plates. The plates were analysed using the SECTOR Imager 2400. 
Immunoassays of murine ACE were performed on a Cobas e601 analyser. 
Mobilization of circulating endothelial and haematopoietic progenitor cells  
Following haemolysis, bone marrow derived progenitors cells (EPC, Endothelial Progenitor Cells 
and HPC, Haematopoietic Progenitor Cells) previously isolated by centrifugation on a human 
Pancoll density gradient from fresh blood samples, were incubated for 30 min at 4°C with 
fluorescein isothiocyanate conjugated anti-mouse vascular endothelial growth factor receptor 
VEGFR-2 antibody, phycoerythrin (PE)-conjugated anti-mouse CD-34 antibody, fluorescein 
isothiocyanate conjugated anti-CD-45 antibody, or immunoglobulin G isotype controls 
(eBiosciences, Paris, France). The cells were then analysed by flow cytometry using a BD 
Biosciences LSRII flow cytometer (BD Biosciences, Le Pont de Claix, France). The percentage of 
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positive cells in each sample was calculated using Kaluza flow cytometry analysis software 
(Beckman Coulter France S.A.S, Villepinte, France). 
Measurements of blood flow velocities (BFV) 
Ultrasound examinations were performed using an echocardiograph (Acuson S3000, Siemens®, 
Erlangen, Germany) equipped with a 14-MHz linear transducer (14L5 SP) (7.5 MHz) under light 
isoflurane anaesthesia. Mean blood flow velocities (mBFV) in the celiac trunk, and in the superior 
mesenteric artery, were repeatedly, and non-invasively, measured from the first day to the 3rd week 
after surgery, as previously described18-21. 
Statistical analysis 
Results are expressed as the means +/- standard error (SEM). Multiple groups were compared using 
the Kruskal–Wallis test, followed by the pairwise Wilcoxon rank-sum test. P-values for multiple 
comparisons were adjusted using Holm's method. A two-sided P-value <0.05 was considered 
statistically significant. Repeated measures were analysed by one-way ANOVA followed by a post 
hoc unpaired Student’s t-test. The relationship between PCI and mBFV was evaluated using the 
Pearson correlation moment.  Statistical analysis was performed using R, the R foundation software 
(http://www.r-project.org/).  
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RESULTS 
Development of an animal model of limited PM  
To mimic human disease, we developed an animal model of PM in immunocompetent mice 
(Balb/c) by injecting different concentrations of murine CRC-derived CT-26luc+ cells (5×105, 
2.5×105, 1.25×105, 6.2×104 and 3×104 cells). Figure 1A shows a dose-dependent increase in PM 
along the increase in concentration of CT-26luc+. Using 3×104 CT-26luc+ cells, we obtained a 
limited PM at day 15 (PCI < 10) without tumour outgrowth at day 20 that would require the 
euthanasia of the animals for ethical reasons. These results are shown in Annex 2. Therefore, this 
concentration was used hereafter in separated animal experiments. As we anticipated an increase in 
PM growth after partial hepatectomy, we obtained a model of limited PM to be able to study the 
kinetic of tumour growth in these animals.  
PM evolution after partial hepatectomy 
At day 1, there was neither macroscopic nor pathological evidence of PM in any of the three 
groups. However, PM was observed and pathologically confirmed in 60% of the mice at day 5 and 
in 100% of the mice at day 20. At the moment of the randomization, no peritoneal metastases were 
noted in any group. PCI was different among the three groups (p< 0.05, Figure 1B), and there was 
a trend towards a higher PCI in LS mice compared to NH animals (3.2±0.8 vs. 0.5±0.2, p=0.058). 
At day 20, there was no difference among the three groups, although a trend was observed between 
LS and NH groups (p=0.07). However, mitotic count at day 20 showed a marked increase in the LS 
group compared to NH and sham groups (83±8 vs. 10±8 cells/field, p=0.0001 and 83±8 vs. 27±10 
cells/field, p=0.009, respectively), suggesting a higher proliferative index of the tumour after partial 
hepatectomy (Figure 1C). Furthermore, macroscopic analysis of the non-carcinomatosis lesions 
showed that three mice of the LS group exhibited haemorrhagic ascites, and one developed diffuse 
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LM in the remnant lobes (confirmed pathologically). Neither extra peritoneal metastases nor 
haemorrhagic ascites were observed in the other groups. In addition, no macroscopic liver 
regeneration was observed in the LS group, even though Ki-67 labelling was significantly increased 
in the remaining lobes compared to the liver of the two other groups from day 5 onwards (p < 0.05 
for all comparisons, Figure 2 A-D). 
Circulating progenitor cells  
At day 1, early after hepatectomy, there was an increase number of EPC (CD-34+/VEGFR-2+) in 
LS mice (9.98±1.43) compared to NH animals (7.18±2.16, p=0.033, Figure 3A). EPC number 
increased at day 5, and a positive trend towards an increased number of EPC in LS animal was 
observed, although not reaching significance (p=0.075). At day 20, the number of EPC was similar 
and low in all three groups. There was no difference in the number of HPC cells (CD-34+/CD-45+) 
in the three groups at any point in time (Figure 3B).   
Cytokines  
Plasma levels of murine ACE were higher in the LS group compared to the others (NH, p=0.0009 
and sham, p=0.006, respectively). The ACE levels were also higher in the sham group compared to 
the NH group (16.6±1.6 vs. 9.3±0.3, p=0.0001). The results are shown in Figure 4L. VEGF-A, 
sVEGFR-1, sVEGFR-2 were increased in LS mice compared to the two other groups from day 5 
onwards (p<0.05 for all comparisons); the same effect was observed for the pro-inflammatory 
cytokine IL-6. We observed an increased plasma concentration of the growth factors (EGF, sEGFR-
1 and HGF) and TGF-β in the late phase, after hepatectomy, during the hepatic regeneration. There 
was no difference in the TNF-α level among all groups.  
Neo-angiogenesis 
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At day 20, the number of CD31-positive blood vessels was markedly increased in the PM of the LS 
(90±8) and sham (86±6) groups compared to the NH animals (20±7, p<0.005 for each comparison). 
Similar results were observed in the surrounding normal peritoneal tissue. In contrast, the number 
of CD-31 positive cells were reduced in the remaining hepatic lobes of the LS mice compared to the 
NH and sham groups (p<0.05 for each comparison) while similar in all three at day 1 (Figure 5).  
Measurements of blood flow velocities (BFV) with Doppler ultrasound  
The mean BVF (mBFV) in the superior mesenteric artery was equally increased in the NH and LS 
groups from 5.3+/-1.9 to 11.2+/-3.6 cm/s (p=0.0010) at day 20. The mBFV in the coeliac trunk 
remained stable from day 1 to day 20 in the NH group (8.9+/-2.3 cm/s) while decreasing in the LS 
group at day 1 after hepatectomy to 5.2+/-1.8 cm/s (p=0.0077 LS vs NH). Compared to day 1, the 
mBFV of the LS group increased to 9.5+/-2.4 at day 5 (p=0.0105), 12.7+/-1.8 at day 10 (p= 0.0021) 
and 14.0+/- 1.9 cm/s at day 20 (p= 0.0017). There was a strong positive correlation between mBFV 
in the coeliac artery and the PCI (R=0.85, p<0.001). These results are shown in Annex 3.  
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DISCUSSION 
 
Recently, the management of patients with PM and LM of CRC origin has undergone major 
improvements, but the surgical approach with curative intent remains controversial. In the case of 
limited LR, several teams reported concomitant peritoneal and LR22. However, if complex or major 
hepatectomy is required, LR was usually delayed and performed during a second procedure, 
especially in cases of functional parenchyma injured by preoperative chemotherapy. The choice of 
an optimal surgical strategy has been highly debated. Togo et al. showed an increased incidence of 
residual liver and lung metastases after a two-stage hepatectomy, when a complete resection is not 
achievable with a single hepatectomy23; the author suggests the pro-tumoural local and systemic 
effects of the major hepatectomy. Surgical strategies, such as portal vein embolization and two-
stage hepatectomy involving liver regeneration, may also be associated with stimulation of tumour 
growth24. Elias et al. have shown that the growth rate of LM may increase eight folds compared to 
normal liver parenchyma after portal vein embolization, suggesting that the process of regeneration 
has a significant proliferative effect on tumour cells25. Consistent with these previous results, we 
observed that indirect parameters were significantly increased after LR that was not observed after 
the sham laparotomy. These results suggest that liver surgery should not be the first procedure 
performed in patients with LM and PM of CRC origin. After hepatectomy, cellular and molecular 
changes secondary to liver regeneration may influence the kinetics of tumour growth26-28 and 
contribute to extra-hepatic and hepatic recurrences29. It is well established that major LR, and 
consequently liver regeneration, results in an increased secretion of cytokines, such as IL-6, and 
angiogenic factors, such as VEGF, that alter the microenvironment of distant dormant tumour 
deposits. Growth factors such as HGF, EGF, TGF-α and TGF-β play an essential pivotal role in 
liver regeneration and induce changes in the microenvironment that stimulate intrahepatic tumour 
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growth30. In this study, the plasmatic concentration of angiogenic cytokines and growth factors 
reflected the stimulation of liver regeneration with an increase of VEGF and EGF receptors in the 
proliferative phase followed by the peak of the angiogenic cytokines and growth factors ligands 
(IL-6, VEGF, EGF, HGF). We found that the presence of a high concentration of angiogenic 
markers correlated with the high propensity of tumour recurrence in the LS group compared to the 
sham and NH groups. Furthermore, in preclinical models, the recruitment of EPC contributes to 
tumour growth, metastases formation and is closely related to the plasmatic level of angiogenic 
cytokines31. After partial hepatectomy, the levels of EPC increase instantaneously32. Consequently, 
the present study shows an increase in EPC recruitment at day 1 after hepatectomy with a peak at 
day 5 in the LS group compared to non-liver injured group, confirming the pro-angiogenic role of 
LR and the direct effect of high plasmatic concentration of angiogenic markers. The extent of 
hepatectomy appears to be an important factor influencing the tumour growth, incidence and 
volume of recurrence33-35. We have chosen a model of major hepatectomy to mimic the human 
tumour. Prior results reported that in the mouse model of LM of CRC origin, 70% partial 
hepatectomy induced a superior tumour growth and extent of extra-hepatic metastases greater than 
37% hepatectomy35,36. Castillo et al. found that a small 42% LR was associated with a significantly 
increased survival in mice and did not produce enough growth factors to stimulate tumour growth37. 
After major hepatectomy, it seems that the liver produces higher levels of growth factors and 
cytokines to restore functional liver parenchyma than the cases of smaller hepatectomies38,39. In our 
study, the effect on the growth of PM after major hepatectomy, consistent with previous studies, 
was associated with an increase in macroscopic PCI. Moreover, plasmatic concentration of growth 
factors was higher after liver surgery than plasmatic levels in non-injured groups. In the currently 
study, we focused our analyses only on the effects of LR on the PM growth. However, to test the 
effects of the peritoneal surgery on the LM growth, we needed to develop a limited LM model, 
preferably localized in the same hepatic lobe. At the moment, this model has not been described in 
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the literature. A possible solution could be to test the ALPPS (Associating Liver Partition and Portal 
Vein Ligation for Staged Hepatectomy) technique40 to divide the liver parenchyma before the 
implant of LM. In the mouse, such a complex surgical model is probably associated with a high 
mortality rate. The surgical trauma and concomitant wound-healing process induces local and 
systemic reactions resulting in acceleration of tumour development41-44. Injury in the peritoneum 
barrier increases exfoliated or free-floating peritoneal tumour cells developing or growing into 
secondary malignancies with an increased adhesion of peritoneal implants45. Previously, animal 
models demonstrated that injury sites are a preferred location for tumour recurrence and surgical 
trauma enhances loco-regional metastasis46-50. Interestingly, the influence of surgery on tumour 
development was not limited to local peritoneal locations. Raa et al. showed that in animal models 
with intraperitoneally injected CRC cells, the thoracotomy enhanced tumour development in the 
peritoneal cavity51. The severity of trauma was shown to correlate with the tumour load, as 
laparoscopy (causing minor trauma) induced less loco-regional tumour load compared with 
laparotomy41. In agreement with previous results, in our study, the sham laparotomy induced a 
significant increase in the PCI compared to the other groups in the early stage after surgery. 
However, the hepatectomy induced an increase in PM in the LS group at day 20. Previously, Leen 
et al. showed that LM were associated with an increased ratio of hepatic arterial to total liver BFV 
measured by Colour Doppler Ultrasonography, which suggests that the measurement of changes in 
liver BFV could be used to detect the presence of occult metastases52 and to identify patients at high 
risk of hepatic recurrence53. In this study, coeliac trunk mBFV changes according with the phases of 
liver regeneration: BFV was decreased at day 1, due to the reduction in liver mass and was 
significantly increased in the late phase after hepatectomy, indicating liver regeneration. The 
analysis of the curvilinear regression between coeliac trunk mBFV and the PCI demonstrated 
proportional changes. This result reflects that the extension of neo-formed tumour vascular 
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networks of PC nodules branched and implanted on the native liver vascular network was enhanced 
after hepatectomy.  
 
CONCLUSIONS 
 
Experimental evidence suggests that liver regeneration may stimulate residual micro- and macro-
metastatic disease. In our PM animal model, LR resulted in an increase in PM without macroscopic 
liver regeneration. This animal model confirms the pro-angiogenic role of hepatectomy, which 
promotes the increase of EPC and their participation in the growth of PC. A clear understanding of 
the underlying processes suggests that peritoneal resection should be the first step in the case of 
two-step liver and peritoneal surgery for patients with colorectal PM and LM to minimize the risk 
of PM growth until a non-treatable stage. 
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FIGURE LEGENDS 
 
Figure 1. 
 
A. Peritoneal Cancer Index (PCI) scores in function of different concentrations of murine CRC-
derived CT-26luc+ cells injected: 5×105, 2.5×105, 1.25×105, 6.2×104 and 3×104 cells.  
B. Macroscopic PCI scores in function of the three groups at different times.  
C. Number of mitosis in function of the groups at different times. 
NH, natural history; LS, liver surgery; PCI, Peritoneal Cancer Index;  
Sham, sham laparotomy. 
A two-sided P-value <0.05 was considered statistically significant (*p<0.05; ** p<0.01). 
 
Figure 2. 
 
A. Cellular proliferation: Ki-67 expression in different tissues (magnification x40). 
B. Ki-67 expression rate in function of the three groups at different times in the carcinomatosis 
nodules. 
C. Ki-67 expression rate in function of the three groups at different times in the remnant liver 
parenchyma. 
D. Ki-67 expression rate in function of the three groups at different times in the normal 
peritoneum tissue. 
NH, natural history; LS, liver surgery; Sham, sham laparotomy. 
A two-sided P-value <0.05 was considered statistically significant (*p<0.05; ** p<0.01). 
 
Figure 3. 
 
The plasmatic concentration of progenitor Derived Bone Marrow Cells (DBMC) in function 
of the three groups at different times. A. Endothelial progenitor cells (EPC). B. 
Haematopoietic progenitor cells (HPC). 
NH, natural history; LS, liver surgery; Sham, sham laparotomy. 
A two-sided P-value <0.05 was considered statistically significant (*p<0.05; ** p<0.01). 
 
Figure 4. 
 
The plasmatic concentration of the cytokines in function of the three groups at different 
times. A. Vascular endothelial growth factor (VEGF). B. Vascular endothelial growth factor 
receptor 1 (VEGFR-1). C. Vascular endothelial growth factor receptor 2 (VEGFR-2). D. 
Epithelial growth factor (EGF). E, Epithelial growth factor receptor 1 (EGFR-1). F. 
Interleukin 6 (IL-6). G. Hepatic growth factor (HGF). H. Tumour necrosis factor alpha 
(TNF-α). I. Tumour growth factor beta (TGF-ß). J. Hypoxia-inducible factor 1 alpha (HIF-
1α). K. Placental growth factor (PlGF). L. Carcinoembryonic antigen (CEA).  
NH, natural history; LS, liver surgery; Sham, sham laparotomy. 
A two-sided P-value <0.05 was considered statistically significant (*p<0.05; ** p<0.01). 
 
Figure 5. 
 
A. Angiogenesis: expression of vascular CD-31 in different tissues (magnification ×40). 
B. Vascular CD-31 expression rate in function of the groups at different times in the 
carcinomatosis nodules.  
C. Vascular CD-31 expression rate in function of the groups at different times in the 
remnant liver parenchyma.  
Figure legend(s)
D. Vascular CD-31 expression rate in function of the groups at different times in the normal 
peritoneum tissue (D). 
NH, natural history; LS, liver surgery; Sham, sham laparotomy. 
A two-sided P-value <0.05 was considered statistically significant (*p<0.05; ** p<0.01). 
 
Annex 1. 
Flow charts of the development of a murine model of PM and liver regeneration. (A) 
Five days after CT26luc+ injection, mice were randomized into three groups: control 
animals that only received the CT26luc+ cells without surgery (natural history, NH, 
n=30), animals subjected to major hepatectomy of 68% of liver parenchyma (liver 
surgery, LS, n=30), and sham laparotomy animals (n=30). 
(B) After randomization, the results were analysed on post-operative days 1, 5 and 20. 
PM were evaluated macroscopically (PCI; presence of ascites). Tumour growth and liver 
regeneration were evaluated by immunohistochemistry (Ki-67 expression rate and 
number of mitosis in cancer cells). The angiogenesis was evaluated by 
immunofluorescence (CD31+ expression rate in cancer cells), circulating progenitor 
cells, plasmatic cytokines and digestive arterial blood flow velocity measurements. 
PM, peritoneal metastases. PCI, Peritoneal Cancer Index. 
 
 
Annex 2. 
The logarithmic correlation between the increase of PCI and the different concentrations 
of tumoural cells injected in the peritoneal cavity of the murine model. In a previous part 
of this experimental study, an intra-peritoneal injection of 1 mL of decreasing 
concentrations of CT-26luc+ cells was performed in 5-week-old mice on day 0 on a total 
of 25 mice (5 in each group): 5×105, 2.5×105, 1.25×105, 6.2×104 and 3×104 cells. To 
reduce the number of animals, we constructed our murine model with 5 mice in each 
group. The animals were euthanized by cervical dislocation on day 20 for ethical 
reasons. The results obtained from our murine model demonstrate a tumour graft rate in 
all mice with variable scores in the different groups: limited PM extent without ascites 
was found in group 1 (mean PCI=10, range 6–15); a moderate carcinomatosis was 
obtained in group 2 (mean PCI=15, range 1–27); extensive carcinomatosis associated 
with the presence of ascites was observed in groups 3, 4 and 5 (mean PCI=26, range 7–
39; mean PCI=32, range 12–39; mean PCI=34, range 12–39, respectively). 
PM, peritoneal metastases; PCI, Peritoneal Cancer Index 
 
Annex 3.  
The sequential digestive arterial blood flow velocity measurements in function of two 
groups (LS, liver surgery; NH, natural history). (A) Mean BFV in the superior 
mesenteric artery. (B) Mean BFV in the coeliac trunk. (C) Mean BFV in the coeliac 
trunk followed proportional modifications of PCI, reflecting the extension of the newly 
formed tumour vascular networks branched off the native liver vascular network boosted 
after hepatectomy.  
A two-sided P-value <0.05 was considered statistically significant (*p<0.05; ** p<0.01).  
** p<0.01 LS vs NH groups at the same time point. # p<0.05; ## p<0.01 vs day 1. 
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1c) ANNEX 1: Preliminary study (not published) 
METHODS 
- Animals 
- Maintenance of colon cancer cell lines 
- Construction of a murine model of limited peritoneal carcinomatosis 
- Bioluminescence 
- Peritoneal Cancer Index (PCI) scores in mice 
RESULTS 
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METHODS 
To mimic human situations, and to evaluate PC growth, an immunocompetent animal model of 
limited murine PC was constructed by intraperitoneal injection of CT-26luc+ cells.  
 
Animals  
Mice, immunocompetent BALB/c 5-week-old females weighing 20 ± 0.5 g, of controlled origin 
(Charles River, Arbresle, France), were housed in an animal laboratory. The laboratory is approved 
by the ministry Agriculture and Fisheries under the aegis of the Departmental Directorate of 
Veterinary Services, and their health checks have validated the presence of SPF mice (free of 
pathogen-specific) especially concerning the absence of virus murine hepatitis. The animals were 
acclimated for one week before experimentation and used in accordance to the guidelines of the 
European Ethics Committee (Decree No. 2001-131 of 6 February 2001, related to 86-609-EEC 
European directive 1986, Project n° 02095.03) as well as the national charter on ethics of animal 
experimentation established in 2008 (www.enseignementsup-recherche.gouv.fr).  
 
Derivation and maintenance of colorectal cancer cell lines 
The CT-26 cell line is derived from a BALB/c mouse colorectal tumor. CT-26 cells have been 
transfected with a gene coding for luciférase (luc+) and kindly provided by Prof. Lea Eisembach 
Weizmann (Institute of Science Rehovot, Israel). CT-26luc+ cells are grown in monolayers with 
DMEM culture medium supplemented with 10% fetal Calf serum (FCS), 5% antibiotic (penicillin 
and streptomycin), 5% Fungizone and 5% of HEPES buffer solution, in an incubator at 37°C (5% 
CO2 and 95% air).  
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RESULTS  
 
The results obtained from our murine model demonstrate a tumor graft rate in more than 99% of the 
mice with variable scores in the different groups: limited PC extent without ascites was found in 
group 1 (mean PCI=10, range 6-15); a moderate carcinomatosis was obtained in group 2 (mean 
PCI=15, range 1-27); Extensive carcinomatosis associated with the presence of ascites was 
observed in groups 3, 4 and 5 (mean PCI=26, range 7-39; mean PCI=32, range 12-39; mean 
PCI=34, range 12-39, respectively). The control group did not show carcinomatosis. Weight was 
calculated every 5 days and the presence of ascites at the euthanizing of the mouse. Statistically 
significant differences found between the groups are showed in the Table 1. 
 
 Group 1 
5 x10
5
 cells  
Group 2 
2.5x10
5
 cells  
Group 3 
1.25x10
5
 cells  
Group 4 
6x10
4
 cells  
Group 5 
3x10
4
 cells  
 
p 
Carcinomatosis  
(at day 15) 
100% 100% 100% 100% 100% ns 
Median PCI   
<10 
10-20 
>20 
34 
1 
0 
4 
32 
1 
0 
4 
26 
1 
1 
3 
15 
2 
1 
2 
10 
3 
2 
0 
0,0284* 
Weight (gr) 26,2 24,8 22 18,8 19,8  0,014 * 
CEA (ng/ml) 34,4 38,8 19,24 8,32 3,62 0,022* 
Ascitis 3 4 4 4 3 ns 
Liver metastases 0 1 0 0 0 ns 
Death 3 1 0 0 0 ns 
 
Table 1: The results from a murine model of peritoneal carcinomatosis obtained with intraperitoneal injection of 
different tumor cell concentrations. 
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We performed a non-invasive evaluation of kinetics of the PC progression by bioluminescence. We 
established a reproducible murine model of limited peritoneal carcinomatosis with a mean PCI <10 
on day 15 by an intraperitoneal injection of 3×104 cells CT-26Luc+.  This concentration was 
retained for further experimentations. 
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1d) ANNEX 2: Preliminary study  
METHODS 
- Construction of a murine model of liver regeneration 
RESULTS 
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During the procedure, a 9% saline infusion (4-5ml) was administered subcutaneously to prevent 
dehydration due to evaporation during laparotomy. An injection of Buprenorphine (0.1 mg/kg) was 
administered after surgery and then repeated every 12h for a 48h period.  
Five days after injection of CT26luc+ cells, the animals were randomized into three groups: in the 
Liver Surgery group (LS), the animals underwent 68% liver resection (as previously described); in 
the second group, animals underwent a sham laparotomy (Sham); in the control group, the animals 
received only injections of intraperitoneal cells, without any other injuries (Natural History, NH).  
 
 
Fig.8: Liver anatomy, hepatic segments  
Partial hepatectomy includes resection of 3 anterior lobes (fig. B-C): right upper lobe (RUL 18%), left upper lobe (LUL 
15%) and lower left lobe (LLL 35%), above 7 total lobes (fig. A): RML, right median lobe; RLL, right lower lobe; CL, 
caudate lobe, CLL Caudate lower lobe. 
 
 
To evaluate neo-angiogenesis and tumor growth, histological and biological analyses were 
performed. Mitosis count, carried out by Ki-67 marker proliferation, and microvessel density, using 
a CD-31 endothelial cell marker, were performed in the peritoneal tumor nodules, peritoneal normal 
tissue, epiploon and remnant liver tissue. Local vascular modification of neo-angiogenesis was 
quantified using the Doppler index for measurements of blood flow velocities (BFV). Systemic 
effects of angiogenesis and liver regeneration were quantified using cytokines plasmatic levels and  
A B C 
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by monitoring the circulating progenitor BMDC mobilization. The Doppler index and the 
monitoring of the mobilization methods for the circulating progenitor BMDC are detailed in article 
1. All experiments were carried out on the three groups on days 1, 5 and 20 after randomization. 
 
RESULTS 
The results of this experiment are described in the Article 1, that currently being submitted to the 
EJSO 
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2) PART TWO 
2a) HYPOTHESIS AND OBJECTIVES 
- Clinical methodology 
In the second part of our study we propose an aggressive approach for patients with concomitant 
liver and peritoneal metastasis from colorectal cancer, traditionally considered a 
contraindication to any surgical approach because the disease is considered to be too advanced. 
This multi-center study is the largest sampling of selected patients with peritoneal 
carcinomatosis from colorectal cancer and simultaneous liver metastasis treated with 
cytoreduction, liver resection and HIPEC.  
An international database was created by the La Sapienza Department of Surgery in Rome and 
the BIG-RENAPE group, which brings together French surgical centers specializing in 
peritoneum pathology. The database has collected 161 cases of combined surgeries with 
hepatectomy and peritoneal resections with CHIP. The agreement of the Scientific Council of 
the BIG-RENAPE was obtained to analyze the databases.  
At first, the international series was analyzed retrospectively: Early and long-term outcomes 
were evaluated to select significant clinical prognostic factors. The present study shows that, in 
expert centers, an aggressive management of multi-metastatic colorectal cancer is feasible, and 
safe, with an acceptable morbidity rate of 15% and no postoperative mortality.   
There are currently no specific criteria to select patients with the highest potential for surgical 
success, nor guidelines concerning the timing of peritoneal and liver surgery. This paper can be 
a valuable aid in selecting those patients.  
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The preliminary results of this study have been submitted and accepted by the 2016 ASCO 
Annual Meeting (Abstract N° 3558; Subcategory: Advanced Disease, Category Gastrointestinal 
(Colorectal) Cancer; Citation: J Clin Oncol 34, 2016 (suppl; abstr 3558)). The original article is 
in the process of submission to the Annals of Surgery. 
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2b) RESULTS AND DISCUSSION 
- Abstract N°3558 May 2016 Journal of Clinical Oncology (ASCO 2016) 
- Article 2 (currently submitted to the Annals of Surgery) 
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ABSTRACT N°3558 May 2016 Journal of Clinical Oncology (ASCO 2016) 
 
Curative treatment for patients (pts.) with synchronous liver metastases (LM) and 
peritoneal carcinomatosis (PC) of advanced colorectal cancer (aCRC): A multicenter 
study of the French Association of Surgery. 
Rea Lo Dico, Guillaume Passot, Diane Goere, Clarisse Eveno, Francois Quenet, Marc 
Pocard; Assistance Publique–Hôpitaux de Paris, Hôpital Lariboisiere, Paris, France; 
Centre Hospitalo-Universitaire Lyon Sud, Lyon, France; Institut Gustave Roussy, Villejuif, 
France; Institut de Cancerologie Montpellier, France 
 
Abstract: 
Background: Aggressive surgical approaches combining hepatectomy associated to 
peritoneal resection with curative intent remain controversial in such a setting and almost 
no data are available on such patients. Pts with synchronous PC and LM are generally 
considered for exclusive systemic palliative chemotherapy. 
 
The aim of this prospective cohort was to assess morbidity, mortality, disease-free survival 
(DFS) and overall survival (OS) of peritoneal and liver metastasis of aCRC patients (pts.) 
treated with an aggressive therapeutic approach combining surgical treatment of liver and 
peritoneal lesions followed by hyperthermic intraperitoneal chemotherapy (HIPEC).  
 
Methods: All patients registered in the French Association of Surgery prospective 
database with PC and synchronous LM who had undergone cytoreductive surgery and LM 
resection followed by intraperitoneal hyperthermic chemotherapy were analysed. The 
primary endpoint was survival from the time of surgery. 
  
Results: From 1993 to 2015, 146 pts. with PC and LM were analyzed. This is the largest 
series actually reported. After a mean follow-up of 36 months, the median OS and DFS, 
were respectively 27,2 and 9.5 months. Postoperative morbidity and mortality was 14.8 
and 0%, respectively. In pts. with a complete cytoreductive surgery OS was 29 months 
(n=), as compared to 4 months in pts. (n=) with incomplete cytoreduction (p=0.0001). 
Rectal primary tumor, PCI of 13 or more, pN+ status, and more than 3 LM were not 
identified as independent factors for poor OS.  
 
Conclusions: This multicenter study confirms that prolonged survival can be achieved 
in selected patients suitable for PC and LM surgery if they underwent multimodality 
treatment including surgical treatment of PC and LM with curative intent, using 
intraperitoneal chemotherapy.  
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MINI-ABSTRACT 
Aggressive surgical approaches combining liver resection and peritoneal cytoreduction with 
curative intent remain controversial. The aim of this prospective multicenter study was to 
assess morbidity, disease-free survival and overall survival of patients with PC and LM of 
CRC treated by combining LR with CRS followed by hyperthermic intraperitoneal 
chemotherapy. 
MiniAbstract
ABSTRACT  
 
Background: Synchronous peritoneal carcinomatosis (PC) and liver metastases (LM) of 
colorectal cancer (CRC) are usually treated with palliative systemic chemotherapy. 
Aggressive surgical approaches combining liver resection (LR) and peritoneal cytoreduction 
(CRS) with curative intent remain controversial.  
Objective: The aim of this prospective multicenter study was to assess morbidity, disease-
free survival (DFS) and overall survival (OS) of patients with PC and LM of CRC treated by 
combining LR with CRS followed by hyperthermic intraperitoneal chemotherapy (HIPEC). 
Methods: From 1993 to 2015, 161 patients underwent LR with CRS and HIPEC of curative 
intent in 18 centers were prospectively registered and analyzed. One hundred and thirty-three 
patients had simultaneous LR with CRS, 13 had two-stage surgery (peritoneal followed by 
subsequent LR).  
Results: After 24-month mean follow-up, the median OS and DFS were 32.32 [95%CI: 
24.57–40.06] and 10.13 [95%CI: 8.85–11.41] months, respectively. The mean number of LM 
was 2 [range: 1–15]. Postoperative grade III–IV morbidities occurred in 14.9% with no 
postoperative mortality. Peritoneal carcinomatosis index >12/39 (aHR 1.67; 95%CI 1.05-2.66, 
P=0.03) was identified as the only independent prognostic factors for OS. Completeness of 
cytoreduction and number of LM>3 were two independent predictive factors (aHR=1.99; 
95%CI: 1.02-3.89, P=0.04 and aHR=3.32; 95%CI: 1.67-6.63, P=0.001, respectively) for DFS. 
Simultaneous LR with CRS was associated with longer hospital stays compared to two-stage 
surgery (24 vs 15 days, P=0.02). The number of LM and the type of LR did not influence the 
rate of postoperative complications. 
Conclusion: This multicenter study is the largest series, to date, confirming the feasibility of 
combined LR with CRS and HIPEC in selected patients with LM and PC of CRC, resulting in 
32 months median OS with limited morbidity. 
Structured Abstract
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INTRODUCTION 
 
Liver metastases (LM) occur in 25–40% of patients with colorectal cancer (CRC).1 Long-term 
outcomes of patients undergoing systemic chemotherapy (CTH) alone is poor, with a median 
overall survival (OS) of 16 months reported in the Cairo trial,2 and up to 31 months achieved 
with treatment intensification as shown in the TRIBE trial.3 A recent meta-analysis by Franko 
et al. reported an OS of 19 months in patients with LM of CRC.4 Curative management of 
LM is based on surgical resection, although, in 70% of cases, LM will recur despite the use of 
multimodal and adjuvant CTH.1 
Peritoneal carcinomatosis (PC) occurs in 8–20% of patients with CRC at the time of 
diagnosis,5-8 and is associated with poor survival as low as 6 months if left untreated.9 The 
presence of isolated PC in patients with CRC is a prognostic factor of poor OS compared with 
isolated non-peritoneal metastasis.4 Using modern systemic CTH, modest improvements in 
survival can be achieved in 12–16 months.4,5,10,11 Cytoreductive surgery (CRS) with 
intraperitoneal chemotherapy, including hyperthermic intraperitoneal chemotherapy (HIPEC) 
is increasingly accepted as the only potentially curative treatment for PC of CRC origin, 
achieving a mean disease-free survival (DFS) of 18 months, an OS mean of 27 months12 and 
an OS of up to 63 months has been reported in highly selected patients.13 
Synchronous LM and PC from CRC is traditionally considered a contraindication to any 
surgical approach as the disease is thought to be too advanced.14-18 However, smaller pilot 
series have reported prolonged survival after management of synchronous colorectal LM and 
PC, reaching up to 3 years in selected patients.19-26 These suggest that LM is not an absolute 
contraindication to peritoneal CRS and that a curative surgical management of LM and PC 
may indeed be possible.27-29 However, to date, no standard management pathway has been 
established for patients with simultaneous LM and PC, especially if a major hepatectomy and 
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an extensive peritoneal CRS have to be performed. Moreover, there are currently no specific 
criteria to select patients with the highest potential for surgical success, nor guidelines 
concerning the timing of peritoneal and liver surgery. 
The aim of this study was to analyze a prospectively maintained multi-institutional database 
in order to describe and assess the early outcomes (morbidity/mortality, hospital length of 
stays) and long-term results (DFS and OS) of CRC patients undergoing liver resection (LR) 
and peritoneal CRS with HIPEC for concomitant PC and LM. The secondary aim was to 
identify potential factors, related to poorer outcomes, in order to establish a basis to guide the 
management of these patients, optimizing the selection of candidates for surgical treatment 
and determining the best sequence of surgical procedures. 
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PATIENTS AND METHODS 
Patients 
A prospective multi-institutional database was established using the French BIG-RENAPE 
database network for colorectal PC and the Italian database from “La Sapienza” University of 
Rome. The French network was developed for collecting the data of all French surgical teams 
performing CRS and HIPEC for primary digestive cancers.30 This study was carried out in 
accordance with the precepts established by the Helsinki Declaration. Using the BIG-
RENAPE and the Italian databases, we identified all patients treated with LR and CRS with 
HIPEC between 1993 and 2015 for PC from CRC origin in 17 French, and one Italian, 
centers. Among these, we identified 161 consecutive patients who had concomitant PC and 
LM and who underwent LR combined with complete CRS and HIPEC. To be included in the 
present study the following criteria were established: patients who had undergone complete 
CRS, HIPEC and LR, with pathological examinations confirming liver and peritoneal 
metastases from CRC origin. The exclusion criteria were non-CRC origin (appendiceal, 
gynecological and peritoneal primary malignancies). Ovarian metastases were considered a 
manifestation of peritoneal disease.31 
 
Standardized Data Collection 
All background clinical, histological, operative and postoperative data for this study were 
prospectively collected and entered into a standardized central electronic database. 
Simultaneous resection was defined as LR during the same operation for PC and separate 
procedures were defined as two-staged. Pre-HIPEC CTH complications were graded 
according to the National Cancer Institute’s Common Toxicity Criteria.32 Postoperative 
complications at 30 days, or until hospital discharge, were graded according to the Dindo-
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Clavien criteria.33 The follow-up period was measured until recurrence for disease free 
survival (DFS) and until death for overall survival (OS).  
 
Surgical Procedure 
The extent of PC was assessed by intraoperative examination and defined according to 
Sugarbaker’s Peritoneal Carcinomatosis Index (PCI).34 The completeness of cytoreduction 
(CCR-) score was used to define the volume of PC remaining in the abdomen after CRS, as 
previously described.34 
HIPEC was administrated after completion of CRS using an open coliseum or closed 
technique according to the team’s preference, to deliver the chemotherapy agent at 42-43°C 
for 30-90 min in a closed circuit. The drugs employed were oxaliplatin or mitomycin C, as 
previously described.12,35 
LR was performed according to the principles of oncologic radicality. Minor hepatectomy 
was defined as any LR of less than three hepatic segments, including atypical resection 
(metastasectomy, segmentectomy and bisegmentectomy) and radiofrequency ablation (RFA) 
for lesions measuring less than 2.5 cm and located far from the main vessels according to 
each team’s preference. Major hepatectomy was defined as the LR of at least three hepatic 
segments. The general approach across the centers was that patients requiring minor 
resections had concomitant LR and peritoneal CRS, whereas in some cases major LR was 
postponed to be performed after CRS and HIPEC. 
 
Endpoints 
The primary endpoints of the analyses were DFS and OS. DFS at 3 years, defined as the time 
from CRS and HIPEC surgery to relapse, or death, whichever occurred first. Second 
colorectal cancers are considered as DFS events, whereas non-colorectal tumors are to be 
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disregarded in the analyses. OS was defined as the time from CRS and HIPEC surgery to the 
time of death due to any cause. In the case of a two-staged procedure, the CRS procedure date 
was considered as the first treatment day. The secondary endpoints were completeness of 
surgical resection, postoperative morbidity/mortality, and duration of hospital stay. 
Postoperative morbidity/mortality was defined according to the Dindo-Clavien 
classification.33 All in-hospital complications were included.  
 
Statistical Analysis 
Categorical data were compared by the χ2 test or the Fisher exact test. For continuous data, 
the independent-samples t-test was used. Survival rates were estimated using the Kaplan-
Meier method. The long-rank test was used to compare survival curves. Follow-up 
information was available for all patients included in the study until death or censored from 
31/12/2015 onwards. Date of tumor recurrence was not available for 20 patients (12.4%). 
Univariate analyses were conducted using a Cox proportional hazard model to identify 
potential prognostic factors of survival. To take into account confounders of survival analysis, 
a multivariate analysis was performed using a Cox proportional hazards model with forward 
stepwise selection of covariates and with entering and removing limits of P<0.10 and P>0.05. 
All statistical analyses were performed using SPSS, version 20.0 (SPSS Inc, Chicago, IL).  A 
P-value <0.05 was considered significant.  
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RESULTS 
 
 
Patient Characteristics 
One hundred and sixty–one consecutive patients from 18 centers were included, 84 of which 
were female (52.2%). The mean age was 56.5 years (SD: 11.1, range, 26-88 years). 
Karnofsky Performance Status was 0-1 in all patients. Patient characteristics are summarized 
in Table 1. Primary tumor locations were the right colon (29.2%), left colon (59.6%), and 
rectum (6.2%). Primary tumors were well differentiated in 52 patients (32.3%), moderately 
differentiated in 70 (43.5%) and poorly differentiated in 10 (6.2%). Differentiation was 
unknown/not reported in 29 cases (18.0%). Lymph node status of the primary tumor was 
recorded for 141 patients (87.6%) being positive in 104 patients (64.6%) and negative in 37 
(23.0%). One hundred and thirty–eight patients (85.7%) were treated with preoperative 
systemic CTH.  
 
Treatment Related Data 
Mean PCI was 9.8 (SD: 7.3, range, 0-39), being ≤12 in 106 patients (data was missing for 5 
patients). A complete CRS (CCR-0) was achieved in 144 patients (89.4%), with a CCR-1 in 
14 (8.7%) and CCR-2 in 3 patients (1.9%). No CCR-3 was reported. The mean number of LM 
was 2 (SD: 1.80, range: 1–15). For 75 patients (46.6%) the LM were synchronous of the 
primary tumor, and metachronous in 71 patients (44.1%). Major LR was performed in 28 
patients (17.4%); 117 patients (72.7%) were treated with limited resections: 92 hepatic 
wedges, 12 hepatic wedges with RFA, 12 RFA alone and 1 hepatic wedge with RFA and 
intra-arterial chemotherapy. One hundred and thirty-three patients (82.6%) underwent LR 
simultaneously with CRS and HIPEC, whereas thirteen had a two-staged procedure (8.1%). 
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Early Outcome 
Forty-height complications were observed: abdominal complications (bleeding (n=6), 
abscesses (n=4), anastomotic (n=9) or bilio-pancreatic leaks (n=4), pancreatitis (n=4), 
gastroparesis (n=2), cardiac complications (n=2), respiratory complications (acute respiratory 
distress (n=2), pneumonia (n=7), pleural effusion (n=11), and hematological toxicity (n=12). 
Severe postoperative morbidity (grades III-IV) occurred in 14.9% (n=24). Surgical 
interventions for complications were required in 13 patients (8.1%). The mean hospital stay 
duration was 23 days (SD: 12.5, range, 8-87 days). No postoperative mortality occurred. 
Simultaneous CRS and LR was associated with a longer postoperative hospital stay than two-
staged surgery (24 (SD: 13.1) vs.15 (SD: 5.8) days, respectively, P=0.02). The number of LM 
and the type of LR were not identified as being associated with the frequency of severe 
postoperative complications (Table 2).  
 
Long-term Outcome 
The mean follow-up was 24 months (range, 0.2 to 102 months). For patients with complete 
data (n=156), median OS was 33 months (range, 0.2 to 102 months), with 1-, 3- and 5-year 
OS rates being 87%, 45%, and 25% respectively (Fig. 1A). Seventy-nine (49%) of the 161 
patients died during the follow-up period. For patients with complete data (n=141), the 
median DFS was 10.1 months (range, 0.3 to 56 months) with 1-, 2- and 3-year DFS rates 
equating to 44%, 17%, and 8% respectively (Fig. 2A). One hundred and twenty-four patients 
had cancer recurrence (87.9%) during the follow-up: 19 patients (13.5%) had peritoneal 
recurrence, 37 patients (26.2%) had extra-peritoneal recurrence and 46 patients (32.6%) had 
both. Site of recurrence was unknown in 22 patients (15.6%). Among patients with extra-
abdominal recurrences, 44 (31.2%) had pulmonary metastases. Among patients with DFS 
available, relapse occurred within the first year in 74 patients (52.5%). On univariate analysis, 
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more than 3 LM and Grade III–IV postoperative complications were identified as prognostic 
factors for lower DFS (Table 3). However, on multivariate analysis, more than 3 LM and 
CCR-1 resection were the only independent predictive factors for decreased DFS (adjusted 
Hazard Ratio [aHR]: 3.32, 95%CI: 1.67-6.63, P=0.001 and aHR: 1.99, 95%CI: 1.02-3.89, 
P=0.04, respectively) (Table 3). Kaplan-Meier curves of all DFS patients, stratified by 
number of liver metastases, are shown (Fig 1A, B).  
On univariate analysis, male sex, PCI >12 and CCR-1 resection were identified as prognostic 
factors for lower OS (Table 4). On multivariate analysis, PCI >12 was the only independent 
predictive factor of decreased OS (aHR 1.67, 95%CI 1.05–2.66, P=0.03). Kaplan-Meier 
curves for OS of all patients and stratified by PCI are shown (Fig 2A,B). 
  
 12 
 
DISCUSSION 
 
Management of patients with liver and peritoneal metastases from CRC has undergone major 
improvements. Whereas OS did not exceed one year with classic systemic CTH based on 5-
FU,36 oxaliplatin and targeted therapies such as anti-angiogenic or anti-EGFR antibodies (for 
wild type RAS) have allowed extending the OS up to 2 years in selected patients.4,22,37 Recent 
studies have suggested that resection of liver and peritoneal metastases combined with HIPEC 
may increase OS up to 3 years, despite an increased risk of morbidity.21,25 Recently, the 
combination of three systemic CTH agents (FOLFOXIRI regimen) have shown an increase 
OS in metastatic CRC compared to classical CTH regimens3 for several months and achieve 
OS similar to extensive surgery. However, the incidence of serious adverse events in patients 
treated with FOLFOXIRI plus bevacizumab is up to 20.4%,38 which is comparable to 
perioperative morbidity of major surgery (5-28% for CRS and HIPEC16 and 5-20% for 
extended liver resection).39-41 
This multicenter study is the largest series of selected patients with PC from CRC and 
simultaneous LM treated with LR, CRS and HIPEC. The present study shows that aggressive 
management of multi-metastatic CRC is feasible with an acceptable morbidity rate of 15% 
and no postoperative mortality. These morbidity and mortality rates are consistent with those 
reported after LM resection and similar to PC treatment alone.25,37,42 We believe these low 
rates of morbidity were achieved by careful selection of patients: if LM required only minor 
LR, this was usually performed at same time as CRS + HIPEC. However, if LM required 
complex or major LR, especially on parenchyma injured by preoperative CTH, LM resections 
were mostly delayed to a second procedure. Interestingly, despite this approach, a major LR 
was not associated with an increased complication rate. However, the authors suggest that this 
concept of a two-staged procedure, already used in complex abdominal and liver surgeries, 
may represent a valuable tool to reduce patient morbidity and mortality rates. Despite this 
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cautionary note, in light of the present data, it should still be concluded that when both LM 
and PC are resectable, aggressive surgery improves chances for selected patients to achieve 
better OS rates.   
Despite the encouraging OS rates in our study, almost 64% of patients recurred within the 
first postoperative year. We also found a significant association between reduced DFS and 
severe complication occurrences, which is in line with previous studies.43 However, we also 
found that OS, surprisingly, was not related to severe morbidity as an earlier recurrence was 
assumed to be related to shorter survival. However, Varban et al. reported similar results.37 
Thus, these data suggest that careful selection of patients, less likely to experience severe 
postoperative complications, may allow for improved DFS. Unfortunately, we did not identify 
any risk factors associated with perioperative severe morbidity. Our study sampling is the 
likely explanation for this. Nevertheless, this association of complications and survival should 
be attentively considered when selecting any patient with LM and PM for surgery. 
The promising long-term results of LM surgery from CRC over the past decade and recent 
trends towards increasing surgical aggressiveness (as illustrated by iterative resections of 
LM44) formed the rationale for the surgical management of both LM and PC, given that CRS 
+ HIPEC may also achieve excellent outcomes. Some series suggest that relatively long 
survival may be achieved with aggressive management, including the simultaneous resection 
of LM and PC.21,26,45 Previous findings have been confirmed in the present study showing that 
OS is significantly prolonged: up to 60 months in selected cases. However, a recent meta-
analysis of de Cuba et al. showed that patients with synchronous PC and LM of CRC seemed 
to fare less well when compared to patients with isolated PC (pooled HR=1.24, 95%CI 0.96–
1.60).22  Despite this, the authors also showed a tendency towards better OS in carefully 
selected patients with PC and LM who were treated with curative resection of both sites plus 
HIPEC compared to treatment with modern systemic CTH alone.  
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The PCI is considered the most widely used tool to evaluate disease extent in primary or 
digestive carcinomatosis.16,46-48 Increased PCI is also recognized as an independent prognostic 
indicator for long-term outcomes in patients with PC from CRC49 and an inverse linear 
relationship between point rise in PCI and OS has been demonstrated.50 Similarly, we found 
that PCI was an independent prognostic factor for OS in patients undergoing simultaneous 
resection of LM and PC. Whilst PCI also influences the likelihood of complete 
cytoréduction,11,51 in the present analysis, incomplete cytoreduction only impacted DFS 
independently (not OS). This finding is not at odds with the literature, as previous studies 
have shown that a large volume of disease is associated with poor long-term survival even if 
complete cytoreduction is achieved.47,49  
The concomitant presence of LM is a poor prognostic factor compared to patients with PC 
alone.16,22,45 Furthermore, Elias et al. reported that completely resected LM during CRS 
remained a negative prognostic factor for patients with PC of CRC.52 However, Maggiori et 
al. suggested that in LM and PC, prolonged survival may still be achieved in highly selected 
patients with limited peritoneal disease (PCI <12).26 In our study, we also found that a 
PCI>12 was associated with a poor OS in both uni and multivariate analysis. Therefore, PCI 
itself could be a useful criterion for patient selection. In line with de Cuba et al., we also 
believe that, based on current data, there is no evidence to support an exclusion of patients 
with PC and LM from aggressive, potentially curative, treatment.22 However, an accurate, 
extensive preoperative evaluation is mandatory before surgery, and thus a diagnostic 
laparoscopy may prove useful in avoiding unnecessary surgery in high PCI and simultaneous 
CRC LM patients.53 
Despite analyzing prospectively maintained databases, this study is limited by its 
retrospective design. Furthermore, great heterogeneity in patient selection and operative 
techniques may have compromised our findings. However, despite these short-comings, this 
 15 
 
study represents the largest multicenter series, to date, and the data provided herein forms a 
basis for future prospective trials.  
 
 
CONCLUSION 
 
This multicenter study shows that concomitant treatment of CRC dissemination in the liver 
and peritoneum, confirms the feasibility of combined hepatectomy, CRS and HIPEC, in 
selected patients with LM and PC of CRC, resulting in 32-month median OS with limited 
morbidity. The present data supports this aggressive treatment strategy; the exact timing of 
these individual complex treatment steps remains unknown. Future studies assessing the 
feasibility of this surgical approach in a prospective, randomized setting (as well as further 
studies elucidating how best to control disease progression following disease recurrence) 
would be helpful in furthering the care of CRC patients with advanced stage of disease.  
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Figures legends 
 
 
Figure 1. 
 
A. Disease free survival of 130 patients treated with cytoreductive surgery and hyperthermic 
intraperitoneal chemotherapy combined with liver resection for simultaneous liver and 
peritoneal metastases from colorectal cancer. 
B. Prognostic impact of the number liver metastases (>3) on disease free survival of 130 
patients (P=0.0001) 
 
 
Figure 2. 
 
A. Overall survival of 161 patients treated with cytoreductive surgery and hyperthermic 
intraperitoneal chemotherapy combined with liver resection for simultaneous liver and 
peritoneal metastases from colorectal cancer. 
B. Prognostic impact of the peritoneal carcinomatosis index (>12) on overall survival of 151 
patients (P=0.008) 
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Table 1. Background and operative characteristics of the study population 
 
 
Characteristics of population 
 
No. of Patients (%) of Patients 
 
Demographics   
Sex 
Male  
Female 
 
77 
84 
 (47.8) 
 (52.2) 
Age  
<60 
≥60 yr 
 
88 
73 
(54.7) 
 (45.3) 
Primary tumor 
Site 
Rectum 
Right Colon 
Left Colon 
NR 
 
10 
47 
96 
8 
(6.2) 
(29.2) 
 (59.6) 
 (5.0) 
Differentiation 
Good 
Moderate 
Poor 
NR 
 
52 
70 
10 
29 
 (32.3) 
 (43.5) 
 (6.2) 
 (18.0) 
Nodal Status 
Positive 
Negative 
NR  
 
104 
37 
20 
  
(64.6) 
(23.0) 
(12.4) 
Chemotherapy   
Pre-HIPEC systemic CTH 
Yes 
No 
138 
23  (85.7) 
(14.3) 
Table
2 
 
Perionteal Carcinomatosis   
PCI 
≤12 
>12 
NR 
 
106 
50 
5 
 (65.8) 
(31.1) 
(3.1) 
Completeness of Cytoreduction 
CCR-0 
CCR-1 
CCR-2 
 
144 
14 
3 
 (89.4) 
(8.7) 
(1.9) 
Type of HIPEC  
Oxaliplatin 
MMC 
 
103 
58 
(64.0) 
(36.0) 
Liver Metastases   
No. of Liver metastases 
≤3 
>3 
NR 
 
130 
16 
15 
 (80.7) 
 (9.9) 
(9.3) 
Type of liver resection 
Major (≥3 segments) 
Minor (<3 segments) 
NR 
 
28 
117 
16 
 (17.4) 
 (72.7) 
(9.9) 
Time of liver resection 
Simultaneous  
Delayed or two-stage 
NR 
 
133 
13 
15 
(82.6) 
(8.1) 
 (9.3) 
Synchronous ovarian metastases 
Yes 
No 
NR 
 
10 
136 
15 
 (6.2) 
 (84.5) 
(9.3) 
3 
 
Surgical data   
Postoperative complications 
Minor 
Major 
 
 
137 
24 
(85.1) 
 (14.9) 
 Second surgical procedure 
Yes 
No 
NR 
 
13 
141 
7 
 (8.1) 
(87.6) 
 (4.3) 
   
Mean hospital stay duration  
   Simultaneous CRS and LR 
      Two-staged surgery 
23 (SD:12.5, range 8-87) 
24 (SD: 13.1, range 9-87) 
15 (SD:  5.8, range 8-26)   
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Table 2.  Predictive Factors for severe post-operative severe complications (DINDO III or IV) on Univariate Analysis 
 
Variables No. Patients (N = 161) 
Univariate Analysis 
OR (95% CI) P 
Male sex 77/161 0.74 (0.31-1.77) 0.50 
Age >60 yr 73/161 0.98 (0.41-2.33) 0.96 
Primary Site 
Rectum 
Right Colon 
Left Colon 
 
10/153 
47/153 
96/153 
 
0.61 (0.07-5.07) 
0.52 (0.21-1.28) 
1.67 (0.22-1.55) 
 
0.65 
0.16 
0.28 
Primary differentiation 
Good 
Moderate 
Poor 
 
52/132 
70/132 
10/132 
 
1.91 (0.72-5.06) 
0.61 (0.23-1.63) 
0.65 (0.08-5.43) 
 
0.20 
0.32 
0.69 
N+ status 104/141 0.78 (0.29-2.08) 0.62 
Pre-HIPEC systemic CTH 138/161 0.84 (0.23-3.07) 0.79 
PCI > 12/39 50/156 1.17 (0.45-3.04) 0.74 
CCR-1* 14/158 0.63 (0.16-2.43) 0.50 
HIPEC with Oxaliplatin 103/161 0.93 (0.38-2.28) 0.87 
Liver metastases >3 16/146 1.35 (0.35-5.18) 0.66 
Major liver resection 28/144 1.74 (0.61-4.95) 0.30 
Simultaneous liver resection 133/146 0.44 (0.06-3.60) 0.45 
 
The values given are number (%). Variables in bold are statistically significant (P < 0.05). CTH indicates chemotherapy. OR 
indicates odds ratio. *Three CCR-2 patients were excluded from this analyze. 
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Table 3. Prognostic Factors for Disease Free Survival on Univariate and Multivariate Analyses 
 
Variables No. Patients (N = 141) 
Univariate Analysis Multivariate Analysis 
HR (95% CI) P aHR (95% CI) P 
Male sex 70/141 0.94 (0.64-1.37) 0.74   
Age >60 yr 63/141 1.35 (0.92-1.98) 0.13   
Primary Site 
Rectum 
Right Colon 
Left Colon 
 
9/136 
44/136 
83/136 
 
0.74 (0.37-1.47) 
0.78 (0.52-1.16) 
1.38 (0.93-2.02) 
 
0.39 
0.22 
0.11 
  
Primary differentiation 
Good 
Moderate 
Poor 
 
47/120 
63/120 
10/120 
 
1.24 (0.82-1.88) 
0.79 (0.52-1.18) 
1.11 (0.54-2.29) 
 
0.32 
0.25 
0.78 
  
N+ status 93/125 0.62 (0.37-1.05) 0.08 1.47 (0.85-2.56) 0.17 
Pre-HIPEC systemic CTH 125/141 0.57 (0.32-1.02) 0.06 1.77 (0.84-3.74) 0.14 
PCI > 12/39 45/138 0.77 (0.52-1.14) 0.19   
CCR-1* 12/140 0.59 (0.33-1.07) 0.08 1.99 (1.02-3.89) 0.04 
HIPEC with Oxaliplatin 94/141 1.17 (0.78-1.73) 0.45   
Liver metastases >3 15/130 3.04 (1.59-5.84) 0.001 3.32 (1.67-6.63) 0.001 
Major liver resection 25/130 1.24 (0.76-2.03) 0.39   
Simultaneous liver resection 119/130 1.14 (0.55-2.36) 0.72   
Severe postoperative  
complication (grade III or IV)  
21/141 1.82 (1.01-3.25) 
 
0.04 1.69 (0.93-3.06) 0.09 
 
For each variable, the number of patients is reported to the number of patients with data and DFS available. Variables in bold are 
statistically significant (P < 0.05). CTH indicates chemotherapy. HR indicates hazard ratio. aHR indicates adjusted hazard ratio. 
*Three CCR-2 patients were excluded from this analyze.
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Table 4. Prognostic Factors for Overall Survival on Univariate and Multivariate Analysis 
 
Variables No. Patients (N = 156) 
Univariate Analysis Multivariate Analysis 
HR (95% CI) P aHR (95% CI) P 
 
Male sex 
 
75/156 
 
1.75 (1.11-2.76) 
 
0.02 
 
1.60 (0.99-2.58) 
 
0.06 
Age >60 yr 70/156 0.77 (0.49-1.20) 0.25   
Primary Site 
Rectum 
Right Colon 
Left Colon 
 
10/148 
45/148 
93/148 
 
1.51 (0.69-3.32) 
0.82 (0.49-1.35) 
1.06 (0.66-1.70) 
 
0.30 
0.43 
0.81 
  
Primary differentiation 
Good 
Moderate 
Poor 
 
51/129 
67/129 
10/129 
 
1.11 (0.69-1.81) 
0.88 (0.54-1.43) 
1.36 (0.54-3.41) 
 
0.66 
0.61 
0.52 
  
N+ status 100/136 1.52 (0.83-2.81) 0.18   
Pre-HIPEC systemic CTH 133/156 1.14 (0.66-1.98) 0.64   
PCI > 12/39 50/151 1.85 (1.18-2.92) 0.008 1.67 (1.05-2.66) 0.03 
CCR-1* 14/153 2.04 (1.11-3.72) 0.02 1.52 (0.79-2.95) 0.21 
HIPEC with Oxaliplatin 99/156 0.85 (0.54-1.34) 0.50   
Liver metastases >3 16/141 1.07 (0.49-2.36) 0.86   
Major liver resection 28/141 0.83 (0.45-1.55) 0.56   
Simultaneous liver resection 129/141 0.64 (0.23-1.77) 0.39   
Severe postoperative complication (DINDO III 
or IV)  
24/156 1.00 (0.52-1.95) 1.00   
For each variable, the number of patients is reported to the number of patients with data and OS available. Variables in bold are 
statistically significant (P < 0.05). CTH indicates chemotherapy. HR indicates hazard ratio. aHR indicates adjusted hazard ratio. 
*Three CCR-2 patients were excluded from this analyze. 
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C. CONCLUSION	and CLINICAL PROSPECTS 
 
In this thesis, there are three principal questions that we wanted to address: 
1. Is it possible to treat patients with synchronous liver and peritoneal metastases, individually 
accessible, to a surgical treatment with curative intent? 
2. In cases of aggressive surgical treatment, what order of surgery should be chosen? 
3. In cases of two-step surgery, what is the effect of liver surgery on peritoneal 
carcinomatosis? 
To answer question number one, firstly, the literature data was analyzed (21 studies [3,27-32,35-
37,132-143] and 6 reviews [33,35,135,144-146] on this subject have been published to date). Among 
these, 16 retrospective series exist comparing patients with PC alone vs PC plus LM 
undergoing CRS with HIPEC and or not liver resection: 7 studies note negative impact of 
concomitant presence of both metastatic sites, 9 studies show no difference. It is clear that 
most have been pauci-centric studies, often retrospectives, with small samplings of patients, 
because this aggressive surgical treatment can only be proposed to a very selected number of 
patients.  
 However, the studies suggest that this aggressive surgery, with curative intent, is possible. 
Even though this surgical treatment has been contraindicated for a long time, it currently 
seems feasible with an acceptable morbidity/mortality rate found at expert centers in 
peritoneal diseases. Subsequently, we have carried out a multicentric study, motivated by the 
fruitful Franco-Italian cotutelle between two expert centers in peritoneal diseases 
(Lariboisiere, Paris and La Sapienza, Rome). A multicentric database, with an increase in the 
number of patients, was the first result of this cooperation. Our preliminary clinical study of 
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161 patients, having undergone combined hepatic and peritoneal surgery, shows the 
feasibility of complex liver and peritoneal surgery. In our study this surgery is associated with 
a low rate of morbidity, similar to that of major abdominal surgery. The OS of these patients 
was greater than that OS achieved with systemic CT treatment alone [33,145]. Nevertheless, it 
should be emphasized, the DFS of our series was poor (10 months: range 0.3 to 56 months); 
87.9% of the patients in our study relapsed with recurrences occurring during the first year. A 
careful selection of patients becomes fundamental if we want to propose an aggressive, 
curative treatment. Indeed, several factors come into play in this situation which determines 
the complexity of clinical cases. Firstly, the intrinsic variability related to multisite, hepatic 
and peritoneal metastases. Although, in our study, we have listed patients able to undergo 
surgical treatment concerning both metastatic sites, the treatments performed could be very 
different depending on the localization and, above all, the extent of the disease in the two 
metastatic sites. The second factor was the variety of chemotherapy used and when it was 
administered (pre- or post-operatively) and, in some patients, between the hepatic and 
peritoneal surgeries. The impact of chemotherapy on the OS of these patients is not 
negligible. Unfortunately, the sampling period was very wide (about 20 years) and much data 
(concerning the type and timing of chemotherapy administered) was missing. These facts, in 
our opinion, represent the limits of this study. We have envisaged three possible solutions. 
Firstly, to improve the patient selection process, in order to collect relevant data concerning 
the impact of systemic chemotherapy (even if the numbers of patients are reduced). Secondly, 
to increase the number of patients, through international collaboration, and then carry out sub-
group analyzes (types of chemotherapy used, ages of treated, choice of surgery performed 
first, etc.). The third possibility is to compare data among patients who have received curative 
surgical treatment and those treated by systemic chemotherapy. De Cuba et al. showed, in 
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their review, that the surgical treatment of liver and peritoneal surgery is associated with a 
high OS compared to modern systemic chemotherapy [33].  
These studies encouraged me to take a short outward mobility where I had the opportunity to 
work in the Peritonectomy Unit (Kogarah Center, Australia), which is part of the Peritoneal 
Surface Oncology Group International (PSOGI). The results obtained (under international 
cooperation) will lead to a prospective database to which a network of expert centers in 
peritoneal diseases of the PSOGI and BIG-RENAPE (French national clinico-biological 
database of peritoneal diseases) will participate. 
Currently underway: 
 a) International Partnership between the centers of the PSOGI, which brings international 
surgical centers, specializing in the pathology of the peritoneum, together. The new 
prospective database has already collected 423 cases of combined surgery with hepatectomy 
and peritoneal resection with HIPEC. The	outcomes results will be presented at the PSOGI 
Congress in Paris at September, 8-11 2018, and will be the subject of a first author 
publication. 
b) A propensity score analysis (PSM), of two populations of patients operated on by two 
different surgical teams to evaluate the morbi-mortality risk of a combined surgical approach: 
(I) a series of patients undergoing resection of isolated LM (Rome cohort); (II) a series of 
patients undergoing hepatic resection associated with peritoneal metastases resection (Paris 
cohort). 
In cases of major and complex surgery, carried out in two stages, the proper surgical 
sequence, between hepatic surgery and peritoneal, remains debatable. No literature offers data 
helping to make a clear choice. Our animal model was conceived to address to this question. 
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In our study, to mimic the human situation of concomitant liver resection and peritoneum 
metastases, and confirm the effects of liver regeneration on peritoneal metastasis growth, we 
have developed a reproducible animal model with limited peritoneal carcinomatosis and liver 
regeneration after major hepatectomy. This model was constructed with immune competent 
mice to mimic the natural human immunity. The model is not perfectly reproducible. Indeed, 
at each concentration, at least 2 out of 5 mice have a PCI greater than expected value. 
However, the mean values of each group were respected and allow us to follow the natural 
evolution of the peritoneal carcinomatosis. For ethical reason we preferred euthanize only 5 
mice per group. 
 
The pro-metastatic role of hepatic surgery, and the consequent effects of liver regeneration, 
are a phenomena noted in basic and clinical studies of the literature [123,147-149]. Therefore, it 
has been postulated that hepatic surgery, if performed as a first procedure, could stimulate 
tumor growth in PC. That is because the production of normally contiguous growth factors 
towards the restitutio ad integrum of the hepatic parenchyma is diverted towards the 
proliferation of tumor cells at the peritoneal level. 
Experimental results were obtained on an animal model that we defined for our specific 
purposes. In our model of major liver surgery, we have analyzed the role of endothelial and 
hematopoietic bone marrow derived cells on the changes of the pre-metastatic niche as well as 
on the promotion of the metastatic process. We have found that the concentration rate of 
tumoral and non-tumoral growth factors and circulating endothelial progenitors, which 
significantly increase after hepatectomy to assist hepatic regeneration and angiogenesis, play 
a crucial role in tumor growth by stimulating tumor cells of carcinomatosis tumor cells. Our 
experimental results confirmed the functional and structural role of the endothelial BMDC. 
 Lo Dico Rea – Thèse de doctorat - 2017 
 125 
These cells stimulate the secretion of pro-angiogenic factors to promote the changes of the 
microenvironment as well as the promotion of a new tumoral vascular network.	In our study, 
the presence, and tumor growth, of PC was monitored, non-invasively, with bioluminescence 
without sacrificing the mouse. Furthermore, we have established a reproducible technique of 
non-invasive evaluation of tumoral angiogenesis by Echo-Doppler. Our results confirm the 
pro-metastatic effect of hepatic surgery on the PC growth. We have also studied the effect of 
surgery, without liver injury, on the PC growth and we have observed smaller increase of 
peritoneal PCI compared to the effect after liver surgery. This result confirms the crucial role 
of the liver regeneration on the tumoral hepatic and extra-hepatic growth. Further analysis, 
currently in progress, should also identify the mechanisms involved in this process, must 
importantly the role played by natural and post-operative immunity. 
 
In clinical practice, what is involved concerning the choice of the surgical sequence can be 
summarized by the following: 
1) Carcinological aspects:  
- If choosing to start by cytoreduction surgery, we treat the metastatic site in light of a poor 
prognosis. However, Cao et al., who analyzed patients with metastatic colorectal cancer, 
showed that there was no difference found between patients undergoing hepatectomy for 
isolated LM versus patients undergoing peritonectomy with HIPEC for isolated PC (37 
months for both groups) [150].  
- In other cases, after major hepatectomy and under pro-metastatic effects, the PC can rapidly 
become non-resecable, as evidenced by our murine model of hepatic regeneration. In our 
department, a pilot study carried out on few patients (n=4) treated with primary hepatectomy, 
showed a rapid evolution on the PC which quickly became non-resectable. 
 Lo Dico Rea – Thèse de doctorat - 2017 
 126 
2) Technical aspects:  
- If choosing to start with cytoreduction surgery, we carry out surgery associated with a 
potentially higher morbidity rate.  
- In other cases, the impact of surgery on tumor growth could be lessened in cases of 
laparoscopy hepatectomy or in case of use of an anti-adhesion barrier film to limit 
postoperative adhesions [38].  
More studies are necessary to establish the best surgical strategy. However, in light of these 
findings, we can affirm that in a situation with concomitant presence of liver and peritoneal 
metastases, when combined surgery is not possible, carrying out peritoneal surgery first is 
associated with lower risk of tumoral growth compared to carrying out liver surgery first. 
Currently, the peritoneal surgery first represents our therapeutic choice in case of synchronous 
liver and peritoneal metastases when the combined surgery is not possible.  
 
Future researches will assist these findings. These include: 
1) Testing anti-angiogenic drugs in our animal model to establish the role of pro-
angiogenic factors produced during liver regeneration after major hepatectomy on the 
metastatic process and tumoral angiogenesis.  
In metastatic colorectal cancer, several biological agents, such as anti-angiogenic 
drugs (Bevacizumab, Aflibercept) [9,12] or anti-EGFR (Cetuximab or Panitumumab) 
[11], are added to the chemotherapy regimen to increase the response to the treatment. 
In our model we have seen that tumor neo-angiogenesis participates in several stages 
of the metastatic process, on the carcinomatosis growth as well as on the hepatic 
regeneration process after major hepatectomy. Contrary to hepatic metastases, the 
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effect of antiangiogenics in PC is not still clear. It is known that the preoperative use 
of anti-angiogenics is responsible for an increase in post-operative morbidity/mortality 
after cytoreduction surgery and HIPEC [151]. Nevertheless, studies by Glehen et al. 
were centered on the interest of pre-operative anti-angiogenics agents administration 
in cytoreductive surgery and HIPEC with results that show that lower IP VEGF level 
prior to surgery is associated with improved OS [152]. The use of preoperative 
intraperitoneal Bevacizumab for patients with a heavy disease load should be 
considered, especially in colorectal cancers. In the further, it would be interesting to 
test the anti-angiogenics molecules after major hepatectomy in the mouse to check if 
the pro-angiogenic and pro-metastatic effects of the hepatic regeneration after 
hepatectomy are antagonized by the anti-angiogenics. In our model of PC and hepatic 
regeneration, testing with new treatments, such as anti-angiogenics and 
immunomodulatory drugs, should, therefore, decrease the risk of peritoneal metastases 
growth by reducing the concentration of circulating EPC and VEGF levels. 
2) Identifying the role of post-operative immunosuppression in our animal model. 
Actually, Immunotherapy is a major focus in basic and clinical research. The recent 
studies of Voron et al., studying the interactions between the immune system and the 
angiogenetic factors, show that VEGF-A produced by tumors, plays a key role in the 
development of an immunosuppressive microenvironment and	enhances expression of 
PD-1 and other inhibitory checkpoints involved in CD8+ T cell exhaustion [153,154]. 
Based on these immunomodulatory properties, in our preclinical model, we could test 
the effects of the immunosuppression of the antiangiogenic molecules as well as find 
an efficient combination among anti-angiogenic drugs associated with 
immunotherapeutic molecules. 
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before the implant of liver metastases. In mouse, is a complex surgical model probably 
associated with a high mortality rate. 
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INTRODUCTION  
 
Following is a short selection of works carried out over the last few years, its 
aim being to understand the development, and the mechanisms of progression, 
of peritoneal carcinomatosis of digestive origin (as well as the study of 
possible therapeutic approaches). 
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Abstract
Objective To show the feasibility and the safety of peri-
toneal carcinomatosis (PC) evaluation by single-incision
flexible endoscopy (SIFE) and to compare it to single-in-
cision rigid endoscopy (SIRE).
Background Direct peritoneal visualization, either by
laparotomy or laparoscopy, continues to be the gold stan-
dard in diagnosing PC. We reported, in animal study, that
combining single-incision laparoscopic surgery and flexi-
ble endoscopy improved evaluation of the peritoneal cavity
in a live porcine model and in four human cadavers.
Methods Patients, undergoing surgical exploration for
diagnosis and staging of PC, were included in a prospective
study. Using a superiority design a sample size of 47
patients was determined. Through a single incision, a
standardized peritoneoscopy was conducted with rigid
(SIRE) and with flexible endoscope (SIFE). Primary out-
come was the access success rates for the 13 regions of the
Peritoneal Carcinomatosis Index (PCI).
Results Overall access to the 13 regions of PCI was
successful in 83 % of the cases with SIRE and in 91.1 %
with SIFE (p\ 10-10). SIFE access rates were superior to
SIREs’ in the regions: R1 (87.2 vs. 61.7 %, p = 0.002), R2
(87.2 vs. 66 %, p = 0.004), R3 (85.1 vs. 59.6 %,
p = 0.001) and R6 (80.9 vs. 61.7 %, p = 0.008). The
mean PCI was higher (p\ 104) with SIFE 12.77 (±11.97)
than with SIRE 11.77 (±11.63).
Conclusion This prospective, comparative study shows
that SIFE was significantly superior to SIRE in the
exploration of some difficult-to-access peritoneal areas,
located in regions 1, 2, 3 and 6. These two minimally
invasive staging procedures are safe, feasible and have to
be seen as complementary rather than competing.
Keywords Minimally invasive surgery ! Single-incision
laparoscopic surgery ! Peritoneal carcinomatosis !
Peritoneoscopy ! Laparoendoscopic single-site surgery
Peritoneal carcinomatosis (PC) was considered a terminal
condition with a merely palliative treatment, which inclu-
ded only supportive care, palliative surgery and the best
systemic chemotherapy. Since the birth of the concept of
cytoreductive surgery (CRS) and hyperthermic intraperi-
toneal chemotherapy (HIPEC), the management of PC
changed dramatically. In fact, it has been proven that CRS/
HIPEC improves survival in patients with PC of colorectal
origin [1]. CRS with HIPEC framed by systemic
chemotherapy is now proposed with curative intention in
selected cases of limited PC from colonic and ovarian
origin [2–4].
The Achilles heel of CRS and HIPEC is appropriate
patient selection, in order to prevent from excessive mor-
bidity and mortality. Among the criteria of patient’s
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and Other Interventional Techniques 
selection, the evaluation of the extension of the peritoneal
disease through the Peritoneal Carcinomatosis Index (PCI)
is one of the most important [5]. The PCI is an independent
prognostic factor for survival. The lower the PCI, the better
the prognosis maybe also due to the fact that a complete
cytoreduction becomes more likely [6].
An accurate evaluation of the PCI is therefore required
in order to select the patients eligible for CRS and HIPEC.
Current imaging methods are not sensitive enough for the
diagnosis and staging of limited PC and often do not detect
small tumor nodules [7].
Computed tomography scan, which remains the standard
imaging modality in the assessment of PC [8], misses
30–45 % of peritoneal nodules or lesions, in particular if
these are smaller than 5 mm [9, 10]. Thus, the extent of PC
is difficult to evaluate preoperatively, and precise evalua-
tion is most often performed during surgical exploration
[11]. Some institutions utilize laparoscopy for that purpose
[12–15].
Due to the risk of tumoral spreading through the lateral
ports into the abdominal wall muscles [16], we believe that
the conventional triangle laparoscopy is not the most
suitable option for the evaluation of PC.
It is true that the reported incidence of port site metastases
in laparoscopic surgery has declined notably compared with
early publications [17]. However, metastatic tumor seeding
in surgical scars in the setting of PC in candidates for CRS/
HIPEC has not been studied as much. In a recently published
study, Nunez et al. [18] showed that one-third (34 %) of the
patients with a history of laparoscopic procedure prior to
CRS/HIPEC had port site metastases at the time of CRS/
HIPEC. This rate reaches 42 %, if laparoscopy was per-
formed for tumor staging purposes.
The occurrence of port site metastases can make the
cytoreduction impossible, especially in some etiologies,
such as mesothelioma [19]. Moreover, an extensive
abdominal wall resection in order to achieve a complete
cytoreduction increases significantly the morbidity of the
procedure [20].
In our institution, all the peritoneal exploration proce-
dures for diagnosis and staging of PC are performed via
single-incision laparoscopic surgery. We called this pro-
cedure single-incision rigid endoscopy (SIRE).
We found, however, that the SIRE did not allow to
properly explore the whole abdominal cavity. In fact, rigid
endoscopy has some limitations in terms of ergonomic and
lack of triangulation, due to the coaxial position of the
instruments. Moreover, this procedure can be challenging,
especially in those patients previously operated on.
We hypothesized that combining single-incision
laparoscopic surgery and flexible endoscopy may over-
come these pitfalls. We called this procedure single-inci-
sion flexible endoscopy (SIFE).
We, therefore, performed an animal study comparing
flexible and rigid single-port peritoneoscopy [21]. A stan-
dardized exploration of the peritoneal cavity was con-
ducted in a porcine model, using the two techniques,
aiming to access 11 elective sites of PC. We found that the
overall rate of access to target was significantly higher in
SIFE than in SIRE, 98 and 87 %, respectively (p\ 0.001).
Based on these encouraging results, we tried to transpose
this new technique to humans.
The aim of this study is to show the feasibility and the
safety of the SIFE technique in clinical practice, than to
evaluate its diagnostic impact through a comparison
between this technique and the rigid endoscopy SIRE.
Materials and methods
This is a prospective study, and all the patients were sys-
tematically informed of the aim of the study. Institutional
review board approval was obtained from the local ethics
committee.
The study was carried out in the Department of Surgical
Oncology in Lariboisie`re Hospital (Assistance Publique
Hoˆpitaux de Paris), which is a tertiary care center for PC.
We included patients, with histologically proven
malignant disease, who underwent surgical exploration for
diagnosis and staging of PC. The indications were staging
of a carcinomatosis already diagnosed with imaging (CT
scan and MRI), restaging after neoadjuvant chemotherapy,
restaging during follow-up in the case of dubious imaging
and restaging after adjuvant chemotherapy.
Through a single incision, a standardized perito-
neoscopy was conducted with a rigid optic (SIRE) and with
a flexible endoscope (SIFE), in a random order and in a
back-to-back manner (i.e., one technique right after the
other during the same operation).
Access to peritoneal cavity
Under general anesthesia, and in a supine position, a
25-mm paraumbilical midline incision was made. A
sponge-like SILSTM port (Covidien France, Elancourt) was
inserted through this incision. The SILSTM port was con-
nected to a standard autoregulated laparoscopic insufflator
(Electronic CO2 Endoflator; Karl Storz Endoscopy,
Guyancourt, France) to create and maintain 12 mm Hg
CO2 pneumoperitoneum.
Single-incision rigid endoscopy (SIRE)
A 10-mm-diameter, 60-cm-long, 30" axial optic (27425 P;
Karl Storz Endoscopy, Guyancourt, France) and two 5-mm
rigid laparoscopic graspers were inserted through the
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SILSTM port. A senior surgeon experienced in laparoscopy
and in oncologic surgery performed all the SIRE
procedures.
Single-incision flexible endoscopy (SIFE)
A 10.8-mm-diameter, 110-cm-long, Fujinon# gastroscope
EG-490ZW5 (Fujifilm Medical Systems France, Montigny
Le Bretec, France) was inserted through the SILSTM port.
The endoscope distal tip could be deflected in four direc-
tions: 210" up, 90" down, 100" left, 100" right. If needed,
two 5-mm rigid laparoscopic graspers were also inserted
through the SILSTM port. Another senior surgeon with
3-year experience in endoscopy performed all the SIFE
procedures.
Peritoneoscopy
Standardized exploration of the peritoneal cavity was
conducted quadrant by quadrant using the two techniques
in random order, aiming to access the 13 regions of PCI as
described by Sugarbaker [22].
The procedures were only exploratory, and no extensive
dissection was made. The viscerolysis was limited to the
essential minimum to avoid iatrogenic lesions. For both
techniques, and in order to facilitate access to the different
regions when not reachable in supine position, the
table was rolled laterally side to side possibly combined
with Trendelenburg or anti-Trendelenburg position, up to
30". These positions were often needed to adequately
expose the pelvis and the diaphragmatic domes.
For each technique, we noted whether a complete
exploration of each of the 13 regions was possible or not,
and then, the PCI was calculated. Evaluation of access to
the different regions was based on operators’ consensus.
An independent nurse scored the results for all the
procedures.
Depending on the region explored, the exploration was
considered successful if it allowed complete visualization
of specific areas and anatomic structures:
• For the Region 0: The greater omentum and the
transverse colon.
• For the Region 1: The superior surface of the right lobe
of the liver and the under surface of the right hemi-
diaphragm to the peritoneal reflection at the level of the
coronary ligament of the liver.
• For Region 2: The left lobe of the liver, the falciform
ligament, the lesser omentum and the hepatic hilum.
• For Region 3: The spleen, the anterior surface of the
stomach and the under surface of the left hemi-
diaphragm to the peritoneal reflection at the level of
the phreno-splenic ligament.
• For Region 4: The descending colon and the left
abdominal gutter.
• For Region 5: The sigmoid colon and the pelvic
sidewall lateral to the sigmoid colon.
• For Region 6: The upper rectum, the Douglas pouch,
the female internal genitalia with ovaries, tubes and
uterus, and the bladder.
• For Region 7: The cecum, the appendix and the right
pelvic sidewall.
• For Region 8: The ascending colon and the right
abdominal gutter.
• For Region 9: The upper jejunum and its mesentery.
• For Region 10: The lower jejunum and its mesentery.
• For Region 11: The upper ileum and its mesentery.
• For Region 12: The lower ileum and its mesentery.
Outcome parameters and statistical analysis
Primary outcome parameters were the feasibility of the
procedure and the access success rates for the 13 regions of
the PCI. Evaluation of the successful access to these
regions was based on operators’ consensus.
Secondary outcomes were the safety of the procedure,
the complications and the diagnostic impact defined as the
difference in PCI between the two techniques.
For the primary endpoint, a superiority design was used
to compare SIFE and SIRE. Using a = 0.05 and
1-b = 0.8, and assuming that SIFE has a sensitivity of at
least 98 % and SIRE a sensitivity of 87 %, a sample size of
at least 47 patients was determined.
Mc Nemar’s test was used for comparison of qualitative
data, and Student’s t test for paired data was used for
comparison of continuous variables.
Results
Between October 2009 and October 2012, 50 patients
underwent surgical exploration for diagnosis and staging of
PC in our institution. Among these patients, 3 were
excluded from the study because of the impossibility to
access the peritoneal cavity. In the remaining 47 cases,
both SIRE and SIFE access to the peritoneal cavity was
successfully achieved.
In 45 patients (95.74 %), the SILSTM port was inserted
through a para-umbilical midline incision. The two other
patients (4.26 %) underwent stoma closure at the same
operative time. The lateral hole of the stoma was therefore
used to introduce the SILSTM port.
Among the patients enrolled in this study, 25 were male
and 22 female. The median age was 54 (range 25–76). The
median weight was 68 kg (range 47–103). The median
3810 Surg Endosc (2016) 30:3808–3815
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BMI was 22.9 kg/m2 (range 16.2–36.5). 74.5 % of the
patients had previous abdominal surgery. The origin of the
suspected carcinomatosis was mostly either colorectal
(51.1 %) or gastric (29.8 %). The patients and tumors
characteristics are summarized in Table 1.
Navigation into the peritoneal cavity was found to be
easy in both techniques. Overall access to the 13 regions of
PCI was successful in 83 % of the cases with SIRE and in
91.1 % with SIFE (p\ 10-10) (Table 2).
Both techniques showed similar access rates to the
regions 0, 4, 5, 7, 8, 9, 10, 11 and 12. SIFE access rates were
superior to SIREs’ in the regions: R1 (87.2 vs. 61.7 %,
p = 0.002), R2 (87.2 vs. 66 %, p = 0.004), R3 (85.1 vs.
59.6 %, p = 0.001) and R6 (80.9 vs. 61.7 %, p = 0.008).
There was no significant difference for successful access
to the different regions of PCI for both SIFE and SIRE,
between male and female, and between the different types
of carcinomatosis. These rates were also independent from
the number of previous laparotomies. The order of proce-
dures (SIFE first or SIRE first) did not significantly influ-
ence the results.
The mean peritoneal score for the extent of the peri-
toneal seeding was significantly higher (p\ 10-4) with the
SIFE procedure 12.77 than with the SIRE procedure 11.77.
The mean difference in PCI was 1 point. The PCI was
the same in half of the cases. There was a difference of at
least 2 points of PCI, in 25 % of the cases. The maximal
difference noted was 5 points.
Patients eligible for HIPEC (PCI\ 20) represented
66 % (31/47) of the patients. For this group, the PCI was
significantly higher (p = 0.0005) with the SIFE procedure
(7.10 ± 6.51) than with the SIRE procedure (6.16 ± 5.89).
The results were similar for the remaining group of patients
with a PCI C20, who represented 34 % (16/47) of the total.
For this group, the PCI with the SIFE (27.06 ± 7.38) was
also significantly higher (p = 0.005) than the PCI with the
SIRE (25.56 ± 7.38).
Three patients (6.4 %) had an evaluation score of PCI
\20 with the SIRE procedure and [20 with the SIFE
procedure.
No postoperative mortality was observed. Postoperative
complications occurred in two patients (4.3 %) and inclu-
ded an acute acalculus cholecystitis in one case and a
postoperative pneumonia in the other. These two Grade II
complications evolved well under medical treatment. The
mean hospital stay was 2.8 days (range 2–6).
Discussion
This prospective study is the first to compare flexible and
rigid endoscopic trans-umbilical exploration of the peri-
toneal cavity. We show that both techniques allow easy and
Table 1 Patients and primary tumor characteristics
Gender
Male 25 (53.2 %)
Female 22 (46.8 %)
Mean age ± SD (year) 53 ± 11.3
Mean weight ± SD (Kg) 68 ± 12.6
Mean size ± SD (m) 1.72 ± 0.09
Mean BMI ± SD (Kg/m2) 23 ± 3.66
Previous surgical history n (%)
None 12 (25.5 %)
Laparoscopy 3 (6.4 %)
One laparotomy 18 (38.3 %)
Two laparotomies 8 (17 %)
Three laparotomies or more 6 (6.4 %)
Primary tumor site n (%)
Colorectal 24 (51.1 %)
Stomach 14 (29.8 %)
PMPa 3 (6.4 %)
Ovary 2 (4.3 %)
Unknown 2 (4.3 %)
Small bowel 1 (2.1 %)
Appendix 1 (2.1 %)
a Pseudomyxoma peritonei
Table 2 Access rates to the different regions of peritoneal carcinomatosis by single-incision rigid endoscopy (SIRE) and single-incision flexible
endoscopy (SIFE)
R0 R1 R2 R3 R4 R5 R6 R7 R8 R9 R10 R11 R12 Total
SIRE 46/47
97.9 %
29/47
61.7 %
31/47
66 %
28/47
59.6 %
43/47
91.5 %
41/47
87.2 %
29/47
61.7 %
42/47
89.4 %
44/47
93.6 %
41/47
87.2 %
47/47
100 %
43/47
91.5 %
43/47
91.5 %
507/611
83 %
SIFE 46/47
97.9 %
41/47
87.2 %
41/47
87.2 %
40/47
85.1 %
45/47
95.7 %
42/47
89.4 %
38/47
80.9 %
43/47
91.5 %
45/47
95.7 %
43/47
91.5 %
47/47
100 %
43/47
91.5 %
43/47
91.5 %
557/611
91.2 %
Pa NAb 0.001 0.004 0.001 0.48 1 0.008 1 1 0.48 NAb NAb NAb \10-11
a McNemar’s Chi-squared test
b Not available—perfect concordance between the two variables
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safe minimally invasive navigation into the peritoneal
cavity and staging of PC.
Despite major advances in imaging technology in the
last few years, the early and adequate detection of peri-
toneal dissemination remains challenging because of the
great variety in size, morphology and location of the
peritoneal lesions. Thus, the gold standard in diagnosing
PC continues to be the direct peritoneal visualization,
either by laparotomy or laparoscopy [11, 23].
Laparoscopic exploration of the abdomen supplements
the information provided by the imaging techniques and
enables direct visual assessment of peritoneal involvement.
It is associated with less pain, shorter hospitalization and
quicker time to recovery in comparison with laparotomy
[8]. Valle and Garofalo [24] used laparoscopy to stage 97
cases of PC and achieved full laparoscopic PCI assessment
in 96/97 cases, while only 2/96 cases were understaged.
There was a good correlation between the open successive
surgery data and the laparoscopic PCI. Pomel et al. [25]
achieved complete cytoreduction in seven of the eight
patients who were considered resectable by laparoscopy.
Despite these advantages, there are two major limita-
tions associated with laparoscopy. First, it is technically
challenging, especially in patients with extensive prior
surgery. In fact, a complete and systematic exploration of
the entire abdominal cavity and the direct palpation of the
peritoneum are only possible with laparotomy [26].
The second major concern is the risk of port track
seeding. In order to prevent this risk, some authors propose
to place all laparoscopy trocars in the midline and to resect
the scars at the time of cytoreduction [25]. In a recently
published study, Nunez et al. [18] showed that 42 % of
patients who underwent diagnostic laparoscopy for staging
of PC developed port site metastases. This complication
was an independent prognosis factor in patients with PC.
In our institution, because of the risk of malignant cells
spread through the trocar tract, all the PC-staging proce-
dures are performed via single-incision laparoscopy. This
minimally invasive technique allows using three instru-
ments through a single port. Several human series have
demonstrated its feasibility, with low morbidity and mor-
tality [27–29].
We found that this procedure was feasible in 94 % of the
cases (47/50). Two of the three failures were cases of
pseudomyxoma peritonei with extensive PCI. The third
case was a patient with PC from colic cancer who had
undergone 4 prior laparotomies. In all three cases, the
access to the peritoneal cavity was impossible, even after a
second upper midline laparotomy, because of thick
cancerous adhesions between the small bowel loops and
the abdominal wall.
However, this single-incision laparoscopic surgery
exploration generates new challenges and magnifies
difficulties compared with conventional laparoscopic sur-
gery [30].
The handling of straight instruments in parallel with the
laparoscope through a small single-incision decreases the
range of movements for the surgeon and complicates the
holding of the camera by the assistant [31]. Furthermore,
the lack of instrument triangulation increases the com-
plexity of organ exposure and exploration.
In order to overcome these pitfalls, we combined single-
incision laparoscopic surgery and flexible endoscopy. We
called this technique SIFE (single-incision flexible endo-
scopy). We showed that this technique consistently allowed
comprehensive evaluation of the peritoneal cavity in a live
porcine model, as well as in four human cadavers [21].
Some authors had described trans-umbilical endoscopic
surgeries, mainly appendectomy and cholecystectomy [32–
34]. This is the first study that evaluates this new technique
in the detection of PC.
We showed that the flexible endoscope allows better
overall access to the 13 regions of PCI than the rigid
laparoscope (91.2 vs. 83 %). The access rates to the regions
1, 2, 3 and 6 were statistically superior by SIFE in com-
parison with SIRE, 87.2 versus 61.7 %, 87.2 versus 66 %,
85.1 versus 59.6 % and 80.9 versus 61.7 %, respectively.
These results can be explained by great deflection capaci-
ties of the distal tip of the flexible endoscope, which
expands visualization possibilities in some areas difficult of
access even with the 30" angled laparoscope. These diffi-
cult-to-access areas include the peritoneal reflection at the
level of the coronary ligament of the liver in the Region 1,
the peritoneal reflection at the level of the phreno-splenic
ligament in the Region 3, the falciform ligament and the
hepatic hilum in the Region 2 and the Douglas pouch in the
Region 6.
There was no difference in the access rates to the other
regions between the two techniques. The small bowel
exploration was excellent with the two techniques. This
result seems obvious because of the central position of the
small bowel. It is also of major importance due to the fact
that an extensive involvement of the small bowel and its
mesentery can compromise the feasibility of cytoreductive
surgery.
The mean PCI was also significantly higher (p\ 104)
with SIFE 12.77 (±11.97) than with SIRE 11.77 (±11.63).
The results were similar for the patients suitable for HIPEC
(p = 0.0005), as well as the patients who had a PCI C20
(p = 0.005). In 25 % of the cases, the difference in PCI
between the two techniques was at least equal to 2. This
fact is of crucial importance, knowing that the PCI is the
main prognosis factor of PC. It serves as an estimate of
probability of complete cytoreduction and has been found
to be an accurate assessment of survival when cytoreduc-
tive surgery and intraperitoneal chemotherapy are used as
3812 Surg Endosc (2016) 30:3808–3815
123
treatment [22, 35, 36]. The evaluation of the PCI with the
SIFE had a therapeutic impact, in that it could help and
even change decision making. In our study, three patients
(6.38 %) with a PCI evaluation with SIRE\20 had in fact
a PCI C20 with SIFE and were, therefore, in theory, not
eligible for HIPEC.
However, a major limitation was associated with SIFE
because of its flexibility. In fact holding a flexible endo-
scope in a stable position in the peritoneal cavity is quiet
difficult. In order to overcome this lack of stability, the
assistant surgeon holds the trocar and maintains the torque
of the flexible endoscope. Moreover, the SILSTM port
system and the abdominal wall thickness allowed a certain
degree of stability compatible with a comprehensive and
convincing peritoneal exploration. This is not the case of
trans-gastric peritoneal exploration, where the lack of sta-
bility is due to the thinness of the gastric wall [37].
Voermens et al. [38] showed in a prospective, randomized,
controlled study in pigs that trans-gastric NOTES was
inferior to laparoscopic surgery for evaluation of PC
extension.
The problem of lack of stability may be solved by the
use of the flexible tip laparoscope [39]. More studies are
needed to evaluate this newly developed technology in
detection and staging of PC.
Although SIFE and SIRE demonstrated significantly
different results in terms of access rates to the different
regions of the PCI, the two techniques should be seen as
complementary rather than competing. In fact, SIRE offers
interesting capabilities in terms of intraperitoneal naviga-
tion, with good overall access to most sites (83 %). It does
not require any experience in endoscopy and is therefore
feasible by the majority of surgeons. SIFE can be associ-
ated with the procedure in order to explore the difficult-to-
access areas that we defined.
The last outcome of this prospective study was the
safety of the procedure. Because many of the components
of the flexible endoscope are temperature sensitive, steam
sterilization was not possible, and low-temperature chem-
ical methods, such as liquid chemical germicide, were
used. However, the SIFE does not seem to increase the
morbidity. In fact, the flexible endoscope was dedicated to
the procedure.
Following the guidelines on reprocessing flexible gas-
trointestinal endoscopes, a high-level disinfection was
performed after each procedure [40].
No mortality was observed. There were 2 grade II
complications [41], an acalculous cholecystitis in one case
and a postoperative pneumonia in the other. The evolution
was good in the two cases under medical treatment.
Garofalo et al. [42] reported a morbidity rate of 2.04 % in
197 patients who underwent laparoscopic staging of peri-
toneal surface malignancies (2 cases of infection of the
trocar insertion site, one diaphragm perforation and one
intraoperative bleeding). We consider that SIRE and SIFE
entail a small risk of complications, which is in contrast to
exploratory surgery where high mortality (20–36 %) and
morbidity (12–23 %) rates are observed in diagnostic
laparotomies performed in advanced tumor case series
[43].
This prospective study demonstrates that both SIRE and
SIFE allow comprehensive evaluation of the peritoneal
cavity for detection and staging of PC. Overall access rate
to the different regions of PCI was higher with SIFE
(91.1 %) than with SIRE (83 %). This difference was due
to the fact that SIFE was significantly superior to SIRE in
the exploration of some difficult-to-access areas, located in
regions 1, 2, 3 and 6. These two minimally invasive staging
procedures are safe and feasible. They have to be seen as
complementary rather than competing and should be
associated in order to appreciate accurately the PCI.
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ABSTRACT
Objective. This study was designed to identify factors
associated with morbidity and mortality in patients older
than 70 years who underwent cytoreductive surgery (CRS)
and hyperthermic intraperitoneal chemotherapy (HIPEC) for
peritoneal carcinomatosis (PC).
Background. Major surgery is associated with higher
morbidity and mortality in elderly patients. For PC, CRS
and HIPEC is the only current potential curative therapy,
but the risks inherent to this patient population have called
its benefits into question.
Methods. We retrospectively analyzed a multi-center
database from 1989 to 2015. All patients who underwent
CRS and HIPEC for PC were selected and patients older
than 70 years were matched 1:4 with a younger cohort
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according to cancer origin, peritoneal cancer index (PCI),
and completeness of cytoreduction. Major morbidity and
mortality were analyzed.
Results. Of 2328 patients, 188 patients older than aged
70 years were matched with 704 younger patients. Patients
older than aged 70 years demonstrated a higher American
Society of Anesthesiologist score (CASA III 10.8 vs. 6.6 %,
p = 0.008). There was no difference in overall 90-day mor-
bidity (C70: 45.7 % vs.\70: 44.5 %; p = 0.171); however,
patients older than 70 years had significantly more cardio-
vascular complications (13.8 vs. 9.2 %, p = 0.044).
Differences between the older and younger cohorts failed to
reach significance for 90-day mortality (5.4 and 2.7 %,
respectively; p = 0.052), and failure-to-rescue (11.6 and
6.1 %, respectively; p = 0.078). In multivariate analysis,
PCI[7 (95 % CI 1.051–5.798, p = 0.038) and HIPEC
duration (95 %CI 1.106–6.235, p = 0.028) were independent
factors associated with morbidity in elderly patients.
Conclusions. CRS and HIPEC appear feasible for selected
patients older than aged 70 years, albeit with a higher risk of
medical complications associated with increased mortality.
Peritoneal carcinomatosis (PC) is a common evolution of
abdominal cancers and is associated with a poor prognosis
without aggressive multimodal therapeutic approaches.1
Since its origin in the 1990s, cytoreductive surgery (CRS)
and hyperthermic intraperitoneal chemotherapy (HIPEC)
have been increasingly used as curative treatment for several
etiologies of peritoneal carcinomatosis.2,3 Cytoreductive
surgery and HIPEC offer the best outcome for pseudomyx-
oma peritonei and mesothelioma and represent the only
current curative treatment for colorectal and gastric PC.4–7
The proportion of North Americans and Western Euro-
peans aged 60 years and older is projected to reach 23 and
25 % of their respective total populations by the year
2020.8 Despite advances in surgical and perioperative care,
age remains independently associated with worse short-
term outcomes after major oncologic resections.9 The
feasibility of major hepatic, pancreatic, or gastric surgery
in elderly populations has been recently described, as had
the multidisciplinary approach required to optimize out-
comes for CRS/HIPEC, which is associated with morbidity
and mortality rates between 20–42 and 0–10 %, respec-
tively.10–15 This is especially true in the elderly, whose
reported post-CRS/HIPEC morbidity and mortality
increase to 19.4–56 and 0–18.2 %, respectively.16–23
Using a multi-institutional database, we present the largest
study of elderly CRS/HIPEC patients to date. Our primary
gaol was to identify specific factors associated with morbidity
and mortality in this otherwise understudied population.
METHODS
Study Population
Three French national databases encompassing 22 dif-
ferent institutions—RENAPE for rare PC, BIGRENAPE
for colorectal and gastric PC, and FROGHI for ovarian
PC—were retrospectively queried for all patients aged 70
or older who underwent CRS and HIPEC between 1989
and 2015.
Demographic and illness-specific data displayed in
Table 1 were obtained for each patient. For each patient,
the following data were extracted: gender, body mass index
(BMI), age at time of surgery, origin of PC, method and
duration of HIPEC, American Society of Anesthesiology
(ASA) score, history of neoadjuvant chemotherapy, extent
of PC determined according to the Peritoneal Cancer Index
(PCI),24 and completeness of cytoreduction according to
the CC score (CC-0, no residual nodule; CC-1, residual
nodes\2.5 mm; CC-2, residual nodules\25 mm; and CC-
3,[25 mm), length of surgery, length of stay in hospital
and postoperative morbidity and mortality.25 Postoperative
morbidity was graded according to the common toxicity
criteria of the National Cancer Institute (NCI-CTC version
3.0).26 Major complications grade III (severe adverse
events) and grade IV (life-threatening adverse events) up to
90 days after surgery were included in our analysis. Sur-
gical complications were defined as those related to the
operative site (abscess, fistula, bleeding, collection, or
incisional dehiscence) and medical complications grouped
according to organ system. Failure-to-rescue was defined
as death in a patient with one or more of the defined major
complications. The failure-to-rescue rate was calculated as
the number of patients who died after a major complication
divided by the total number of patients who developed a
major complication. This study was performed in accor-
dance with the precepts established by Helsinki
declaration.
Perioperative Evaluation and Management
Preoperative workup included a full history and physi-
cal, contrast CT scans of the chest, abdomen and pelvis,
and preoperative blood work including relevant tumor
markers. Eligibility for CRS/HIPEC was determined dur-
ing multidisciplinary conference involving medical and
surgical oncologists, radiologist, anesthesiologists, and
pathologists. Following CRS/HIPEC, all patients were
admitted to the ICU for at least one postoperative day
before transfer to progressively lower acuity units as
determined by the healthcare team.
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Cytoreductive Surgery and Hyperthermic
Intraperitoneal Chemotherapy
All centers performing CRS employ a team of surgeons,
anesthesiologists, and nurses specifically trained in this
procedure. Following laparotomy, PCI was assessed by
exploration of the entire abdominal cavity. Cytoreductive
surgery was performed with the goal of achieving complete
excision of tumor deposits, affected organs, and the
visceral and parietal peritoneum as described by Sugar-
baker.27 The CC score was determined upon completion of
CRS via visual assessment of the operative field.
Following CRS, HIPEC was performed by circulating a
heated solvent infused with chemotherapeutic medication
throughout the abdomen. This was performed using either
an open (‘‘Coliseum’’) or closed technique according to the
preference of the operating team. The choice of cytotoxic
agent and duration of hyperthermia depended on the origin
TABLE 1 Comparative clinicopathological, perioperative data for patients undergoing cytoreductive surgery for peritoneal carcinomatosis
according to the age (70 years and older and younger than 70 years)
Characteristic C70
(n = 188)
\70
(n = 704)
p value
Median age (range), year 72.47 (70.0–82.6) 56.74 (17.6–70.0) \0.001
Gender
Male 66 (35.1) 201 (28.6) 0.081
Female 122 (64.9) 503 (71.4)
Body mass index (kg/m2), median (range) 24.4 (15.8–42.4) 23.4 (13.3–45.3) 0.082
Preoperative chemotherapy 114 (60.6) 425 (60.5) 0.980
Nb of preoperative cycle of chemotherapy, median (range) 6 (2–70) 6 (1–44) 0.440
Delay between diagnosis and CRS/HIPEC in months (range) 10.5 (0–156) 10 (2–254) 0.825
Origin of PC
Colorectal 29 (15.4) 112 (15.9) 1
Ovarian 52 (27.7) 199 (28.3)
PMP 61 (32.4) 240 (34.1)
Gastric 6 (3.2) 24 (3.4)
MMP 25 (13.3) 91 (12.9)
Serous 9 (4.8) 26 (3.7)
Appendix 3 (1.6) 6 (0,9)
Other 3 (1.6) 6 (0.9)
ASA score
1–2 132 (89.2) 478 (93.4) 0.008
3–4 16 (10.8) 34 (6.6)
PCI, median (range) 12 (0–39) 12 (0–39) 0.765
Length of surgery (min), median (range) 300 (150–660) 330 (90–900) 0.096
CC score
0 136 (73.9) 537 (76.3) 0.637
1 33 (17.9) 123 (17.5)
2 5 (2.7) 20 (2.8)
3 10 (5.4) 24 (3.4)
HIPEC technique
Open 81 (43.5) 313 (45.4) 0.647
Closed 105 (56.5) 376 (54.6)
Median hospital stay in days (range) 20 (2–139) 19 (5–164) 0.489
Readmission 30 (26.1) 13428 0.675
Values in table are numbers of patients (percentages) unless otherwise indicated
PMP pseudomyxoma peritonei, MMP malignant mesothelioma of the peritoneum, Serous peritoneal serous carcinoma, PCI Peritoneal cancer
index, CC completeness of cytoreduction score, HIPEC hyperthermic intraperitoneal chemotherapy
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of carcinomatosis. The cytotoxic agents used, alone or in
combination, included cisplatin, mitomycin C, oxaliplatin,
doxorubicin, and irinotecan. No age-based adjustments to
HIPEC regimens were made.
Case-Matching
Each individual subject meeting the above criteria was
matched with patients aged \70 years from the same
databases according to pathology and similar PCI (±5) and
CC scores. To raise power, each subject was matched with
up to four younger patients.
Statistical Analysis
Descriptive results were expressed as a number (per-
centage) for qualitative variables and by mean ± standard
deviation (SD) or median (minimum–maximum) for
quantitative variables. Comparisons were performed using
v
2 test (or Fisher exact test when conditions for v2 were not
fulfilled) for qualitative variables and by Student’s t test (or
Mann–Whitney test in cases of non normality) for quanti-
tative variables. Univariate analysis for complications was
performed using logistic regression with an adjustment for
center. Multivariate analyses were done using a stepwise
TABLE 2 Postoperative morbidity and mortality, and treatment modality
C70
(n = 188)
\70
(n = 704)
p
Death within 90 days 10 (5.4) 19 (2.7) 0.052
Surgical complications 34 (18.1) 134 (19.0) 0.709
Intra-abdominal abscess 12 (6.4) 47 (6.7) 0.632
Digestive fistula 13 (6.9) 59 (8.4) 0.665
Intra-abdominal bleeding 6 (3.2) 51 (7.3) 0.064
Incisional dehiscence 4 (2.1) 3 (0.4) 0.026
Wound infection 3 (1.6) 3 (0.4) 0.154
Medical complications 77 (41) 270 (38.4) 0.095
Hematologic 23 (12.2) 121 (17.2) 0.591
Hemoglobin\80 g/L (4.9 mmol/L)
Hemoglobin\65 g/L (4 mmol/L)
Neutrophil granulocytes\1000/mm3
Associated with hyperthermia ([ 38.5)
Platelet\50,000/mm3
Cardiovascular 26 (13.8) 65 (9.2) 0.044
Cardiac arrhythmia
Digestive arterial thrombosis
Deep venous thrombosis or pulmonary embolism
Gastrointestinal 21(11.2) 87 (12.4) 0.884
Anorexia needing parenteral alimentation
Pancreatitis
Respiratory 31(16.5) 88 (12.5) 0.052
Acute respiratory distress syndrome
Renal 20 (10.6) 46 (6.5) 0.066
Renal insufficiency needing dialysis 8 (4.3) 15 (2.1) 0.056
At least one complication 86 (45.7) 313 (44.5) 0.171
More than one complication 43 (50) 146 (46.6) 0.595
Treatment
Interventional radiology 15 (9.4) 71 (10.8) 0.903
Endoscopic 30 (16.6) 77 (11.2) 0.208
Surgery 17 (13.6) 77 (15.8) 0.621
Values are numbers of patients (percentages) unless otherwise indicated
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logistic regression model. The significance level was set at
p = 0.05.
RESULTS
Population
Among 2328 patients treated with CRS and HIPEC for
PC, 188 patients were aged 70 years or older. They were
matched with a control group of 704 patients. Table 1
reports clinicopathological and perioperative data for the
matched cohorts. Peritoneal pseudomyxoma was the most
common etiology for patients older than age 70 years.
After matching, patients older than age 70 years displayed
a significantly higher ASA score (p = 0.008). There was
no difference regarding hospital stay and readmission.
Postoperative Morbidity and Mortality
Table 2 reports 90-day mortality and morbidity. For
patients aged C70 years, the 90-day mortality and mor-
bidity were 5.4 and 45.7 %, respectively. Cause of death
was preferentially due to medical complications (Table 3).
Cardiovascular complications in particular were signifi-
cantly more prevalent among older patients (13.8 vs.
9.2 %, p = 0.044). There was no significant difference in
mortality (5.4 vs. 2.7 %, p = 0.052, respectively) or mor-
bidity compared with the younger cohort (45.7 vs. 44.5 %,
p = 0.171, respectively). Similarly, failure to rescue was
higher in older patients (11.6 %) than younger (6 %),
although this also was not significant (p = 0.078). In
multivariate analysis, for patients aged C70 years, there
was no independent factor associated with mortality, but
PCI [7 (odds ratio 2.469; 95 % CI 1.051–5.798,
p = 0.038) and the HIPEC duration (odds ratio 2.626;
95 % CI 1.106–6.235, p = 0.028) were independently
associated with increased morbidity (Table 4).
DISCUSSION
Our study suggests that, given appropriate patient
selection, postoperative mortality and morbidity after
CRS/HIPEC is comparable between patients aged
[70 years and their younger counterparts. Nonetheless
and despite no statistically significant difference, the
failure-to-rescue rate was higher in elderly group (11.6
vs. 6.1 %, p = 0.078), supporting the prevailing opinion
that elderly patients are at a higher risk of death fol-
lowing a complication. The mortality rate in our study
was similar to that after major hepatic or pancreatic
surgery and the mortality previously reported after CRS/
HIPEC in elderly patients.10–13,16–23 To the best of our
knowledge, this study is the largest series of elderly
patients undergoing CRS/HIPEC to date and supports the
feasibility and the safety of CRS/HIPEC in well-selected
elderly patients.
Age is directly related with comorbidities and a reduced
capacity to recover after surgery.28,29 In addition, this
increased risk has been argued to be due preexisting
medical disease as shown in studies demonstrating greater
postoperative complications after noncardiac surgery
among patients older than 70 years.30 Our results support
this argument; there was no difference in surgical com-
plications, but medical complications were more frequent
for elderly patients and associated with an increased risk of
failure-to-rescue. However, this risk may be mitigated by
careful patient selection and age-appropriate care, includ-
ing geriatric consultation, supplemental enteral nutrition,
and early rehabilitation placement planning.31 In the past,
age alone has been considered a limiting factor when
TABLE 3 Cause of death for patients C70 years
Patient Age (years) Malignancy Cause(s) of death
1 71.9 Mesothelioma Cerebral hemorrhage
2 70.6 Pseudomyxoma peritonei MSOF, renal failure
3 72.4 Pseudomyxoma peritonei Massive intrapulmonary hemorrhage
4 70.3 Cancer primitive of peritoneum MSOF
5 73.9 Colon Enterocutaneous fistula, renal failure
6 82.5 Ovarian Pancreatic leak, renal failure
7 70.3 Colon renal failure
8 71.7 Colon ARDS
9 70.5 Pseudomyxoma peritonei MSOF, pneumonia
10 70.0 Ovarian Hemorrhagic shock
MSOF multisystem organ failure, ARDS acute respiratory distress syndrome
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pursuing major abdominal surgery. However, this dogma
appears outdated and several recent studies shown that age
does not influence the oncologic outcome of surgery and
that cancer-specific survival in these patients is similar to
that of younger patients.10,32,33 Therefore, elderly patients
might benefit from being offered CRS/HIPEC for PC as
well as other major intra-abdominal surgeries.
Our study focused on 90-day outcomes due to the high
physiologic impact of this complex surgical procedure. The
overall mortality and morbidity in that time period were 5.4
and 45.6 %, respectively, with a 26.1 % risk of readmis-
sion. These data are comparable with data reported by
Chua et al. for the general population after CRS/HIPEC.34
Similar morbidity and mortality rates for performing CRS
and HIPEC for elderly patients compared with younger
patients also have been reported previously (Table 5).16–23
However, strict selection of the patients appears to be even
more important in this population, as demonstrated by as
TABLE 4 Univariate and multivariate analyses of risk factors for major complications and mortality after CRS/HIPEC for patient C70 years
Post-operative complication Post-operative mortality
Univariate Multivariate Univariate
Risk factor p Odds ratio 95% CI p p
Lower Upper
Age 0.761 0.208
Origin of peritoneal carcinomatosis 0.991 0.468
PCI 0–7 versus[7 0.067 2.469 1.051 5.798 0.038 0.937
PCI 0–10 versus 11–15 versus[16 0.061 0.951
PCI 0–18 versus[18 0.232 0.448
Gilly score 0–1–2 versus 3–4 0.406 0.930
ASA score 1 versus 2 versus 3 0.609 0.451
CCR score 0 versus 1 versus 2 0.217 0.868
CCR score 0 versus 1 ? 2 0.151 0.850
Hepatic resection 0.840 0.194
HIPEC technique: close versus open 0.465 0.961
HIPEC duration 0.008 2.626 1.106 6.235 0.028 0.987
HIPEC with cisplatin 0.909 0.191
HIPEC with doxorubicin 0.429 0.959
HIPEC with mitomycin 0.662 0.606
TABLE 5 Reported morbidities and mortalities of CRS/HIPEC in the elderly population
Study (yr) N Ages Carcinomatosis origin Morbidity (%)a Mortality (%)
Alyami (2016)b 188 C70 Colorectal, ovarian, mesothelioma, pseudomyxoma, gastric, other 45.7 5.4
Huang (2015) 124 C65 Colorectal, mesothelioma, appendix, pseudomyxoma 40 3
Delotte (2015) 15 C70 Ovarian 20 0
Cascales-Campos (2014) 9 C75 Ovarian 56 0
Spiliotis (2014) 30 C70 Colorectal, ovarian, gastric, pseudomyxoma, sarcoma, mesothelioma 50 3.3
Votanopolous (2013) 81 C70 Appendiceal, mesothelioma, ovarian, colon, gastric 38 13.5
Tabrizian (2013) 35 C65 Colorectal, ovarian, appendiceal, mesothelioma, pseudomyxoma, gastric 19.4 11.4
Klaver (2012) 24 C70 Colorectal 33.3 0
Macri (2011) 11 C65 Colorectal, ovarian, gastric 27.3 18.2
Total (mean %) 517 36.6 6.08
a Where reported, Grade I-II morbidity was excluded
b Our study
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demonstrated by the strong impact of the PCI on the
occurrence of complications. Peritoneal carcinomatosis
index[7 and HIPEC duration were two independent risk
factor for postoperative complications in the elderly
patients. The potential benefit of extended CRS for elderly
patients with PCI[7 is questionable.
We recognize that the current study is limited in its
retrospective nature and high selection bias of elderly
patients who are offered CRS/HIPEC. It does, however,
demonstrate the surgical outcomes of CRS/HIPEC proce-
dures across multiple institutions, regardless of primary
tumor etiology, on a population that will continue to grow
in the future.8 We believe that rigorous patient selection is,
in fact, the key to maintaining low complications rates for
older patients. In addition to strict patient selection criteria,
both the patient and their families must understand the
considerable risks of these procedures as well as the
potential impact to their quality of life, which may be
negatively impacted for up to 6 months.35,36 Unfortunately,
quality of life data for our experimental group were not
available. Nonetheless, appropriately selected patients
stand to gain a considerably improved quality of life from
this aggressive surgical therapy. Therefore, CRS and
HIPEC should not be withheld from elderly patients who
stand to improve quality of life and survival, especially
when selected in a multidisciplinary fashion and treated at
high-volume centers.
CONCLUSIONS
CRS and HIPEC can achieve comparable perioperative
outcomes in well-selected patients previously thought too
old to undergo these procedures. The results of this study
should encourage surgeons to offer potentially curative
CRS/HIPEC to elderly patients according to a multidisci-
plinary preoperative evaluation.
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Abstract
Background: Pseudomyxoma peritonei (PMP) is a rare carcinomatosis limited to the peritoneal cavity, mainly supplied by the superior
mesenteric artery (SMA). The only curative treatment is cytoreductive surgery (CRS) associated with hyperthermic intraperitoneal chemo-
therapy. This study aimed to evaluate the ability of blood flow volume (BFV) recorded in the SMA using Doppler ultrasonography pre-
operatively to predict the extent and resectability of the disease and post-operatively to assess clinical outcome.
Methods: BFV was measured in the SMA of forty-nine patients before and the year following CRS. Patients were categorized in 3 groups
according to clinical and surgical outcomes: group-1 (n ¼ 22): patient with completed CRS, group-2 (n ¼ 16): incomplete resection with
slowly progressive disease (alive at 2 years without severe clinical symptoms), group-3 (n ¼ 11): incomplete resection and with severe
clinical symptoms or dead within two years.
Results: Pre-operative mean SMA BFV was higher in group-2 (510 mL/min, p ¼ 0.027) and in group-3 (572 mL/min, p ¼ 0.004) than in
group-1 (378 mL/min). After surgery, BFV dropped to normal values (203 mL/min, p ¼ 0.001) in group-1, and to 423 mL/min ( p ¼ 0.047)
in group-2. It remained elevated in group-3 (626 mL/min, p ¼ 0.566). BFV allowed stratification of 1) resectability before CRS (group-2
and -3 vs group-1, area under the ROC curve: 0.794 [0.650e0.939]), and 2) non progression after incomplete CRS (group-3 vs group-2, area
under the ROC curve: 0.827 [0.565e1.00].
Conclusions: Pre-operative BFV in the SMA correlates with extent and resectability of PMP. After incomplete surgery, post-operative BFV
might aid in identifying patients who may benefit of post-operative therapy.
! 2017 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.
Keywords: Pseudomyxoma peritonei; Cytoreductive surgery; Hyperthermic intraperitoneal chemotherapy; Doppler ultrasonography; Superior mesenteric
artery
Introduction
Pseudomyxoma peritonei (PMP) is a rare disease with
an estimated incidence of one to two per million per year
that is characterized by diffuse intra-abdominal gelatinous
ascites.1 The only curative treatment for PMP consists of
a combination of cytoreductive surgery (CRS) with hyper-
thermic intraperitoneal chemotherapy (HIPEC).2 When
resection is complete, this treatment may achieve a
20-year survival rate of 70%.3,4
The World Health Organization (WHO) has recently
classified PMP into two pathological categories: low and
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high grade tumors. While some studies suggested that the
grade correlates with prognosis (overall 5-year survival of
63% for low grade and 23% for high grade re-
spectively),1e5 others have suggested that recurrence
and survival are quite variable for PMP of the same
grade.6
When complete surgical resection is not achievable,
therapeutic options are limited. Many oncologists propose
the same chemotherapy regimen as that used in colorectal
cancer; especially in case of high grade PMP.7 Others
have suggested the use of anti-angiogenic agents, which
have conferred benefits in case studies.8 However, clinical
outcome in PMP is not related to disease grade alone as
some patients with high grade disease may have few
symptoms and live longer than those with lower grades
whose disease may be complicated by compression of
digestive structures and severe clinical symptoms leading
to death.6 Low grade PMP is far more frequent than high
grade PMP (78 vs 22%, respectively), and among patients
with low grade PMP, those with slowly progressive dis-
ease will benefit of a therapeutic pause, while patients
with aggressive disease may benefit of a post-operative
chemotherapy and anti-angiogenic agents as high grade
PMP.7,9
To date, there are no clinical, biological or patholog-
ical criteria to assess the activity of PMP and to distin-
guish between aggressive and less aggressive PMP.
Imaging evaluation of patients with PMP is based on
morphological examination such as computed tomogra-
phy or magnetic resonance imaging (MRI), but assess-
ment of progression or stability of the disease is
difficult as there are no standardized and not well-
established criteria as those used for solid tumors.10
Numerous studies have demonstrated that Doppler ultra-
sonography (Doppler-US) of the arteries supplying the
alimentary tract is a reliable imaging modality to
monitor blood flow velocities (BFVels) or blood flow
volume (BFV) in inflammatory bowel disease and he-
patic malignancies.11e13 Moreover, it has been sug-
gested that measurement of the BFVels or BFV in the
feeding artery upstream of the tumor vascular network
allows for the semi-quantitative analysis of the develop-
ment or the involution of tumor vasculature.14,15 Of
note, Dohan et al. have demonstrated that Doppler-US
of the superior mesenteric artery (SMA) can be used
to monitor tumor angiogenesis and response to antian-
giogenic therapy after CRS in an orthotopic murine
model of PMP.16
As blood flow is supplied to PMP mainly from the SMA,
we anticipated that the increased blood supply to the PMP
would be reflected in BFV in this vessel, which had never
been evaluated before. The objectives to the current study
were to evaluate the ability of BFV recorded in the SMA
by Doppler-US, 1) pre-operatively to predict the extent
and resectability of PMP and 2) post-operatively to assess
clinical outcome in patients with PMP.
Patients and methods
Patient cohort
After IRB approval, all patients gave their informed con-
sent to be enrolled in this prospective single center study,
from October 1st, 2011 to October 1st 2016. Patients
were included into the study when they were scheduled
to undergo surgical resection of PMP or after surgery.
The first step of the surgical procedure was a peritoneal
exploration with determination of the peritoneal carcinoma-
tosis index (PCI) followed by the decision to perform HI-
PEC.4,17 All patients had a pathological analysis with an
evaluation of the tumor grade according to the WHO
classification.5
The study population comprised 49 consecutive patients,
22 (45%) men and 27 (55%) women, with a mean age of 57
[26e87] years (mean [minemax]). Among these 49 pa-
tients, 41 (82%) had SMA BFV measurement during the
month (mean: 1.3 months) before the CRS, and 30 (60%)
within the 6e12 months following surgery (10.1
[6.1e11.9] months). Twenty two (45%) patients had
Doppler-US examination before and after surgery, 19
(39%) only before surgery, 8 (16%) only during follow-
up. A group of 14 healthy patients was constituted as a con-
trol group to determine the normal values of SMA BFV
(Fig. 1).
Classification of patients according to clinical
outcome
Patients were distributed into 3 groups according to their
clinical and surgical outcome as follows. Completeness of
resection was graded according to Sugarbaker’s complete
cytoreduction (CCR) score as follows: CCR0: no residual
tumor; CCR1: residual tumor < 0.25 cm; CCR2: residual
tumor between 0.25 and 2.5 cm; CCR3: residual
tumor > 2.5 cm.4
- Group-1: patients with complete resection (CCR0 or
CCR1 score), HIPEC and absence of recurrence within
two years after surgery or at last follow-up (n ¼ 22,
among them, 6 patients had SMA BFV measurements
before and after surgery);
- Group-2: patients with incomplete resection (CCR2 or
CCR3 score) with slowly progressive disease: alive 2
years after surgery or at last during follow-up without
severe clinical symptoms (performance status ¼ 0 or
1), (n ¼ 16, among them, 11 patients had SMA BFV
measurements before and after surgery);
- Group-3: patients with incomplete resection (CCR2 or
CCR3 score) with severe active progressive disease:
dead within 2 years after surgery or with severe clinical
symptoms (performance status >1), (n ¼ 11, among
them, 5 patients had SMA BFV measurements before
and after surgery).
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Superior mesenteric artery ultrasound imaging
The sonographer was blinded to the clinical and radio-
logical status of each patient; the surgeon and the radiolo-
gist were blinded to the SMA BFV. The SMA BFV was
not included as an element of the surgical decision or as
an element of the follow-up.
Doppler-US was performed at rest in patients in 45#
seat-position after an overnight fast using an ultrasound
scanner (Acuson S2000", Siemens, Erlangen, Germany)
equipped with a curvilinear transducer type CH4-1 (6-
4 MHz) as previously described.11 The SMA was studied
in its long axis in the sagittal plan. M-mode was activated
for measurement of inner diameters. Pulsed Doppler was
activated for blood flow velocity (BFVel) waveforms acqui-
sition 2e3 cm after the SMA origin. Great attention was
given to angle correction application in order to record ac-
curate velocities. Spatial-average-time-average BFVel was
calculated from the spectral analysis of the Doppler signal
by integrating the area under instantaneous mean velocity
curve. BFV was calculated using the following formula:
BFV ¼ [(BFVel 0.60). (p. (D/2)2)], where BFV is the blood
flow volume in mL/min, BFVel is the spatial-averaged-
time-averaged mean blood flow velocity in cm/s, and D
the SMA diameter in cm. For each patient, BFV was
measured five times during quiet breathing and averaged.
Accuracy of the superior mesenteric artery blood flow
volume measurement
Repeatability of SMA diameter, BFVel and BFV mea-
surements was investigated in the controls through the
calculation of the repeatability coefficient (RC) (British
Standards Institution Precision of Test Method).18 Two
series of paired measurements separated by 2 min interval
performed by the same investigator were compared accord-
ing to the formula: RC2 ¼ SDi2/N, where N is the sample,
Di is the relative (positive or negative) differences within
each pair of measures. This coefficient is the standard devi-
ation of the estimated difference between two repeated
measurements. The RC values for intra-observer repeat-
ability were 0.05 mm for the inner diameter, 0.4 cm/s for
the spatial-averageetime-average mean blood flow velocity
and 5.0 mL/min for the BFV.
Blood tests
All patients had carcinoembryonic antigen (CEA) serum
level measurement before and after surgery. For the 13 pa-
tients who were included after surgery, pre-operative CEA
was collected retrospectively. Carbohydrate antigen CA125
and CA19-9 were not routinely collected and not available
for all patients.
Statistical analysis
Continuous variables are reported as mean [minemax].
The Gaussian distribution of the continuous variables was
assessed using the ShapiroeWilk test. Survival curves in
the 3 groups were estimated according to the KaplaneMe-
ier method. Comparisons between the survivals of the
different groups were performed using the Log-rank test.
Categorical data were analyzed using the Chi-squared test
or Fischer’s exact test when appropriate, whereas differ-
ences in continuous variables (SMA BFV, and CEA serum
level) before and after CRS, according to the patients
groups were analyzed with a two-way ANOVA with post-
hoc Bonferroni correction and paired or unpaired Student
Figure 1. Flow chart of patient enrolled in the study. SMA BFV indicates superior mesenteric artery blood flow volumes, CRS, cytoreductive surgery, HIPEC,
hyperthermic intra peritoneal chemotherapy.
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t-test. For the 22 patients with both pre- and post-operative
value of SMA BFV, an ANOVA for repeated measurements
was performed between pre- and post-operative values with
patients groups as between-subjects factor. A polynomial
regression was calculated between the pre-operative SMA
BFV and the PCI. A receiver operating characteristics
(ROC) curve of pre- or post-surgical BFV was built and a
cut-off value was calculated to discriminate 1) between pa-
tients who benefited from completeness of resection from
the others or 2) between patients who had severe active pro-
gressive disease (group-3) from those with slowly progres-
sive disease (group-2). Areas under curves (AUC) were
calculated. Sensitivity and specificity obtained with the
respective cut-off BFV values were calculated (MedCal"
Software, Mariakerke, Belgium). P values < 0.05 were
considered significant.
Results
Survival
Overall survival was higher in group 1 than in group 2
( p ¼ 0.003), in group-1 than in group-3 ( p < 0.001) and
in group-2 compared to group-3 ( p ¼ 0.021) (Fig. 2). There
was no difference in age, sex ratio and low/high grade ratio
between the three groups. PCI were different between
group-1 (16 [0e39]) vs group-2 (31 [20e39], p < 0.001)
and group-3 (33 [23e39] vs group-1, p < 0.001). There
was no difference in PCI between group-2 and group-3
( p ¼ 0.453). Affected areas counts were also different be-
tween group-1 (7 [1e13]), group-2 (12 [9e13], p ¼ 0.002)
and group-3 (13 [12e13], p < 0.001 vs group-1), without
any difference between group-2 and group-3 ( p ¼ 0.270).
Patients’ characteristics are summarized in Table 1.
Pre-operative blood flow volume measurements
Before surgery, BFV in the SMA was lower in group-1
than in group-2 (378 [220e779], vs 510 [338e840] mL/
min respectively; p ¼ 0.027) and that in group-3 patients
(572 [265e889] mL/min, p < 0.001, Table 1). No differ-
ence was observed in baseline BFV between group-2 and
group-3 patients ( p ¼ 0.388) (Fig. 3a). We found a polyno-
mial regression between the baselines BFV and PCI
(R ¼ 0.65, p < 0.001, Fig. 3b). There was no difference
in baseline BFV between patients with high histological
grade (488 [225e775] mL/min) and patients with low
grade (434 [220e889] mL/min, p ¼ 0.429).
A ROC curve showed the ability of pre-operative BFV
to distinguish resectable (group-1) from unresectable
PMP (groups-2 and -3). The area under the curve (AUC)
was 0.794 [95%CI: 0.650e0.932]. A pre-operative BFV
>450 mL min$1 yielded a sensitivity of 68.2% and a spec-
ificity of 78.9% for predicting incomplete resection (group-
2 or -3) (Fig. 4a).
Post-surgical blood flow volume measurements
In group-1, BFV in the SMA dropped from 378
[200e779] to 214 [150e265] mL/min ( p ¼ 0.001) after
surgery reaching values of healthy controls (236
[179e309] mL/min, p ¼ 0.091). In the group-2 the BFV
decreased from 510 [338e840] to 406 [265e630] mL/
min, ( p ¼ 0.026). No effect of surgery was found regarding
the BFV in group-3 (572 [265e889] before to 645
[528e773] mL/min after surgery, p ¼ 0.057). Two-way
ANOVA showed a significant interaction between patients
groups and pre-/post-operative SMA BFV values
( p ¼ 0.037) illustrative of the drop in SMA BFV after sur-
gery in group-1 and -2, and the trend of increase in the
group-3. For the 22 patients with both pre- and post-
operative Doppler-US examinations, the pre- and post-
operative SMA BFV modifications were highly significant
between the three groups ( p < 0.001, ANOVA for repeated
measurements). In group-2, 5/16 (31%) patients and in
group-3, 3/11 (27%) patients had post-operative chemo-
therapy ( p ¼ 0.360). The use and the type of chemotherapy
was: Folinic acid and 5-Fluorouracil associated to Oxalipla-
tin (FOLFOX) (n ¼ 5) or Irinotecan (FOLFIRI) (n ¼ 3). No
difference in BFV was found between patients who did and
did not receive post-operative chemotherapy.
A ROC curve showed the ability of post-operative BFV
to distinguish group-2 from group-3 patients. The AUC was
0.827 [95%CI: 0.565e1.00]. A post-operative BFV
>530 mL min$1 yielded a sensitivity of 80.0% and a spec-
ificity of 93.3% for the diagnosis of aggressive PMP
(group-3) (Fig. 4b).
Figure 2. Survival curves in the three different groups of patients. Patients
with completed CRS and HIPEC (group-1) were alive after 2 years. Sur-
vival of patients with uncompleted CRS and progressive PMP was lower
than group-1 (group-3 vs group-1, p < 0.001), and survival of patients
with uncompleted CRS and slowly progressive PMP was also slower
than group-1 (group-2 vs group-1, p ¼ 0.003). Survival was higher in
group-2 compared to group-3 ( p ¼ 0.021).
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Blood tests
Pre- and post-operative CEA serum levels were not
different among the 3 groups (Table 1).
Discussion
This study demonstrates that pre-operative BFV
measured in the SMAwith Doppler-US correlates with sur-
gical PCI and might be helpful to predict resectability.
SMA BFV measurements showed an interesting predicting
value for incomplete resection (sensitivity of 68.2% and
specificity of 78.9%). Moreover, we found that post-
operative SMA BFV may help discriminate between
aggressive and slowly progressive PMP in patients who
have incomplete surgical resection, with a sensitivity of
80.0% and a specificity of 93.3%. This technique may
help early stratify patients with a poor prognosis and those
who might benefit of additional chemotherapy. Conversely,
patients with slowly progressive PMP as identified using
post-operative BFV measurement may be considered for
withdrawal from therapy.
We found that patients who had complete CRS and HI-
PEC (group-1) had post-operative SMA BFV values similar
to those of healthy controls. These patients are assumed to
have a very good prognosis. The return to normal BFV
values in the SMA after surgery suggests the absence of re-
newed tumor vascular network development and thus the
absence of recurrence of the PMP. Conversely, a persis-
tently high SMA BFV one year after surgery suggests
continued progression of the tumor vasculature to meet
metabolic needs, thus reflecting recurrence of the disease.
According to Poiseuille’s law, local BFV is adjusted by
variations of local hemodynamic resistance.19 When tumor
tissues develop on or in an organ, metabolic demands in-
crease, inducing sprouting angiogenesis from the vascular
network of the native organ, resulting in an extension of
the micro-vascular network downstream from the feeding
artery of the affected organ. Local hemodynamic resistance
thus falls and the BFV in the feeding artery increases.
Table 1
Patients’ baseline characteristics, Doppler ultrasonography and laboratory findings.
Group-1 (n ¼ 22) Group-2 (n ¼ 16) Group-3 (n ¼ 11) One-way or two-way
ANOVA, p value
Age
(years)
Mean
(SD)
[range]
56
(14)
[26e76]
58
(13)
[35e73]
57
(14)
[34e87]
0.874
Gender Women
Men
15
7
6
10
6
5
0.172
Grade Low
High
19
3
12
4
9
2
0.671
PCI Mean
(SD)
[range]
16
(11)
[0e39]
31
(7)
[20e39]
33
(6)
[23e39]
<0.001
Affected areas count Mean (SD)
[range]
7
(5)
[1e13]
12
(1)
[9e13]
13
(1)
[12e13]
<0.001
Delay between diagnosis
and surgery
(month)
Mean (SD)
[range]
34
(56)
[0e159]
7
(8)
[1e31]
55
(90)
[2e258]
0.181
Post-
operative chemotherapy
yes
no
0
23
5
11
3
8
0.360
Before
CRS
After
CRS
Before
CRS
After
CRS
Before
CRS
After
CRS
Between groups
p value
After/Before
p value
SMA BFV
(mL/min)
Mean
(SD)
[range]
378
(151)
[220e779]
214***
(46)
[150e265]
510
(146)
[338e840]
406*
(101)
[265e630]
572
(184)
[265e889]
645
(107)
[528e773]
<0.001 0.069
Delay
Doppler-US/Surgery
(month)
Mean
(SD)
[range]
1.0
(0.8)
[0.3e2.5]
e 1.0
(0.7)
[0.2e2.3]
e 0.9
(0.7)
[0.2e2.7]
e 0.941 e
Delay
Surgery/
Doppler-US
(month)
Mean
(SD)
[range]
e 10.4
(2.1)
[7.0e11.9]
e 9.7
(2.3)
[5.1e11.8]
e 9.8
(2.3)
[6.1e11.6]
0.961 e
ACE (mg/l) Mean
(SD)
[range]
41
(87)
[1e304]
6
(7)
[1e16]
16
(20)
[1e50]
82
(241)
[1e600]
31
(25)
[1e67]
51
(11)
[39e60]
0.762 0.581
SD standard deviation, PCI Peritoneal Cancer Index, SMA BFV Blood flow volume in the superior mesenteric artery, CRS cytoreductive surgery; *p < 0.05,
***p < 0.001 after vs before CRS.
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Although it has been suggested, but only in small-scale
studies, that tumor grade correlates with vascularity and de-
gree of enhancement on MRI or degree of glucose uptake
on positron emission tomography,20,21 pre-operative SMA
BFV did not correlate with tumor grade in our study. More-
over, it has been suggested that CEA levels may aid follow-
up decisions in high grade PMP, but serum CEA levels did
not reflect tumor activity, PCI or disease free survival.22
There was no difference in survival between patients
with low and high grade PMP in our series, but this might
be because of the low rate of high grade patients. As PMP is
rare and high grade PMP less frequent than low grade PMP,
validation of criteria predicting the grade would require a
larger number of patients which is rarely achieved in imag-
ing studies.23
Unresectable high grade PMP is usually treated with
chemotherapy and there is no consensus on the manage-
ment of unresectable low grade PMP. Our study shows
that SMA BFV might be helpful to stratify patients with
indication of antiangiogenic treatment (high-perfused
PMP).8,16 Our hypothesis was that a decrease in SMA
BFV was related to the decrease in tumor burden and to
the decrease of angiogenic activity of the tumor. This func-
tional relationship has been previously shown in a murine
model of PMP.16
While our cohort was small (49 patients), it was neverthe-
less sizeable for a single-center prospective study PMP and a
rare disease. Our rare cancer group network (RENAPE)
treated w100 patients affected by PMP during the last 10
Figure 3. (a) Blood flow volume (BFV) in the superior mesenteric artery
(SMA) before and after surgery. (*p < 0.05, **p < 0.01, baseline BFV
in the SMA related to the patients groups; #p < 0.05; ##p < 0.01, BFV
measured before and after surgery; zzzp < 0.001, BFV measured after sur-
gical treatment related to patients groups). (b) Polynomial regression be-
tween blood flow volume (BFV) measured in the superior mesenteric
artery (SMA) and peritoneal carcinomatosis index (PCI) before surgery.
Tumours grade are noted with coloured dot. ( low grade,C high grade).
Figure 4. (a) Graph shows ROC curves for pre-surgical BFV in differenti-
ating between patients with resectable PMP (group-1) and patients with
unresectable PMP (groups-2 and -3). The area under the curve was
0.794 [95%CI: 0.650e0.932]. A pre-operative BFV > 450 mL min$1
yielded a sensitivity of 68.2% and a specificity of 78.9%for predicting
incomplete resection (group-2 or -3). (b) Graph shows ROC curves for
post-surgery BFV in differentiating between patients with aggressive
PMP (group-3) and patients with slowly progressive PMP (group-2). The
area under the curve was 0.827 [95%CI: 0.565e1.00]. A post-operative
BFV >530 mL min$1 yielded a sensitivity of 80.0% and a specificity of
93.3% for the diagnosis of aggressive disease (group-3).
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years. Follow-upwas in some cases compromised by distance
from patients home and the hospital. In addition, because of
advanced age (>80 years) some patients were excluded
from the HIPEC procedure. This could explain why we did
not observe recurrence in group-1 patients. The current study
should thus be expanded to other reference centers to validate
BFVas a biomarker of disease activity, particularly in combi-
nationwithMRI. Doppler-US offers a quantitative evaluation
of SMA BFV. Although the technique is known to be
operator-dependent, the application of strict procedural mea-
surement protocols reduces inter-observer variation.
In conclusion, our results suggest that post-operative
BFV measured in the SMAwith Doppler-US helps differen-
tiate aggressive versus slowly progressive PMP in patients
who had incomplete surgical resection. This technique
may allow the early identification of patients who may
benefit from post-operative chemotherapy and those who
have achieved full benefit from therapy (CRS % HIPEC).
Moreover, we found that pre-operative BFV correlates
with surgical PCI and might be helpful to predict resect-
ability. Assessment of BFV in the SMA may thus serve as
a quantitative biomarker that adds functional information
to diagnostic morphological techniques. Doppler-US imag-
ing is a widely accessible, cheap, easy-to-repeat and non-
invasive modality that could allow functional evaluation of
tumor progression to be included in future decision algo-
rithms and scoring systems. Our study is the first to report
measurement of the BFV in the SAM to follow the progres-
sion of a peritoneal disease. This study represents the neces-
sary pilot study to establish the proof of concept but needs
further validation by multicenter clinical trial.
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ABSTRACT 
BACKGROUND: In patients with synchronous peritoneal spread from gastric cancer, only palliative 
treatment is proposed. Asiatic surgeons, develop a new concept using bidirectional combination of 
intraperitoneal and intravenous chemotherapy with high response rate and low incidence of toxicity. 
We conducted the first pilot study in Western country, using bidirectional combination of European-
standard drugs for gastric cancer. The main endpoint was to evaluate the feasibility and safety of this 
treatement. Secondary endpoint was success of therapeutic strategy reflected by overall survival (OS) 
and the decrease of 25% of attempted peritoneal cancer index (PCI) evaluated by laparoscopy. 
METHODS: All patients with non-resectable peritoneal carcinomatosis (exclusive?) from gastric 
cancer, confirmed by laparoscopy, underwent a bidirectional chemotherapy using intraperitoneal 
docetaxel and intravenous 5-fluorouracil (5FU) and oxaliplatin (FOLFOX). Docetaxel at 30mg/m2 
administrated intraperitoneally at day 1, 8 and 15 and IV FOLFOX intravenous at day 1 and 15	
followed by 7 days’ rest, as one course. After three courses, the PCI was evaluated with a second 
laparoscopy.  
RESULTS: We enrolled six consecutives patients. The average age was 47.1 years [range 24-66], 
performance status ECOG 0-1. The mean PCI was 34 (range 30-39). After one bidirectional cycle, 
major complications (grade 3/4) occurred in two patients (hematologic and asthenia). One patient had 
major PCI response, 3 partial PCI response and 2 clinical progressions.  The mean PCI decrease to18 
(range 12 – 29). The median OS was 10.3 months (range 5-23); 1-year OS rate was 50%. One patient 
was operated with CC0 resection after major response, with a PFS of X months  
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CONCLUSION: This pilot study confirms the feasibility and safety of bidirectional treatment with 
IP and IV chemotherapy for patients with advanced gastric cancer and peritoneal carcinomatosis, 
resulting in 10.3-months median OS with limited morbidity. The decrease of PCI after one 
bidirectional cycle is promising. Further phase I-II studies are required for the validation of that 
strategy.  
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INTRODUCTION 
 
More than 50% of patients with advanced gastric cancer patients die of peritoneal recurrence. 
Peritoneal carcinomatosis (PC) is frequent (up to 20%), induces symptoms and often limits treatment 
options. The median overall survival (OS) of patients with PC from gastric cancer treated with 
chemotherapeutic agents such as taxanes, platinum salts and 5-fluorouracile (5-FU) is poor, between 
3 to 8 months in HER-2 negative tumors (Wagner Cochrane Database Sist Rew 2010, Thomassen 
IJC 2014). This limited survival did not really increase during the last years, for that new treatment 
options are required. Several reports have suggested that cytoreductive surgery and peritonectomy 
procedures combined with hyperthermic intraperitoneal chemotherapy (HIPEC) and/or postoperative 
intraperitoneal chemotherapy may lead to cure in selected patients with PC from various digestive 
and extra-digestive cancers (Glehen Lancet Oncol 2004, Armstrong NEJM 2006). However, for PC 
from gastric origin, the efficiency of this combined procedure remains highly controversial. The 
experience of few single institutions have reported encouraging survival results, in patients treated 
with cytoreductive surgery (CRS) combined with intraperitoneal chemohyperthermia (HIPEC) 
(Glehen Arch Surg 2004, Yonemura Surgery 1996). Moreover, many patients are not candidates to 
such treatment and consequently treated with palliative systemic chemotherapy only. 
In such patients, Asiatic surgeons have recently proposed a new concept using neoadjuvant 
intraperitoneal and systemic (NIPS) chemotherapy associated with high response rate and low 
toxicity (Yonemura EJSO 2006, Yonemura JSO 2009). This bidirectional treatement combined 
intraperitoneally administration of docetaxel and systemic administration of 5-FU or administration 
of oral S-1. Japan authors claimed that such chemotherapeutic agents comnination, known to be active 
on gastric cancer, can increase the rate of patients eligible for CRS and HIPEC procedure, and 
potentially offer curative approaches with acceptable toxicity (Canbay Ann Surg Oncol 2014). 
However, gastric cancers in Western country have been considered as different from gastric cancer 
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in Japan in terms of epidemiology and clinical response to the surgery (Kim Medicine (Baltimore) 
2016). More, the oral S-1 is considered as inefficient on European Caucasian patient and is not 
delivered in Europe. We planned a novel therapeutic strategy for Western Country combining 
administration of IP docetaxel with IV FOLFOX-4 (5-fluorouracil and oxaliplatin) in patients with 
non-resectable PC from gastric cancer in order to facilitate the setup of a phase I trial. The main 
endpoint of our pilot study was evaluated the feasibility and safety of this neoadjuvant bidirectional 
treatement. Secondary endpoint was to evaluate the success of therapeutic strategy reflected by OS 
and the decrease of 25% of the peritoneal spread evaluated by laparoscopy. 
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METHODS 
 
Patients 
From Mars 2014 and Mars 2016 the patients were enrolled in this first pilot study in Western country. 
Informed consent, according to the Institutional Guideline, was obtained from all patients. The 
inclusion criterias were: age between 18 to 65 years; histological evidence of primary gastric 
adenocarcinoma (endoscopy with biopsie) and PC (confirmed by laparoscopy, synchronous or 
metachronous); extended carcinomatosis considered non resectable with a PCI index ≥ 15; absence 
of hematogenous metastasis and remote lymph node metastasis (ovarian metastases were considered 
as a manifestation of peritoneal disease (Evers Br J Surg 2011); Eastern Clinical Oncology Group 
(ECOG) score (Luckett Ann Oncol 2011) less than 2; adequate bone marrow, liver, cardiac, and renal 
function; absence of other severe medical conditions or synchronous malignancy, absence of 
contraindication for major surgery.   
Standardized Data Collection 
All patients underwent a total body CT-Scan and gastric endoscopy with multiples biopies to confirm 
the primitive gastric cancer. PC was diagnosed by systematic biopsy using laparoscopy and the 
cytologic examination of ascites.  
Surgical Procedure 
A laparoscopic exploration was performed with a 30° optic by Single Incision Laparoscopy Surgery 
(SILS) approach (Najah Surg Endosc 2016): a single-port was placed through the umbilicus. The 
extent of PC was assessed intraoperatively with the Sugarbaker’s Peritoneal Cancer Index (PCI) 
(Jacquet Cancer Treat Res 1996). The assessment of the completeness of the cytoreduction (CCR-), 
performed at the end of the surgical procedure, as previously described (Jacquet Cancer Treat Res 
1996). After the cytological, histological diagnosis and complete evaluation of peritoneal 
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dissemination, a port system (Bard Port, C.R. Bard Inc., USA) was introduced into the abdominal 
cavity, the tip placed on the cul-de-sac of Douglas and the port introduced through a 3 cm skin and 
fascia incision (Kuschnir Clinical Ovarian & Other Gynecologic Cancer 2012).  
Bidirectional Chemotherapy 
All patients received the bidirectional treatement in the Medical Oncological Departement: Docetaxel 
at 30mg/m2 was administrated intraperitoneally over 30 min in 1000 ml of saline at day 1, 8 and 15 
and IV 5FU and oxaliplatin intravenous at day 1 and 15 followed by 7 days’ rest, as one course 
(Figure 1). A systematic Granulocyte colony-stimulating factor was administered at the investigator’s 
discretion. Before and after bidirectional treatment, 500 ml of saline was injected into the peritoneal 
cavity through the port, and fluid was recovered for cytology. After three courses, the PCI response 
was evaluated with a second laparoscopy. If major response was observed and carcinomatosis was 
evaluated resectable, surgery was performed. If partial response or stability with non resectable 
carcinomatosis was observed, treatment can be repeat for others three courses, followed by a new 
laparoscopic evaluation. If progression was observed, patient was proposed for a palliative care (new 
line of systemic chemotherapy or best supportive care).  
Endpoints 
The primary endpoint of our pilot study was to evaluate the feasibility and safety of combined 
bidirectional IV and IP chemotherapy. The secondary endpoints were the OS, the succes of combined 
therapeutic strategy, the quality of life, postoperative morbidity and mortality. The National Cancer 
Institute Common Toxicity Criteria (NCICTC) version 2 was applied to evaluate adverse drug 
reactions (Common Terminology Criteria for Adverse Event” (CTCAE)). OS was defined as the time 
from the diagnosis of primary tumor to the time of death due to any cause. Success of combined 
therapeutic strategy was defined by a 25% decrease of PCI betwen two laparoscopy.  For evaluation 
of performance status we used the ECOG score. Quality-of-life (EORTC QLQ-C30) assessment was 
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performed at two times: at registration of the patients and after the administration of the first course 
of the bidirectional treatement. The morbidity of the surgical procedure was defined according to the 
Dindo-Clavien classification (Dindo Ann Surg 2004). All in-hospital complications were included. 
All patients were followed up until clinical progression and/or death, if it occurred.  
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RESULTS 
Patient Characteristics 
Six consecutives patients were included in this pilot study. Four of them were female (66.7%). The 
average age was 48 years (range 24-66 years). Patient characteristics are summarized in Table 1. Four 
patients had synchronous PC and the two others had isolated peritoneal recurrence after gastrectomy. 
Cytology of peritoneal fluid was positive in 5 patients (83%) before the bidirectional treatment. Four 
patients had ascites at diagnosis (66%). Six patients underwent one complete cycle of NIPS, one 
patient had a second cycle. Four patients (66%) had second laparoscopy and only one patient a third 
laparoscopy.  
 
Outcomes 
The average PCI during first laparoscopy was 34 (range 30-39). The average PCI during the second 
laparoscopy decreased to 18, therefore a reduction of 46%, well above to the planned cut-off (Table 
2). After the first Bidirectional cycle: one patient (17%) had major response and consequently 
underwent cytoreductive surgery with HIPEC with curative intent (Figure 2); three patients (50%) 
had partial response with lower PCI; two patient had progression of disease (33%). One patient 
underwent a second cycle of NIPS with progression of PC diagnosed during the third laparoscopy. 
Peritoneal cytology remained positive in the 5 patients with previous positive cytology. Median 
Follow-up was 12 months. Median overall survival was 10 months (range 5-23 months), 1-year OS 
was 50%. Two patients died for chronic occlusive symptoms severe malnutrition. Four patients were 
alive at the time of analysis. During the first cycle, two patients had grade 3/4 complications: one 
patient had grade 3 bone marrow suppression and one patient severe asthenia (Table 3). Adverse 
effects occuring during the procedure are summarized in Table 4. After one cycle, ascites decreased 
in only one patient. Four patients had a good quality of life during the NIPS chemotherapy: one patient 
an ECOG 0, three patients had an ECOG 1 and two patients an ECOG 2.  
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DISCUSSION 
 
PC from gastric cancer was considered as a terminal disease (Sadeghi EVOCAPE 1 Cancer 2000). 
Patients who are not amenable to curative resection generally receive palliative chemotherapy to 
control related symptoms and improve OS (Wagner Cochrane 2010). Despite new drugs regimen, 
emerging strategy data and better understanding of tumor biology, OS remains poor in metastatic 
gastric cancer (Guimbaud JCO, Bang Lancet, Sohn BH Clin Cancer research 2017). Unfortunately, 
systemic neoadjuvant chemotherapy has never significantly downstaged peritoneal seeding and many 
consider the presence of carcinomatosis as an inadequate therapeutic option (Kamarag	J Clin Oncol 
2006). 
Cytoreductive surgery (CRS) combined with HIPEC is accepted as the only potentially curative 
treatment for colorectal PC (Glehen J Clin Oncol 2004, Glehen Cancer 2010,	Verwaal Surg Oncol 
2008). Similarly, recent studies have suggested that radical resection of macroscopic disease and 
perioperative chemotherapy to treat microscopic	disease could be the potentially curative treatment 
for advanced gastric cancer with limited carcinomatosis (Yonemura EJSO 2010, Glehen Ann Surg 
Oncol 2010). The new locoregional therapeutic approaches combining cytoreductive surgery with 
perioperative intraperitoneal chemotherapy suggest improved survival	(Glehen Arch Surg 2004). In 
a Glehen’s study including 159 patients with gastric carcinomatosis treated by cytoreductive surgery 
followed by intraperitoneal (hypertermic or not) chemotherapy with curative intent, the median OS 
was 9.2 months and 1-, 3-, and 5-year survival rates were 43, 18, and 13%, respectively. (Glehen Ann 
Surg Oncol 2010). Moreover, there is still no a standard of therapy for the intraperitoneal treatment 
for gastric PC. Nevertheless, this large study of Glehen et al. demonstrates that long-term survival for 
patients with PC from gastric cancer is a realistic endpoint in selected patients and PC should not be 
considered a terminal event. The high rate of mortality (27.8%) underlines the necessity of strict 
selection of patient.  
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A multimodality approach including neoadjuvant systemic chemotherapy followed by surgery 
appears as a reasonable strategy for the tumour down staging and the early elimination of 
micrometastases to improve OS. Two randomized trials comparing perioperative chemotherapy with 
surgery alone, showed efficacy of this approach in resectable gastric cancers (Cunningham NEJM 
2006, Ychou JCO 2011). More recently, the FLOT regimen has emerged as as new standard of care 
in the peri-operative setting (Al Batran, Lancet oncol 2016, ASCO 2017). 
Neoadjuvant chemotherapy has been proposed as a treatment modality that would increase the rate 
of gastric cancer patients with peritoneal seeding who could receive a complete clearing of the 
peritoneal dissemination (Yonemura Surgery 1996). This concept is close to what is nowadays done 
for unresectable colorectal liver metastases (Karanicolas Curr Oncol 2014, Kemeny JCO 2009).  The 
approach with neoadjuvant intravenous chemotherapy combined with intraperitoneal chemotherapy 
without hyperthermia has shown its efficacy with an acceptable toxicity profile in Japanese trials 
(Yonemura J Clin Oncol 2009, Ishigami Ann Oncol 2010, Imano Eur Surg Res 2011, Fujiwara J Surg 
Oncol 2012, Fushida Cancer Chemother Pharmacol 2013, Yamaguci Cancer 2013). However, in 
Caucasian patients, the efficacy of this bidirectional treatment remains to be evaluated. The present 
pilot study designed to determine the safety and efficacy of neoadjuvant bidirectional chemotherapy 
(IP and IV) for patients with unresectable gastric carcinomatosis. To the best of our knowedge, no 
prior report on that topic have been published in western Europe.  
The peritoneal cavity acts as a sanctuary against systemic chemotherapy due of the existence of a 
blood peritoneal barrier consisting of stromal tissue between mesothelial cells and submesothelial 
blood capillaries. This barrier accounts for a total thickness of 90 µm and inhibits the movement of 
drugs from submesothelial capillaries to the peritoneal cavity. Accordingly, only a small amount of 
systemic drugs is capable of penetrating this barrier and passing into the peritoneal cavity so a higher 
percentage of the administered drugs instead moves to the bone marrow and vital organs other than 
the peritoneum, resulting in the development of adverse effects (Jacquet Kluwar Academic Publisher 
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1996). The fundamental goal of IP administration is to maximize the total amount of drug delivered 
into the peritoneal surface, while minimizing that delivered to the systemic circulation. 
The efficacity of IP taxane therapy was demonstrated in phase II studies in advanced gastric cancer	
(Yonemura J Clin Oncol 2009, Fujiwara J Surg Oncol 2012, Fushida Cancer Chemother Pharmacol 
2013). Pharmacocynetic studies shown that IP chemotherapy provides high concentrations of a 
cytotoxic agent directly to the peritoneal space (Dedrick Cancer chemother Pharmacol 1978, 
Minchiton Nat Rev Cancer 2006, Yonemura EJSO 2010 Review). Systemic concentrations of drugs 
are, however, achievable because of absorption of the agent through the peritoneal surfaces. Taxanes 
(docetaxel and paclitaxel) are hydrophobic with high weitgh molecular drugs. When itraperitoneally 
administrated, the taxanes are drained from the peritoneum lymphatic stoma into the pleural space 
(Flessner Am J Physiol 1985, Wang  Anat Rec 2010).   The taxanes drug molecules, remaining in 
high IP concentration for 48-72h in contact to the peritoneal nodules, produce antitumoral effect 
making them the ideal chemotherapic agents for intraperitoneal administration (Table 5). 
Morgan et al. established that administration of IP docetaxel can be safely delivered at a dose of 100 
mg/m2 every 3 weeks (Morgan Cancer Clin Res 2003). According to phase ? studies, the 
recommended doses (RD) of IP docetaxel combined with oral cancer drugs (TS-1) are 45-60 mg/m2 
(Fushida Cancer Chemothep Pharmacol 2013, Fujiwara Anticancer Res 2010). Yonemura et al., 
associating dual IP anticancer drugs, lower the concentration of IP docetaxel to 30	mg/m2 with milde 
toxicity (Yonemura JSO 2009). However, in our experience, we use a concentration of 30 mg/m2 
taxotere to reduce toxicity when administrated in associate with FOLFOX IV. Therefore, we preferred 
to use a lower dose than that reported in the first papers in literature. In a previous report, adverse 
effects after NIPS were found in 11% (9/81) of cases, and no chemotherapy related deaths were 
experienced (Yonemura WJGO 2010). Accordingly, in our study only two patients had grade 3-4 
toxicity correlated to systemic chemotherapy. Repetead paracentesys for refractary ascite was 
necessary for 4 patients with consequent severe malnutrition for one of them. During the 
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laparoscopies, no abdominal adverse effects were reported except one infection of the catheter; the 
abdominal pain was controlled with mild analgesics. For that NIPS appears to be a safe method for 
induction chemotherapy.  
In our experience, we have evaluated only the macroscopic response to NIPS with the laparoscopy. 
Major difference regarding carcinomatosis is that preoperative radiologic evaluation is inefficient to 
evaluate carcinomatosis (resectability and peritoneal index). For that laparoscopy is mandatory (Valle	
Eur J Surg Oncol 2006, Najat Surg Endosc. 2016) and used to place a peritoneal access chamber 
(PAC). If IP chemotherapy is performe during the perioperative period when adhesions have not yet 
developed, the entire abdominal cavity can be equally treating. The number of NIPS chemotherapy 
treatments depends on the effect on tumors and the accurate preoperative evaluation of PC is 
mandatory to propose the secondary complete cytoreduction of PC.  
In our study, only one patient had a complete CRS followed by HIPEC. However, in the study of 
Yonemura et al., 30 of 61 enrolled patients had an operative intervention and 14 of them could be 
made disease-free with a long-term survival (20.4 and 15 months of OS, respectively) and without 
major toxicities (Yonemura EJSO 2006). However, in our study we enrolled patients with high 
volume of carcinomatosis (PIC >15) while the heterogeneity of the population in Asiatic (patients 
with macroscopic carcinosis and patients with only positive cytology withouth macroscopical 
carcinosis) was probably responsible to the good results in term of OS.  
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CONCLUSION 
The combination of IV and IP chemotherapy should be considered in patients with carcinomatosis 
from gastric cancer. Accordingly, the bidirectional chemotherapy appears to be safe and may be the 
preferred strategy in the pre-operative setting in highly selected patients with young age, ECOG 0-1 
status, normal nutritional status and elevated PCI. The NIPS procedure should be evaluated more 
extensively in phase I-II studies. 
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FIGURES AND TABLES: 
 
Table 1. Demographic, clinical and histological characteristic of the patients included 
ADK, adenocarcinoma; ACDI adenocarcinoma independent cells; neg, negative; PC, peritoneal carcinomatosis; Pres-NIPS	sCT, previous neoadjuvant intra-petitoneal 
systemic chemotherapy; DOC, docetaxel 
 
  
 
Patient 
 
Sex 
 
Age,  
Years 
 
Histology 
 
Cytology  
 
Her2+ 
 
PC Type 
 
Prev-NIPS sCT 
 
NIPS sCT IV 
 
NIPS CT IP 
 
1st   
2nd  
3th 
4th  
5th  
6th  
 
 
M 
F 
M 
F 
F 
F 
 
66 
48 
42 
45 
24 
60 
 
ADK 
ADCI, linitis plastica 
ADCI, linitis plastica 
ADCI, linitis plastica 
ADCI, linitis plastica 
ADCI, linitis plastica 
 
neg 
+ 
+ 
+ 
+ 
+ 
 
neg 
neg 
1+ 
2+ 
2+ 
2+ 
 
Recurrence 
Synchronous 
Recurrence 
Synchronous 
Synchronous 
Synchronous 
 
3 ECF, 12 Folfox 
No 
8 TEFOX 
No 
No 
8 TEFOX  
 
LV5FU2 
FOLFOX 
FOLFOX 
FOLFOX 
FOLFOX 
LV5FU2 
 
DOC 
DOC 
DOC 
DOC 
DOC 
DOC 
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Table 2. Early and long Outcomes for the patients treated by bidirectional treatment 
 
NIPS, neoadjuvant intra-petitoneal systemic chemotherapy; IP, intraperitoneal; PCI, peritoneal cancer index; CRS, cytoreductive surgery; GT, total gastrectomy;  
 
  
 
Patient 
 
Cycles 
of NIPS  
 
IP tolerance 
 
ECOG  
 
1° Laparoscopy  
PCI (N = 6) 
 
2° Laparoscopy  
PCI (N = 4) 
 
Results 
 
CRS +/- HIPEC 
 
OS (months) 
 
1st   
2nd  
3th 
4th  
5th  
6th  
 
 
1 
1.5 
1 
1 
2 
1 
 
good 
medium 
medium 
good 
good 
godd 
 
1 
2 
2 
0 
1 
1 
 
34 
30 
30 
36 
39 
32 
 
 
- 
12 
- 
13 
29 
18 
 
 
Progression 
Good response 
Progression 
Good response 
Partial response 
Good response 
 
0 
0 
0 
CRS + GT+ 
HIPEC  
Ovariectomy 
0 
 
15 
5 
6 
23 
14 
7 
 
   Mean 
 
 
 
   
33.5 
 
18 
 
 
  
10.3 
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Table 3. Toxicity during the bidirectional treatment 
      
Toxicity* 
 
 
 
 
 
   
  
Not IP catheter-related 
 
Anemia  
Leucopenia  
Febrile neutropenia  
Thrombocytopenia  
Asthenia  
Diarrhea  
Neuropathy  
Nausea/Vomiting/Dehydration 
Renal/metabolic 
 
Grade 1-2 
 
2 
2 
0 
1 
2 
1 
1 
1 
0 
 
Grade 3-4 
 
0 
1 
0 
0 
1 
0 
0 
0 
0 
 
   
Total 
 
2 
3 
0 
1 
3 
1 
1 
1 
0 
*	Toxicity was assessed during the the bidirectional treatment according to the National Cancer Institute (NCI-CTC)  
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Table 4. Adverse effects during the bidirectional treatment 
Adverse effects 
 
 
 
 
 
   
      
Catheter- related 
 
IP catheter Infection  
IP catheter blocked  
Acces Problems 
 
1° Laparoscopy 
PCI (N = 6) 
 
1 
0 
0 
 
2° Laparoscopy 
PCI (N = 4) 
 
0 
0 
0 
 
3° Laparoscopy 
PCI (N = 1) 
 
0 
0 
0 
 Total 
 
 
1 
0 
0 
 
Possibly IP Treatment related 
 
Other Infection  
Abdominal pain 
Patient refusal 
Bowel complication/ Peritonitis 
Refractory ascites 
Paracentesis 
Severe denutrition  
 
1° Laparoscopy 
PCI (N = 6) 
 
0 
1 
0 
0 
4 
4 
2 
 
2° Laparoscopy 
PCI (N = 4) 
 
0 
1 
0 
0 
2 
1 
0 
 
3° Laparoscopy 
PCI (N = 1) 
 
0 
1 
0 
0 
1 
1 
1 
  
 
 
0 
3 
0 
0 
7 
6 
3 
      
23	
	
 
Table 5. Pharmacocynetic parameters for docetaxel 
Docetaxel 40 mg 
  
Molecular weight (daltons) 861.9 
AUC peritoneal/plasma ratio 207*-552 
Drug penetration distance in IP 
administration 
NA 
Recommended  IV dose (mg/m2) 100 
Recommended IP dose (mg/m2)** 45-60 
* in hyperthermic chemoperfusion; ** combined with oral cancer drugs; AUC, area under curve; 
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THESIS SUMMARY  
 
Title : Analysis of tumoral evolution and prognostic factors of colorectal multisite metastatic process, 
peritoneal and hepatic : from animal model to an international clinical study 
 
Abstract : The synchronous presence of liver metastases (LM) and peritoneal carcinomatosis (PC) 
from colorectal cancer (CRC) is associated with poor outcome and is traditionally considered a 
contraindication to any surgical approach. However, few series reported a prolonged survival after 
surgical management, reaching 3 years in selected patients thus suggesting that a curative surgical 
management may be possible. To date, no standard management pathway has been established, 
especially if a major liver and peritoneal surgery has to be performed. We postulated that liver 
regeneration after liver resection could promote PC growth. We constructed an immunocompetent 
animal model of limited PC. The objective of our study was to analyze the effects of major LR and 
liver regeneration after hepatectomy on peritoneal carcinomatosis growth and the associated 
angiogenesis process. Furthermore, we have analyzed a prospective international cohort of patients 
undergoing synchronous liver resection and cytoreductive surgery with HIPEC. The aim of this study 
was to describe the outcomes, to identify variables potentially related to poor outcome, in order to 
establish future guideline for the management of these patients, to optimize the selection of candidates 
for surgical treatment and determine the best surgical strategy. 
 
Keywords : peritoneal carcinomatosis, liver metastases, angiogenesis, surgery, liver regeneration, 
circulating derived bone marrow progenitors cells 
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Titre : Analyse de l'évolution tumorale et des facteurs pronostiques du processus métastatique 
multisite, péritonéal et hépatique : a travers un modèle animal à un ‘étude clinique internationale 
 
Résumé : La présence synchrone de métastases hépatiques (MH) et carcinose péritonéale (CP) 
d'origine colorectale (CRC) est associée à une survie globale médiocre et est traditionnellement 
considérée comme une contre-indication à l’approche chirurgicale curative. Cependant, suite aux 
résultats encourageants après traitement chirurgicale, quelques séries ont rapporté une survie 
prolongée atteignant 3 ans chez des patients sélectionnés, ce qui suggère qu’un traitement chirurgicale 
curative est possible. À ce jour, en cas de chirurgie majeure hépatique et péritonéale associée, aucune 
stratégie thérapeutique n'a été établie, Nous avons postulé que la régénération hépatique après une 
résection hépatique pourrait favoriser la croissance de la CP. Nous avons construit un modèle animal 
immunnocompetent de CP limitée. L'objectif de l’étude était d'analyser les effets de l’hépatectomie 
majeure et de la régénération hépatique dans notre modèle murin de PC et le processus d'angiogenèse 
associé. En outre, nous avons analysée une cohorte prospective multicentrique de patients ayant eu 
une résection hépatique et une chirurgie cytoréductive avec HIPEC synchrone. L'objectif de cette 
étude était d'évaluer les outcomes et identifier les facteurs pronostiques afin d'optimiser la sélection 
des candidats au traitement chirurgical et de déterminer la stratégie chirurgicale optimale. 
 
Mots clefs : carcinose péritonéale, métastases hépatiques, angiogenèse, chirurgie, régénération 
hépatique, progéniteurs dérivées de la moelle osseuse	
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Résumé substantiel en Français 
Analyse de l'évolution tumorale et des facteurs pronostiques d’un processus métastatique 
multi site, péritonéal et hépatique : d’un modèle animal à une étude clinique internationale 
 
 
La présence synchrone des métastases hépatiques et d’une carcinose péritonéale d'origine 
colorectale est associée à une survie globale médiocre et est traditionnellement considérée 
comme une contre-indication à l’approche chirurgicale curative. Cependant, suite aux 
résultats encourageants récents après traitement chirurgicale, quelques séries ont rapporté une 
survie prolongée atteignant 3 ans chez des patients sélectionnés, ce qui suggère qu’un 
traitement chirurgical curatif est possible. À ce jour, en cas de chirurgie majeure hépatique et 
péritonéale associée, aucune stratégie thérapeutique n'a été établie.  
Dans ce travail de thèse trois questions principales ont été abordés : 1) est-il possible de traiter 
les patients avec des métastases hépatiques et péritonéales synchrones, individuellement 
accessible à un traitement chirurgical à visée curative ? 2) en cas de traitement chirurgical 
agressif, quel ordre de chirurgie devrait être choisi ? 3) en cas de chirurgie en deux étapes, 
quel est l'effet de la chirurgie du foie sur la carcinose péritonéale ?  
Pour répondre à la première question, nous avons analysée une cohorte prospective 
multicentrique de 161 patients provenant des Centres Experts Français en Maladies Rares du 
Péritoine (réseau BIG RENAPE) et de l’Université Roma La Sapienza ayant eu une résection 
hépatique carcinologique et une chirurgie de cytoréduction péritonéale complète avec HIPEC 
(Hyperthermic intraperitoneal chemotherapy) à but curatif pour une carcinose péritonéale 
associée à des métastases hépatiques synchrones. Cette cohorte est issue d’une coopération 
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entre les centre spécialisés pour les maladies du péritoine dans le deux Pays, France et Italie et 
est à la base de la cotutelle de cette thèse; au total, 18 centres ont participé au recueil 
prospectif des données. L'objectif de cette étude était d'évaluer les outcomes précoces 
(morbidité/mortalité, durée de séjour hospitalier) et à long terme (DFS, Desease Free Survival 
et OS, Overall Survival) et identifier les facteurs pronostiques afin d'optimiser la sélection des 
candidats au traitement chirurgical et de déterminer la stratégie chirurgicale optimale. 
L'objectif secondaire de cette analyse était d'identifier des facteurs pronostiques négatifs, afin 
d'établir des guidelines dans la prise en charge de ces patients et optimiser la sélection des 
candidats auxquels proposer un traitement chirurgical complexe. Après un follow-up moyen 
de 24 mois, les résultats de cette analyse ont montré que cette chirurgie complexe est associée 
à un faible taux de morbidité (14.9%, n=24 patients), similaire à celui de la chirurgie 
abdominale majeure. Aucune mortalité dans les 30 jours postopératoires n'a pas été observée. 
La moyenne d’hospitalisation était de 23 jours. La chirurgie simultanée des métastases 
hépatiques et de la carcinose péritonéale était associés à un séjour hospitalier postopératoire 
plus long que la chirurgie en deux temps (24 (SD : 13,1) vs 15 (SD : 5,8) jours, 
respectivement, P = 0,02). L’OS était de 33 mois (range 0.2 à 102 mois), supérieure à celle 
obtenue avec un traitement par chimiothérapie systémique seule (24 mois). Le taux d’OS à 1, 
3 et 5 ans était respectivement de 87%, 45%, et 25% des patients. La DFS de notre série était 
égal à 10 mois (range 0,3 à 56 mois). Le taux de DFS à 1, 3 et 5 ans était respectivement de 
44%, 17%, et 8% des patients. 124 patients (87,9%) ont récidivé ou cours du follow-up; parmi 
eux, 74 patients (52.5%) ont récidivé au cours de la première année. En analyse univariée, la 
présence de plus de 3 métastases hépatiques et les complications postopératoires de grade III-
IV selon Clavien-Dindo ont été identifiées comme facteurs pronostiques de DSF diminuée. 
Cependant, en analyse multivariée, la présence de plus de 3 métastases hépatiques et la 
résection incomplète de la carcinose péritonéale (classée comme CCR-1) étaient les seuls 
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facteurs prédictifs indépendants de DFS diminuée (adjusted Hazard Ratio [aHR] : 3,32, IC à 
95% : 1,67-6,63, P = 0,001 et aHR : 1,99, IC à 95% : 1,02-3,89, P = 0,04, respectivement). En 
analyse univariée, le sexe masculin, une carcinose limitée et la résection incomplète de la 
carcinose péritonéale ont été identifiés comme facteurs pronostiques d’OS diminuée. En 
analyse multivariée, une carcinose limitée avec un Peritoneal carcinomatosis index < 12/39 
(selon Sugarbaker) était le seul facteur prédictif indépendant d’OS diminuée (aHR : 1,67, IC à 
95% : 1,05-2,66, P = 0,03). Le nombre de métastases hépatiques et le type de résection 
hépatique (majeure ou mineure) n’influence pas le taux de complication post-opératoire. En 
conclusion, cette étude multicentrique représente la plus grosse série analysée jusqu’à présent, 
montre que le traitement curatif des métastases synchrones hépatiques et péritonéales 
d’origine colorectale est possible et confirme la faisabilité de l'hépatectomie combinée à une 
chirurgie de cytoréduction péritonéale complète et HIPEC pour des patients sélectionnés.  
Les données actuelles soutiennent cette stratégie de traitement agressif : une sélection 
rigoureuse des patients devient fondamentale si l'on veut proposer un traitement curatif 
agressif. Le choix du timing, en cas de chirurgie en deux temps, reste inconnu. En cas 
d'approche chirurgicale agressive à visée curative, il n'y a pas des guidelines pour choisir la 
chirurgie que doit être faite en premier : devrions-nous en premier opérer le foie ou le 
péritoine? La question de la séquence optimale reste non résolue. Le choix dépend 
principalement du nombre et de l'emplacement des métastases hépatiques. Si les métastases 
hépatiques nécessitent une résection mineure et non compliquée, la résection hépatique et la 
cytoréduction avec HIPEC peut être effectuée de manière simultanée. Si les métastases 
hépatiques nécessitent une résection complexe, notamment sur un parenchyme lésé (post-
chimiothérapie), une résection hépatique et une cytoréduction avec HIPEC se déroulera en 
deux temps dont la première procédure pourrait être soit une chirurgie hépatique, soit une 
chirurgie péritonéale associée à HIPEC.  
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Pour trouver une réponse à ces questions, dans la deuxième partie de ce travail de thèse, nous 
avons postulé que la régénération hépatique qui suit une résection hépatique pourrait favoriser 
la croissance tumorale de la carcinose péritonéale. Nous avons donc construit un modèle 
murin immunocompétent de carcinose péritonéale limitée avec l’injection intrapéritonéale de 
cellules tumorales murines d’origine colorectale CT-26 marquées à la luciférase (CT-26luc+). 
Pour obtenir ce modèle, cinq concentrations décroissantes de CT-26luc+ ont été testés (5×105, 
2.5×105, 1.25×105, 6.2×104 et 3×104 cellules). L’extension de la carcinose péritonéale a été 
évalué macroscopiquement, post-mortem, grâce au Péritonéal Cancer Index (PCI) score de 
Sugarbaker adapté à la taille des nodules tumoraux de la souris. En utilisant 3×104 CT-26luc+ 
cellules, nous avons obtenu le modèle carcinose péritonéale limitée souhaité. Sur ce modèle 
on a réalisé une hépatectomie majeure du 68% du parenchyme hépatique, pour mimer la 
situation clinique humaine. L'objectif de l’étude était d'analyser les effets de l’hépatectomie 
majeure et de la régénération hépatique sur la croissance tumorale de la carcinose péritonéale 
et le processus d'angiogenèse associé. La croissance tumorale a été évalué en 
immunohistochimie par la compte des mitoses cellulaires et l’expression du Ki-67 dans les 
nodules tumoraux péritonéaux; la néo-angiogenèse tumorale a été évalué en 
immunofluorescence par l’expression du CD31 par les néo-vaisseaux, par le taux des 
progeniteurs endothéliaux et hématopoïétiques circulants dérivés de la moelle osseuse et par 
la mesure en Echo-doppler de la vélocité du flux sanguin dans les artères digestives (artère 
mésentérique supérieure et tronc cœliaque). La régénération hépatique a été évalué en 
immunohistochimie par la compte des mitoses cellulaires et l’expression du Ki-67 dans le 
parenchyme hépatique le lobe restant. 
Cinque jours après l’injection intrapéritonéale de CT-26luc+, les souris ont été randomisées 
en trois groupes: le groupe contrôle (Natural History = NH) comprenant les animaux ayant 
reçu seulement l’injection de CT-26luc+ (n = 30), le groupe hépatectomie (Liver Surgery = 
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LS) comprenant les animaux opérés d’une hépatectomie majeure (n = 30), et le groupe 
laparotomie (Sham Laparotomy = Sham) comprenant les animaux opérés d’une laparotomie 
blanche (n = 30). Les animaux ont été euthanasiés par dislocation cervicale. Le sang a été 
obtenu par ponction cardiaque, et foie, poumons, ganglions lymphatiques abdominaux et tissu 
péritonéal ont été prélevés pour analyse histologique. Pour évaluer la cinétique de la 
croissance tumorale de la carcinose péritonéale, 10 souris de chaque groupe ont été sacrifiées 
1, 5 et 20 jours après la randomisation.  
Les résultats de cette étude montraient un PCI différent parmi les trois groupes (P < 0,05); une 
tendance à un PCI plus élevée chez les souris du groupe LS par rapport aux autres groupes a 
été mise en évidence à j20 (P = 0,058 pour le groupe NH et P = 0,07 pour le groupe Sham). 
Le compte des mitoses a montré une différence significative entre le groupe LS et les autres 
(83 ± 8 vs 10 ± 8 cellules/champ, P = 0,0001 pour le groupe NH et 83 ± 8 vs 27 ± 10 
cellules/champ, P = 0,009 pour le groupe Sham), ce qui suggère un indice de prolifération 
tumorale plus élevé après hépatectomie. L'analyse macroscopique des lésions extra-
péritonéales a montré la présence d’ascite hémorragique et des métastases hépatiques 
seulement dans le groupe LS. Il n’a pas été observé de signes macroscopiques de régénération 
hépatique dans le lobe restant du groupe LS après chirurgie hépatique, bien que le marquage 
du Ki-67 ait été significativement augmenté dans le lobe restant après hépatectomie par 
rapport au foie non opéré des deux autres groupes, et ça à partir du cinquième jour. Après 
hépatectomie, le nombre des Progéniteurs Endothéliaux Circulants (EPC) CD-34+/VEGFR-
2+ était augmenté précocement dans le groupe LS par rapport au groupe NH (P=0,033 à j1 et 
P=0,075 à j5); était similaire et faible dans les trois groupes dans les phases tardives. La néo-
angiogenèse tumorale, évaluée par le nombre des vaisseaux sanguins marqués CD31+ dans 
les nodules péritonéaux, a montré un marquage augmenté dans le groupe LS (90±8) et Sham 
(86±6) par rapport au groupe NH (20±7, P<0,005 pour chaque comparaison). En revanche, le 
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nombre des cellules CD-31+ a été réduit dans les lobes hépatiques restants du groupe LS par 
rapport aux autres deux groupes (P<0,05 pour chaque comparaison). Le flux moyen dans 
l'artère mésentérique supérieure était également augmenté dans les groupes NH et LS à j20 de 
5,3 +/- 1,9 à 11,2 +/- 3,6 cm / s (P = 0,0010). Le flux moyen dans le tronc cœliaque est resté 
stable de j1 à j20 dans le groupe NH (8,9 ± 2,3 cm / s) ; après l'hépatectomie était diminué à 
j1 dans le groupe LS à 5,2 ± 1,8 cm / s (p = 0,0077 LS vs NH), augmenté à 9,5 +/- 2,4 cm / s à 
j5 (P = 0,0105), augmenté à 14,0 +/- 1,9 cm / s à j20 (P = 0,0017). Il y avait une forte 
corrélation entre le flux moyen dans l'artère cœliaque et l'PCI (R = 0,85, p <0,001). 
En conclusion dans notre modèle animal de carcinose péritonéale, l’hépatectomie a entraînée 
une augmentation des nodules péritonéaux sans régénération macroscopique du foie. Ce 
modèle animal confirme le rôle pro-angiogénique de l'hépatectomie, qui favorise 
l'augmentation des EPC et leur participation à la croissance de la carcinose péritonéale. Ces 
résultats suggèrent que, chez les patients atteints de métastases péritonéales et hépatiques 
d’origine colorectale associées, la résection péritonéale devrait être la première étape en cas 
de chirurgie hépatique et péritonéale en deux temps afin de minimiser le risque de croissance 
de la carcinose jusqu'à un stade non curatif. 
 
 
